0000012208-17-000041.txt : 20170807 0000012208-17-000041.hdr.sgml : 20170807 20170807152832 ACCESSION NUMBER: 0000012208-17-000041 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170807 DATE AS OF CHANGE: 20170807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO RAD LABORATORIES INC CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 171011323 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 10-Q 1 a10q63017.htm 10-Q 6/30/17 Document
0.350.350.35false--12-31Q220170000012208YesLarge Accelerated FilerBIO RAD LABORATORIES INCNoYes244540485123883245002495125094244539265122966244961275124177P9YP1YP8YP1YP12YP3YP9YP1YP9YP2YP0YP0YP8YP4YP9YP1YP8YP1YP12YP2YP14YP2YP9YP2YP0YP0YP7YP4Y01229174122917 0000012208 2017-01-01 2017-06-30 0000012208 us-gaap:CommonClassAMember 2017-07-27 0000012208 us-gaap:CommonClassBMember 2017-07-27 0000012208 bio:TreasuryClassAMember 2016-12-31 0000012208 2017-06-30 0000012208 2016-12-31 0000012208 us-gaap:CommonClassAMember 2017-06-30 0000012208 bio:TreasuryClassBMember 2017-06-30 0000012208 us-gaap:CommonClassAMember 2016-12-31 0000012208 us-gaap:CommonClassBMember 2016-12-31 0000012208 bio:TreasuryClassAMember 2017-06-30 0000012208 us-gaap:CommonClassBMember 2017-06-30 0000012208 bio:TreasuryClassBMember 2016-12-31 0000012208 2016-04-01 2016-06-30 0000012208 2017-04-01 2017-06-30 0000012208 2016-01-01 2016-06-30 0000012208 2016-03-31 0000012208 2015-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2017-01-01 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2017-06-30 0000012208 bio:RainDanceTechnologiesInc.Member 2017-01-01 2017-03-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-06 0000012208 us-gaap:DeferredTaxAssetDomain bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-01 2016-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:ProjectedVolatilityOfSalesMemberMember 2017-01-01 2017-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:MarketPriceOfRiskMember 2017-01-01 2017-06-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2017-01-01 2017-06-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2017-06-30 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2017-01-01 2017-06-30 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2017-01-01 2017-06-30 0000012208 bio:CellsorterMember 2017-01-01 2017-06-30 0000012208 bio:GnuBIOMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2017-06-30 0000012208 bio:CellsorterMember 2012-09-30 2016-09-30 0000012208 bio:CellsorterMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2017-06-30 0000012208 bio:CellsorterMember 2012-09-30 0000012208 bio:GnuBIOMember 2014-04-10 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2017-06-30 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-06-30 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-06-30 0000012208 us-gaap:CustomerRelationshipsMember 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0000012208 us-gaap:TradeNamesMember 2016-12-31 0000012208 bio:KnowHowMember 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2017-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember 2017-06-30 0000012208 bio:KnowHowMember 2017-06-30 0000012208 us-gaap:LicensingAgreementsMember 2017-06-30 0000012208 us-gaap:NoncompeteAgreementsMember 2017-06-30 0000012208 us-gaap:TradeNamesMember 2017-06-30 0000012208 bio:ClinicalDiagnosticsMember 2017-01-01 2017-06-30 0000012208 bio:LifeScienceMember 2016-12-31 0000012208 bio:LifeScienceMember 2017-01-01 2017-06-30 0000012208 bio:LifeScienceMember 2017-06-30 0000012208 bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-06-30 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2017-04-01 2017-06-30 0000012208 us-gaap:LineOfCreditMember 2017-06-30 0000012208 us-gaap:StandbyLettersOfCreditMember 2017-06-30 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2016-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2017-06-30 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2016-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2017-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-04-01 2016-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-04-01 2016-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-04-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-04-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-06-30 0000012208 bio:USFederalMember 2017-04-01 2017-06-30 0000012208 bio:USFederalMember 2016-01-01 2016-06-30 0000012208 bio:USFederalMember 2017-01-01 2017-06-30 0000012208 bio:USFederalMember 2016-04-01 2016-06-30 0000012208 bio:LifeScienceMember 2016-01-01 2016-06-30 0000012208 bio:ClinicalDiagnosticsMember 2016-01-01 2016-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-04-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2016-04-01 2016-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-04-01 2017-06-30 0000012208 us-gaap:OperatingSegmentsMember 2017-01-01 2017-06-30 0000012208 us-gaap:OperatingSegmentsMember 2016-04-01 2016-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2017-04-01 2017-06-30 0000012208 us-gaap:OperatingSegmentsMember 2016-01-01 2016-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2016-04-01 2016-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-04-01 2016-06-30 0000012208 us-gaap:OperatingSegmentsMember 2017-04-01 2017-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2016-04-01 2016-06-30 0000012208 bio:ClinicalDiagnosticsMember 2016-04-01 2016-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2017-04-01 2017-06-30 0000012208 bio:LifeScienceMember 2017-04-01 2017-06-30 0000012208 bio:ClinicalDiagnosticsMember 2017-04-01 2017-06-30 0000012208 bio:LifeScienceMember 2016-04-01 2016-06-30 0000012208 us-gaap:CostOfGoodsTotalMember 2017-04-01 2017-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-06-30 0000012208 us-gaap:CostOfGoodsTotalMember 2017-01-01 2017-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-04-01 2017-06-30 0000012208 us-gaap:EmployeeSeveranceMember 2017-01-01 2017-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:pure xbrli:shares


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 10-Q
(Mark One)
 
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2017
or
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from______________to __________

Commission file number 1-7928

BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware
 
94-1381833
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
1000 Alfred Nobel Drive, Hercules, California
 
94547
(Address of principal executive offices)
 
(Zip Code)
(510) 724-7000
(Registrant's telephone number, including area code)
No Change
(Former name, former address and former fiscal year, if changed since last report.)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
Yes    x
     No     o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
 
Yes    x
     No     o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.  (Check one):
Large accelerated filer
x
 
Accelerated filer
o
Non-accelerated filer
o
(Do not check if smaller reporting company)
Smaller reporting company
o
 
 
 
Emerging growth company
o
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 
Yes    o
     No     x
 
 
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Title of Class
 
Shares Outstanding at July 27, 2017
Class A Common Stock, Par Value $0.0001 per share
 
24,528,198
Class B Common Stock, Par Value $0.0001 per share
 
5,109,777
 



BIO-RAD LABORATORIES, INC.

FORM 10-Q JUNE 30, 2017

TABLE OF CONTENTS



2


INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this report include forward-looking statements, such as statements with respect to our future financial performance, operating results, plans and objectives that involve risk and uncertainties.  Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions.  Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements.  We have based these forward-looking statements on our current expectations and projections about future events.  However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including, but not limited to, those identified under “Part II, Item 1A, Risk Factors” of this Quarterly Report on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.


3




PART I – FINANCIAL INFORMATION

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share data)
 
June 30, 2017
 
December 31, 2016
ASSETS:
 (Unaudited)
 
 
Cash and cash equivalents
$
321,584

 
$
456,264

Short-term investments
391,268

 
383,176

Restricted investments
4,560

 
4,560

Accounts receivable, net
392,842

 
372,348

Inventories:
 
 
 
Raw materials
115,043

 
116,540

Work in process
133,055

 
125,982

Finished goods
332,483

 
282,439

Total inventories
580,581

 
524,961

Prepaid expenses
125,655

 
91,014

Other current assets
10,038

 
12,201

Total current assets
1,826,528

 
1,844,524

Property, plant and equipment, at cost
1,277,970

 
1,227,388

Less: accumulated depreciation and amortization
(774,641
)
 
(738,774
)
Property, plant and equipment, net
503,329

 
488,614

Goodwill, net
530,287

 
477,115

Purchased intangibles, net
184,819

 
161,609

Other investments
1,040,959

 
830,790

Other assets
57,537

 
47,852

Total assets
$
4,143,459

 
$
3,850,504

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY:
 
 
 
Accounts payable, accrued payroll and employee benefits
$
277,566

 
$
296,473

Current maturities of long-term debt and notes payable
505

 
334

Income and other taxes payable
33,308

 
28,124

Other current liabilities
143,731

 
146,391

Total current liabilities
455,110

 
471,322

Long-term debt, net of current maturities
434,386

 
434,186

Deferred income taxes
294,843

 
222,919

Other long-term liabilities
148,123

 
135,318

Total liabilities
1,332,462

 
1,263,745

 
 
 
 
Stockholders’ equity:
 
 
 
Class A common stock, shares issued 24,500,249 and 24,454,048 at 2017 and 2016, respectively; shares outstanding 24,496,127 and 24,453,926 at 2017 and 2016, respectively
2

 
2

Class B common stock, shares issued 5,125,094 and 5,123,883 at 2017 and 2016, respectively; shares outstanding 5,124,177 and 5,122,966 at 2017 and 2016, respectively
1

 
1

Additional paid-in capital
347,658

 
332,911

Class A treasury stock at cost, 4,122 shares and 122 shares at 2017 and 2016, respectively
(895
)
 
(12
)
Class B treasury stock at cost, 917 shares at 2017 and 2016
(89
)
 
(89
)
Retained earnings
1,853,372

 
1,836,180

Accumulated other comprehensive income
610,948

 
417,766

Total stockholders’ equity
2,810,997

 
2,586,759

Total liabilities and stockholders’ equity
$
4,143,459

 
$
3,850,504

The accompanying notes are an integral part of these condensed consolidated financial statements. 

4


BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
Net sales
$
504,666

 
$
516,777

 
$
1,004,717

 
$
987,974

Cost of goods sold
231,367

 
236,545

 
461,431

 
443,713

Gross profit
273,299

 
280,232

 
543,286

 
544,261

Selling, general and administrative expense
213,027

 
205,536

 
407,967

 
395,252

Research and development expense
62,623

 
49,811

 
112,111

 
98,397

Impairment loss on long-lived asset
—

 
2,360

 
—

 
2,360

Income (loss) from operations
(2,351
)
 
22,525

 
23,208

 
48,252

Interest expense
5,770

 
5,632

 
10,811

 
11,212

Foreign currency exchange losses, net
2,516

 
1,237

 
4,305

 
2,366

Other (income) expense, net
(11,757
)
 
(11,208
)
 
(13,175
)
 
(12,385
)
Income before income taxes
1,120

 
26,864

 
21,267

 
47,059

Benefit (provision) for income taxes
3,915

 
(8,850
)
 
(3,819
)
 
(16,769
)
Net income
$
5,035

 
$
18,014

 
$
17,448

 
$
30,290

 
 
 
 
 
 
 
 
Basic earnings per share:
 
 
 
 
 
 
 
Net income per basic share
$
0.17

 
$
0.61

 
$
0.59

 
$
1.03

Weighted average common shares - basic
29,613

 
29,398

 
29,597

 
29,381

 
 
 
 
 
 
 
 
Diluted earnings per share:
 
 
 
 
 
 
 
Net income per diluted share
$
0.17

 
$
0.61

 
$
0.58

 
$
1.03

Weighted average common shares - diluted
30,006

 
29,589

 
29,962

 
29,549



The accompanying notes are an integral part of these condensed consolidated financial statements. 


5


BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Comprehensive Income
(In thousands)
(Unaudited)

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Net income
$
5,035

 
$
18,014

 
$
17,448

 
$
30,290

Other comprehensive income:
 
 
 
 
 
 
 
Foreign currency translation adjustments
41,679

 
(18,424
)
 
60,522

 
19,512

Foreign other post-employment benefits adjustments, net of income taxes
(1,938
)
 
535

 
(2,053
)
 
(105
)
Net unrealized holding gains on available-for-sale (AFS) investments, net of income taxes
54,564

 
62,109

 
134,713

 
58,015

Other comprehensive income, net of income taxes
94,305

 
44,220

 
193,182

 
77,422

Comprehensive income
$
99,340

 
$
62,234

 
$
210,630

 
$
107,712




The accompanying notes are an integral part of these condensed consolidated financial statements.


6



BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands, unaudited)
 
Six Months Ended
 
June 30,
 
2017
 
2016
Cash flows from operating activities:
 
 
 
Cash received from customers
$
999,779

 
$
1,020,149

Cash paid to suppliers and employees
(970,116
)
 
(935,587
)
Interest paid, net
(10,315
)
 
(10,911
)
Income tax payments, net
(19,066
)
 
(11,085
)
Investment proceeds and miscellaneous receipts, net
13,947

 
12,810

Excess tax benefits from share-based compensation
—

 
(75
)
Payments for forward foreign exchange contracts, net
(8,029
)
 
(5,594
)
Net cash provided by operating activities
6,200

 
69,707

Cash flows from investing activities:
 
 
 
Capital expenditures
(64,951
)
 
(56,865
)
Proceeds from dispositions of property, plant and equipment
21

 
21

Payments for acquisitions and long-term investments
(73,573
)
 
(11,477
)
Payments for purchases of intangible assets
(3,920
)
 
(6
)
Payments for purchases of marketable securities and investments
(142,993
)
 
(148,423
)
Proceeds from sales of marketable securities and investments
39,362

 
42,386

Proceeds from maturities of marketable securities and investments
98,379

 
64,036

Net cash used in investing activities
(147,675
)
 
(110,328
)
Cash flows from financing activities:
 
 
 
Net payments on line-of-credit arrangements and notes payable
(36
)
 
—

Payments on long-term borrowings
(149
)
 
(156
)
Payments of contingent consideration
(3,105
)
 
(3,500
)
Proceeds from issuances of common stock for share-based compensation
3,778

 
6,875

Payments for purchases of treasury stock
(883
)
 
—

Excess tax benefits from share-based compensation
—

 
75

Net cash (used in) provided by financing activities
(395
)
 
3,294

Effect of foreign exchange rate changes on cash
7,190

 
(1,571
)
Net decrease in cash and cash equivalents
(134,680
)
 
(38,898
)
Cash and cash equivalents at beginning of period
456,264

 
457,549

Cash and cash equivalents at end of period
$
321,584

 
$
418,651

Reconciliation of net income to net cash used in operating activities:
 
 
 
Net income
$
17,448

 
$
30,290

Adjustments to reconcile net income to net cash used in operating activities:
 
 
 
Depreciation and amortization
70,688

 
71,668

Share-based compensation
10,579

 
9,407

Losses (gains) on dispositions of securities
310

 
(66
)
Excess tax benefits from share-based compensation
—

 
(75
)
Changes in fair value of contingent consideration
(8,700
)
 
(1,873
)
(Increase) decrease in accounts receivable
(1,849
)
 
32,067

Increase in inventories
(37,870
)
 
(50,979
)
Increase in other current assets
(14,878
)
 
(2,561
)
Decrease in accounts payable and other current liabilities
(24,160
)
 
(32,564
)
(Decrease) increase in income taxes payable
(13,208
)
 
11

(Decrease) increase in deferred income taxes
(3,057
)
 
4,060

Net decrease/increase in other long-term assets/liabilities
10,897

 
10,322

Net cash provided by operating activities
$
6,200

 
$
69,707

The accompanying notes are an integral part of these condensed consolidated financial statements.

7


BIO-RAD LABORATORIES, INC

Notes to Condensed Consolidated Financial Statements
(Unaudited)

1.BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2016.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.

Recent Accounting Standards Updates

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our condensed consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for

8


capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. In several foreign locations, we are statutorily required to provide a lump sum severance or termination indemnity to our employees and are currently evaluating the applicability of ASU 2017-07 to our situation.

In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. There was no impact of ASU 2017-04 on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the

9


carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principal on January 1, 2017, and made a policy election to account for forfeitures as they occur. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by $0.3 million, and increased Additional paid-in capital and Deferred tax assets by $0.4 million and $0.1 million, respectively, in the Condensed Consolidated Balance Sheet.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the condensed consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting

10


principle on January 1, 2017, which did not have a material impact on our condensed consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We are in the process of assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.


2.ACQUISITIONS

RainDance Technologies, Inc.
In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $76.6 million including certain assumed net liabilities. Cash payments at closing were $72.8 million. In addition, we had a cash payment of $10.0 million for a one-time expense associated with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.
The preliminary allocation of the payments were $10.0 million for the one-time expense, $35.0 million to purchased intangibles consisting primarily of a large patent and license portfolio, limited know how and customer relationships, $3.8 million to assumed net liabilities, and $36.2 million to goodwill. We recorded a deferred tax liability of $12.9 million related to the purchased intangibles and a deferred tax asset of $18.3 million related to the acquired net operating losses. The purchase price allocation is preliminary as additional time is required to complete the valuation of the intangibles.
RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers with solutions for a wide range of nucleic acid detection applications.

11



Propel Labs, Inc.

In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date.

The fair value of the consideration as of the acquisition date was $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel. The amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, and was recognized at its estimated fair value of $26.7 million as of June 30, 2017 (see Note 3, "Fair Value Measurements").

The fair values of the net assets acquired from Propel as of the acquisition date were determined to be $32.7 million of definite-lived intangible assets and $0.1 million of goodwill. The goodwill related to this acquisition will be deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology.

In addition, Bio-Rad contracted with Propel to provide development services concurrent with and included in the purchase agreement. Bio-Rad is receiving future manufacturing, engineering and marketing support from Propel on which payments will be made upon the successful completion of all contracted services. As a result, these services are not included in the total purchase consideration and a majority will be expensed in future periods.


3.FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2017 are classified in the hierarchy as follows (in millions):


12


 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
15.2

 
$
—

 
$
15.2

Foreign time deposits
12.4

 
—

 
—

 
12.4

Money market funds
4.6

 
—

 
—

 
4.6

Total cash equivalents (a)
17.0

 
15.2

 
—

 
32.2

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
201.7

 
—

 
201.7

U.S. government sponsored agencies
—

 
72.1

 
—

 
72.1

Foreign government obligations
—

 
3.0

 
—

 
3.0

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
13.8

 
—

 
13.8

Marketable equity securities
980.1

 
—

 
—

 
980.1

Asset-backed securities
—

 
58.1

 
—

 
58.1

Total available-for-sale investments (b)
980.1

 
352.3

 
—

 
1,332.4

Forward foreign exchange contracts (c)
—

 
0.4

 
—

 
0.4

Total financial assets carried at fair value
$
1,001.7

 
$
367.9

 
$
—

 
$
1,369.6

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.0

 
$
—

 
$
1.0

Contingent consideration (e)
—

 
—

 
26.7

 
26.7

Total financial liabilities carried at fair value
$
—

 
$
1.0

 
$
26.7

 
$
27.7




13


Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
14.1

 
$
—

 
$
14.1

Foreign time deposits
11.8

 
—

 
—

 
11.8

Domestic time deposits
—

 
20.0

 
—

 
20.0

U.S. government sponsored agencies
—

 
1.1

 
—

 
1.1

Money market funds
5.9

 
—

 
—

 
5.9

Total cash equivalents (a)
17.7

 
35.2

 
—

 
52.9

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
179.4

 
—

 
179.4

U.S. government sponsored agencies
—

 
82.5

 
—

 
82.5

Foreign government obligations
—

 
4.4

 
—

 
4.4

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
15.4

 
—

 
15.4

Marketable equity securities
767.8

 
—

 
—

 
767.8

Asset-backed securities
—

 
62.5

 
—

 
62.5

Total available-for-sale investments (b)
767.8

 
347.8

 
—

 
1,115.6

Forward foreign exchange contracts (c)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
790.1

 
$
383.6

 
$
—

 
$
1,173.7

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.3

 
$
—

 
$
1.3

Contingent consideration (e)
—

 
—

 
38.5

 
38.5

Total financial liabilities carried at fair value
$
—

 
$
1.3

 
$
38.5

 
$
39.8


(a)
Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

(b)
Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30,
2017
 
December 31, 2016
Short-term investments
$
391.3

 
$
383.2

Other investments
941.1

 
732.4

Total
$
1,332.4

 
$
1,115.6



(c)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.

(d)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.


14


(e)
Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
June 30, 2017
 
December 31, 2016
Other current liabilities
$
3.2

 
$
14.5

Other long-term liabilities
23.5

 
24.0

   Total
$
26.7

 
$
38.5



In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a cell sorting system from Propel. Since 2012, we have paid $32.0 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million. The remaining liability of $3.1 million was paid in February 2017.

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount through December 31, 2020. The contingent consideration was accrued at its estimated fair value of $26.7 million as of June 30, 2017.

The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):

January 1, 2017
$
28.5

Cell sorting system:
 
Payment of sales milestone
(3.1
)
 
 
Analytical flow cytometer platform:
 
Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense
1.3

June 30, 2017
$
26.7



The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of June 30, 2017. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
 
 
 
 
Valuation Technique
Unobservable Input
 
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
10.5
%
 
 
Cost of debt
4.3
%
 
 
 
 



In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The contingent

15


consideration was revalued to a fair value of $10.0 million as of December 31, 2016 and was reversed to selling, general and administrative expenses during the first quarter of 2017 due to reaching a favorable outcome with GnuBIO, Inc.

To estimate the fair value of Level 2 debt securities as of June 30, 2017 and December 31, 2016, our primary pricing provider uses S&P Capital IQ as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is S&P Capital IQ as the primary pricing source and then our custodian as the secondary pricing source. If S&P Capital IQ does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing.

For commercial paper as of June 30, 2017 and December 31, 2016, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par.

Our pricing provider performs daily reasonableness testing of the S&P Capital IQ prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the S&P Capital IQ prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
June 30, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
201.6

 
$
0.4

 
$
(0.3
)
 
$
201.7

Brokered certificates of deposit
3.6

 
—

 
—

 
3.6

Municipal obligations
13.8

 
—

 
—

 
13.8

Asset-backed securities
57.9

 
0.1

 
(0.1
)
 
57.9

U.S. government sponsored agencies
72.4

 
0.1

 
(0.4
)
 
72.1

Foreign government obligations
3.0

 
—

 
—

 
3.0

Marketable equity securities
32.5

 
7.0

 
(0.3
)
 
39.2

 
384.8

 
7.6

 
(1.1
)
 
391.3

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
886.4

 
—

 
940.9

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
886.4

 
—

 
941.1

Total
$
439.5

 
$
894.0

 
$
(1.1
)
 
$
1,332.4




16


 
December 31, 2016
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
179.7

 
$
0.2

 
$
(0.5
)
 
$
179.4

Brokered certificates of deposit
3.6

 
—

 
—

 
3.6

Municipal obligations
15.5

 
—

 
(0.1
)
 
15.4

Asset-backed securities
62.2

 
0.1

 
(0.1
)
 
62.2

U.S. government sponsored agencies
83.1

 
0.1

 
(0.7
)
 
82.5

Foreign government obligations
4.4

 
—

 
—

 
4.4

Marketable equity securities
32.4

 
3.7

 
(0.4
)
 
35.7

 
380.9

 
4.1

 
(1.8
)
 
383.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
677.6

 
—

 
732.1

Asset-backed securities
0.3

 
—

 
—

 
0.3

 
54.8

 
677.6

 
—

 
732.4

Total
$
435.7

 
$
681.7

 
$
(1.8
)
 
$
1,115.6



The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares.

The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
June 30,
2017
 
December 31, 2016
Fair value of investments in a loss position 12 months or more
$
8.1

 
$
11.8

Fair value of investments in a loss position less than 12 months
$
164.8

 
$
160.5

Gross unrealized losses for investments in a loss position 12 months or more
$
0.3

 
$
0.3

Gross unrealized losses for investments in a loss position less than 12 months
$
0.8

 
$
1.5



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at June 30, 2017 or at December 31, 2016.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of June 30, 2017 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income.

17



The following is a summary of our forward foreign exchange contracts (in millions):
 
June 30,
 
2017
Contracts maturing in July through September 2017 to sell foreign currency:
 
Notional value
$
76.8

Unrealized loss
$
0.2

Contracts maturing in July through September 2017 to purchase foreign currency:
 
Notional value
$
327.0

Unrealized loss
$
0.4



The following is a summary of the amortized cost and estimated fair value of our debt securities at June 30, 2017 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
156.2

 
$
156.2

Mature in one to five years
144.9

 
144.9

Mature in more than five years
51.4

 
51.2

Total
$
352.5

 
$
352.3



The estimated fair value of financial instruments that are not recognized at fair value in the Condensed Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which have fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):

 
June 30, 2017
 
December 31, 2016
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
93.7

 
$
1,265.8

 
2
 
$
92.8

 
$
984.2

 
2
Total long-term debt, excluding leases and current maturities
$
422.8

 
$
456.7

 
2
 
$
422.5

 
$
454.2

 
2


We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over 35% of the outstanding voting shares (excluding treasury shares) of Sartorius as of June 30, 2017.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ Board of Directors, nor do we have the ability to exercise significant

18


influence over the operating and financial policies of Sartorius.  We account for this investment using the cost method.  The carrying value of this investment is included in Other investments in our Condensed Consolidated Balance Sheets. As the stock is thinly traded and in conjunction with the valuation method discussed above, we have classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock.


4.GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1, 2017:
 
 
 
 
 
Goodwill
$
207.1

 
$
311.7

 
$
518.8

Accumulated impairment losses
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
179.9

 
297.2

 
477.1

 
 
 
 
 
 
Acquisitions
36.2

 
—

 
36.2

Currency fluctuations
0.4

 
16.6

 
17.0

 
 
 
 
 
 
Balances as of June 30, 2017:
 
 
 
 
 
Goodwill
243.7

 
328.3

 
572.0

Accumulated impairment losses
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
$
216.5

 
$
313.8

 
$
530.3



In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions), we recorded $36.2 million of goodwill and $35.0 million for licenses.

Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
June 30, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
90.0

 
$
(59.5
)
 
$
30.5

Know how
1-9
 
190.2

 
(149.2
)
 
41.0

Developed product technology
2-12
 
129.8

 
(63.3
)
 
66.5

Licenses
2-14
 
74.8

 
(33.9
)
 
40.9

Tradenames
4-7
 
3.6

 
(2.7
)
 
0.9

Covenants not to compete
2-9
 
7.9

 
(2.9
)
 
5.0

     Total definite-lived intangible assets
 
 
$
496.3

 
$
(311.5
)
 
$
184.8



19


 
December 31, 2016
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
84.4

 
$
(52.8
)
 
$
31.6

Know how
1-9
 
182.6

 
(136.9
)
 
45.7

Developed product technology
3-12
 
125.9

 
(56.3
)
 
69.6

Licenses
1-9
 
39.0

 
(30.6
)
 
8.4

Tradenames
4-8
 
3.5

 
(2.5
)
 
1.0

Covenants not to compete
2-9
 
7.8

 
(2.5
)
 
5.3

     Total definite-lived intangible assets
 
 
$
443.2

 
$
(281.6
)
 
$
161.6



Amortization expense related to purchased intangible assets is as follows (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
Amortization expense
$
8.7

 
$
9.6

 
$
15.6

 
$
19.0




5.PRODUCT WARRANTY LIABILITY

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):

January 1, 2017
$
17.6

Provision for warranty
13.9

Actual warranty costs
(13.8
)
June 30, 2017
$
17.7




20




6.    LONG-TERM DEBT

The principal components of long-term debt are as follows (in millions):

 
June 30,
2017
 
December 31, 2016
4.875% Senior Notes due 2020 principal amount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(2.2
)
 
(2.5
)
Long-term debt less unamortized discount and debt issuance costs
422.8

 
422.5

Capital leases and other debt
12.1

 
12.0

 
434.9

 
434.5

Less current maturities
(0.5
)
 
(0.3
)
Long-term debt
$
434.4

 
$
434.2




Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.

Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of June 30, 2017 or December 31, 2016, however $0.5 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of June 30, 2017. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the borrowing rate would have been 2.55% at June 30, 2017.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of June 30, 2017.

21




7.    ACCUMULATED OTHER COMPREHENSIVE INCOME

Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2017:
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
60.5

(2.5
)
213.2

271.2

Amounts reclassified from Accumulated other comprehensive income
—

—

—

—

Income tax effects
—

0.5

(78.5
)
(78.0
)
Other comprehensive income (loss), net of income taxes
60.5

(2.0
)
134.7

193.2

Balances as of June 30, 2017:
$
61.8

$
(20.6
)
$
569.7

$
610.9


 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2016:
$
33.7

$
(20.7
)
$
369.1

$
382.1

Other comprehensive income (loss), before reclassifications
19.5

(0.6
)
92.3

111.2

Amounts reclassified from Accumulated other comprehensive income
—

0.6

(0.5
)
0.1

Income tax effects
—

(0.1
)
(33.8
)
(33.9
)
Other comprehensive income (loss), net of income taxes
19.5

(0.1
)
58.0

77.4

Balances as of June 30, 2016:
$
53.2

$
(20.8
)
$
427.1

$
459.5



The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:

 
Income before taxes impact (in millions):
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
 
June 30,
 
June 30,
 
 
Components of Comprehensive income
 
2017
 
2016
 
2017
 
2016
 
Location
Amortization of foreign other post-employment benefit items
 
$
0.2

 
$
(0.3
)
 
$
—

 
$
(0.6
)
 
Selling, general and administrative expense
Net holding (losses) gains on available-for-sale investments
 
$
(0.2
)
 
$
0.5

 
$
—

 
$
0.5

 
Other (income) expense, net

Reclassification adjustments are calculated using the specific identification method.

22




8.    EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Basic weighted average shares outstanding
29,613

 
29,398

 
29,597

 
29,381

Effect of potentially dilutive stock options and restricted stock awards
393

 
191

 
365

 
168

Diluted weighted average common shares
30,006

 
29,589

 
29,962

 
29,549

Anti-dilutive shares
—

 
75

 
15

 
74




9.    OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Interest and investment income
$
(12.0
)
 
$
(10.6
)
 
$
(13.1
)
 
$
(11.9
)
Net realized loss (gain) on investments
0.2

 
(0.6
)
 
(0.1
)
 
(0.5
)
Other (income) expense, net
$
(11.8
)
 
$
(11.2
)
 
$
(13.2
)
 
$
(12.4
)



23



10.    INCOME TAXES
 
Our effective income tax rate was (350)% and 33% for the three months ended June 30, 2017 and 2016, respectively. Our effective income tax rate was 18% and 36% for the first half of 2017 and 2016, respectively. The effective tax rate for the second quarter of 2017 was unusually low because of discrete tax benefits related to share-based compensation and the transfer of intangibles associated with our European reorganization, combined with low earnings before tax. The effective tax rate for the first half of 2017 was lower primarily due to the second quarter discrete tax benefits.
  
Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate including Switzerland and Singapore have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35%.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

As of June 30, 2017, based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $3.5 million. Substantially all such amounts will favorably impact our effective income tax rate.
 
11.    SEGMENT INFORMATION

Information regarding industry segments for the three months ended June 30, 2017 and 2016 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2017
$
179.4

 
$
322.1

 
$
3.2

 
2016
$
180.0

 
$
333.7

 
$
3.1

 
 
 
 
 
 
 
Segment net (loss) profit
2017
$
(23.0
)
 
$
17.9

 
$
0.2

 
2016
$
(5.1
)
 
$
23.9

 
$
(0.3
)


Information regarding industry segments for the six months ended June 30, 2017 and 2016 is as follows (in millions):

24


 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2017
$
353.6

 
$
644.4

 
$
6.7

 
2016
$
345.8

 
$
635.4

 
$
6.8

 
 
 
 
 
 
 
Segment net (loss) profit
2017
$
(41.8
)
 
$
58.9

 
$
0.4

 
2016
$
(8.4
)
 
$
48.6

 
$
0.1



Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment.  During the second quarter of 2017, our Clinical Diagnostics segment had an asset purchase for an early stage device for $7.5 million that was recorded in Research and development expense. See Note 13 for a discussion of restructuring costs. The following reconciles total segment profit to consolidated income before taxes (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Total segment (loss) profit
$
(4.9
)
 
$
18.5

 
$
17.5

 
$
40.3

Foreign currency exchange losses, net
(2.5
)
 
(1.2
)
 
(4.3
)
 
(2.4
)
Net corporate operating, interest and other expense not allocated to segments
(3.3
)
 
(1.6
)
 
(5.1
)
 
(3.2
)
Other income (expense), net
11.8

 
11.2

 
13.2

 
12.4

Consolidated income before income taxes
$
1.1

 
$
26.9

 
$
21.3

 
$
47.1




12.    LEGAL PROCEEDINGS

On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our then current directors and one former director. We were also named as a nominal defendant. In the complaint, the plaintiff alleged that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors had been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff sought an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it was not in the best interests of the

25


Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption was City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”.

On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our then current directors and one former director. We were named as a nominal defendant in the complaints. The complaints alleged that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs asserted claims for breach of fiduciary duty and unjust enrichment and requested an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.

The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that set forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement included the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants did not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. The Court held a hearing for final approval of the settlement on March 2, 2017, and the Court approved the settlement.

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.

Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleges that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. We are cooperating with the District and are investigating the allegations. No formal proceeding has been initiated by the District.

26



We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


13.    RESTRUCTURING COSTS

For the three and six months ended June 30, 2017, we recorded less than $0.1 million related to restructuring actions that include the elimination or relocation of various positions. These actions are generally intended to streamline and focus our efforts and more properly align our cost structure with projected future revenue streams.
 
The following table summarizes the activity of our restructuring reserves for severance (in millions):
 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance at December 31, 2016
 
$
3.2

 
$
5.8

 
$
9.0

Charged to expense
 
—

 
—

 
—

Adjustment to expense
 
—

 
—

 
—

Cash payments
 
(0.7
)
 
(1.2
)
 
(1.9
)
Foreign currency translation losses
 
0.3

 
0.4

 
0.7

Balance at June 30, 2017
 
$
2.8

 
$
5.0

 
$
7.8



In May, 2016, management announced that it will take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded less than $0.1 million of adjustments in restructuring charges related to severance and other employee benefits for the three and six months ended June 30, 2017. The liability of $7.8 million as of June 30, 2017 encompassed a short-term liability of $5.2 million and a long-term liability of $2.6 million, and is anticipated to be paid through 2019. The amounts recorded were reflected in Cost of goods sold of less than $0.1 million and $(0.2) million, and in Selling, general and administrative expense of less than $0.1 million and $0.2 million in the Condensed Consolidated Statements of Income for the three and six months ended June 30, 2017, respectively. The amounts adjusted were primarily due to employees finding other positions within Bio-Rad or leaving prematurely.


27



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This discussion should be read in conjunction with the information contained in both our Consolidated Financial Statements for the year ended December 31, 2016 and the financial statements for the three and six months ended June 30, 2017.

Overview.  We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products.  Our business is organized into two reportable segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and clinical diagnostics.  

We sell more than 8,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components.  Because our customers require standardization for their experiments and test results, much of our revenues are recurring.  

We are impacted by the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control government social spending by many governments limits opportunities for growth. Adding to this uncertainty was the referendum in the United Kingdom to withdraw from the European Union, and a change in the U.S. executive branch of government. Approximately 39% of our year-to-date 2017 consolidated net sales are derived from the United States and approximately 61% are derived from international locations, with Europe being our largest international region.  The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens.  When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites as well as non-U.S. suppliers, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.

In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $76.6 million including certain assumed net liabilities. Cash payments at closing were $72.8 million. In addition, we had a cash payment of $10.0 million for a one-time expense associated with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers with solutions for a wide range of nucleic acid detection applications. See Note 2 to the condensed consolidated financial statements.

The preliminary allocation of the payments were $10.0 million for the one-time expense, $35.0 million to purchased intangibles consisting primarily of a large patent and license portfolio, limited know how and customer relationships, $3.8 million to assumed net liabilities, and $36.2 million to goodwill. We recorded a deferred tax liability of $12.9 million related to the purchased intangibles and a deferred tax asset of $18.3 million related to the acquired net operating losses. The purchase price allocation is preliminary as additional time is required to complete the valuation of the intangibles.

28



In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination and is included in our Life Science segment's results of operations from the acquisition date. The fair values of the net assets acquired from Propel as of the acquisition date were determined to be $32.7 million of definite-lived intangible assets and $0.1 million of goodwill.

The fair value of the consideration as of the acquisition date was $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel. The amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount through December 31, 2020. The contingent consideration was accrued at its estimated fair value of $26.7 million as of June 30, 2017.

The following shows cost of goods sold, gross profit, expense items and net income as a percentage of net sales:

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Net sales
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
Cost of goods sold
45.8

 
45.8

 
45.9

 
44.9

Gross profit
54.2

 
54.2

 
54.1

 
55.1

Selling, general and administrative expense
42.2

 
39.8

 
40.6

 
40.0

Research and development expense
12.4

 
9.6

 
11.2

 
10.0

Net income
1.0

 
3.5

 
1.7

 
3.1



Critical Accounting Policies and Estimates

As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016, we have identified accounting for income taxes, valuation of goodwill and long-lived assets, valuation of inventories, warranty reserves, valuation of investments, allowance for doubtful accounts and litigation accruals as the accounting policies and estimates critical to the operations of Bio-Rad.

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements.  Management believes that there have been no significant changes during the three and six months ended June 30, 2017 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.  For a full discussion of these policies and estimates, please refer to our Form 10-K for the period ended December 31, 2016 filed with the SEC.

29



Three Months Ended June 30, 2017 Compared to
Three Months Ended June 30, 2016

Results of Operations -- Sales, Margins and Expenses

Net sales (sales) for the second quarter of 2017 were $504.7 million compared to $516.8 million in the second quarter of 2016, a decrease of 2.3%.  Excluding the impact of foreign currency, second quarter 2017 sales decreased by approximately 1.6% compared to the same period in 2016.  Currency neutral sales decreased primarily in Europe and the U.S. In anticipation of going live with the third deployment of our global single instance ERP system in Western Europe that was implemented in April 2017, the sales decline during the second quarter of 2017, especially in Clinical Diagnostics, was impacted due to customers ordering essential products during the first quarter of 2017 to avoid disruption to their operations. Additionally, a slowing of productivity in our supply chain operations occurred associated with the transition to a new ERP system in Western Europe, which had a substantial negative impact on sales during the second quarter of 2017.

The Life Science segment sales for the second quarter of 2017 were $179.4 million, a decrease of 0.3% compared to the same period last year.  On a currency neutral basis, sales increased 0.3% compared to the second quarter in 2016. The currency neutral sales increase was primarily in our Droplet Digital™ PCR product line and the RainDance acquisition, partially offset by a decline in process chromatography mostly due to customer ordering patterns. Currency neutral sales increases occurred in North America and Asia Pacific, excluding Japan. Declines occurred in Europe that were related to the ERP deployment, and in Latin America.

The Clinical Diagnostics segment sales for the second quarter of 2017 were $322.1 million, a decrease of 3.5% compared to the same period last year.  On a currency neutral basis, sales decreased 2.7% compared to the second quarter in 2016.  Currency neutral sales decrease was primarily attributable to declines in infectious disease and immunohematology product lines, both with major manufacturing in Europe and participants in the current ERP deployment. On a geographic view, currency neutral sales for the quarter were down in Europe and the Americas, partially offset by growth in Asia Pacific.

Consolidated gross margins were 54.2% for the second quarter of 2017, were flat compared to 54.2% for the second quarter of 2016.  Included in the second quarter of 2016 was $1.7 million for restructuring costs. Life Science segment gross margins for the second quarter of 2017 decreased from the prior year period by approximately 1.9 percentage points primarily due to lower margins in cell biology, food science and gene expression, and higher acquisition intangible amortization, partially offset by antibody and protein quantification margin increases. Clinical Diagnostics segment gross margins for the second quarter of 2017 increased by approximately 0.8 percentage points from the same period last year. The increase compared to the second quarter of 2016 was primarily driven by lower amortization of intangibles and favorable manufacturing variances versus the prior year period.

Selling, general and administrative expenses (SG&A) increased to $213.0 million or 42.2% of sales for the second quarter of 2017 compared to $205.5 million or 39.8% of sales for the second quarter of 2016.  Increases to SG&A primarily included professional fees and other temporary support, primarily related to our latest ERP deployment, and increase for the inclusion of RainDance, facilities, contingent consideration and software. Employee-related expenses, our largest cost, included increased annual salary and benefit costs in the second quarter of 2017. Also during the current quarter, a transition took place from local sales and finance support to a new European shared services center, resulting in higher employee-related costs during the transition. Reductions in headcount and expense are expected to begin in the third quarter of 2017. In the second quarter of 2016, we recorded 10.0 million of restructuring costs associated with the European reorganization announced in June 2016 (see Note 13).

Research and development expense (R&D) increased to $62.6 million or 12.4% of sales in the second quarter of 2017 compared to $49.8 million or 9.6% of sales in the second quarter of 2016.  Life Science segment R&D increased in the second quarter of 2017 from the prior year period primarily due to milestone expense of $4.0

30


million in the second quarter of 2017 associated with the Propel 2016 acquisition, and increased project activities, including our recent RainDance acquisition. Clinical Diagnostics segment R&D increased in the second quarter of 2017 from the prior year period primarily driven by an asset purchase for an early stage diagnostic device for $7.5 million. During the second quarter of 2016, we impaired an intellectual property license associated with a R&D project for $2.4 million.

Results of Operations – Non-operating

Interest expense for the second quarter of 2017 increased to $5.8 million compared to $5.6 million for the second quarter of 2016 primarily due to lower capitalization of interest expense as the third deployment of our global single instance ERP platform was implemented in April 2017 in Europe. As we implement the remaining phases of the ERP platform, we expect capitalized interest to be lower going forward as the largest segments of our deployment are now complete.

Foreign currency exchange gains and losses consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk.  Foreign currency exchange losses, net for the quarter ended June 30, 2017 increased compared to the prior year period primarily due to the timing of product shipments and intercompany debt payments, and the higher cost of hedging.

Other (income) expense, net for the second quarter of 2017 increased to $11.8 million income compared to $11.2 million income for the second quarter of 2016. The increase was due to higher Sartorius dividends in 2017 for the ordinary and preferred shares of our investment in Sartorius AG, partially offset by lower investment income.

Our effective income tax rate was (350)% and 33% for the three months ended June 30, 2017 and 2016, respectively. The effective tax rate for the second quarter of 2017 was unusually low because of discrete tax benefits related to share-based compensation and the transfer of intangibles associated with our European reorganization, combined with low earnings before tax.

Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate including Switzerland and Singapore have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35%.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes in the mix of earnings in the U.S. and jurisdictions with tax rates lower than the U.S. statutory rate, tax benefits from share-based compensation, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and tax credits.

As of June 30, 2017, based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $3.5 million. Substantially all such amounts will positively impact our effective income tax rate.

31



Six Months Ended June 30, 2017 Compared to
Six Months Ended June 30, 2016

Results of Operations -- Sales, Margins and Expenses

Net sales (sales) for the first half of 2017 were $1.0 billion compared to $988.0 million in the first half of 2016, an increase of 1.7%.  Excluding the impact of foreign currency, the first half of 2017 sales increased by approximately 2.3% compared to the same period in 2016.  Currency neutral sales increased primarily in Asia Pacific, excluding Japan. Sales were impacted by our transition to a new global ERP system in Western Europe in April 2017, causing a decrease in our supply chain operations.

The Life Science segment sales for the first half of 2017 were $353.6 million, an increase of 2.3% compared to the same period last year.  On a currency neutral basis, sales increased 3.2% compared to the first half of 2016. The currency neutral sales increase was primarily in our Droplet Digital™ PCR product line and the RainDance acquisition, partially offset by a decline in process chromatography mostly due to customer ordering patterns. The currency neutral sales increase was primarily reflected in Asia Pacific, excluding Japan, partially offset by declines in Latin America.

The Clinical Diagnostics segment sales for the first half of 2017 were $644.4 million, an increase of 1.4% compared to the same period last year.  On a currency neutral basis, sales increased 1.9% compared to the first half of 2016.  The currency neutral sales increase was primarily attributable to growth across immunology, diabetes and quality control product lines. On a geographic view, currency neutral sales for the first half of 2017 were up in Asia Pacific, and slightly down in North America and Europe.

Consolidated gross margins were 54.1% for the first half of 2017 compared to 55.1% for the first half of 2016. Included in the first half of 2016 was $1.7 million for restructuring costs. Life Science segment gross margins for the first half of 2017 decreased from the prior year period by approximately 3.3 percentage points primarily due to a $10.0 million one-time expense associated with the RainDance acquisition and higher acquisition intangible amortization, partially offset by higher margins in antibody, gene expression, protein quantification, and a decline in royalty expense for a license agreement relating to amplification reagents. Clinical Diagnostics segment gross margins for the first half of 2017 increased by approximately 0.2 percentage points from the same period last year. The increase compared to the first half of 2016 was primarily driven by lower amortization of intangibles and favorable manufacturing variances.

Selling, general and administrative expenses (SG&A) increased to $408.0 million or 40.6% of sales for the first half of 2017 compared to $395.3 million or 40.0% of sales for the first half of 2016.  Increases to SG&A primarily included employee-related expenses, our largest cost, primarily due to increased annual salary and benefit costs starting in the second quarter of 2017. Also during the current quarter, a transition took place from local sales and finance support to a new European shared services center, resulting in higher employee-related costs during the transition. Reductions in headcount and expense are expected to begin in the third quarter of 2017. In the second quarter of 2016, we recorded $10.0 million of restructuring costs associated with the European reorganization announced in June 2016 (see Note 13). Other increases in the first half of 2017 compared to the prior year period were in professional fees and other temporary support, primarily for the third ERP deployment, and increases for the inclusion of RainDance, facilities and software. These expenses were partially offset by a benefit for contingent consideration. Beginning in June of 2017 and as announced in June 2016 (see Note 13), a reduction in force began, in accordance with various local social plans that will produce future costs reductions from our current level.

Research and development expense (R&D) increased to $112.1 million or 11.2% of sales in the first half of 2017 compared to $98.4 million or 10.0% of sales in the first half of 2016.  Life Science segment R&D increased in the first half of 2017 from the prior year period primarily due to a milestone expense of $4.0 million in the second quarter of 2017 associated with the Propel 2016 acquisition, and increased project activities, including our recent RainDance acquisition. Clinical Diagnostics segment R&D increased in the first half of 2017 from the prior year

32


period primarily driven by an asset purchase for an early stage diagnostic device for $7.5 million. During the second quarter of 2016, we impaired an intellectual property license associated with a R&D project for $2.4 million.


Results of Operations – Non-operating

Interest expense for the first half of 2017 decreased to $10.8 million compared to $11.2 million for the first half of 2016 primarily due to higher capitalization of interest expense associated with the third deployment of our global single instance ERP platform that was implemented in April 2017 in Western Europe. Capitalized interest primarily ceased during the second quarter of 2017 with the implementation of the third deployment of our global ERP platform. As we implement the remaining phases of the ERP platform, we expect capitalized interest to be lower going forward as the largest segments of our deployment are now complete.

Foreign currency exchange gains and losses consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk.  Foreign currency exchange losses, net for the first half of 2017 increased compared to the prior year period primarily due to the timing of product shipments and intercompany debt payments.

Other (income) expense, net for the first half of 2017 increased to $13.2 million income compared to $12.4 million income for the first half of 2016. The increase was due to higher Sartorius dividends in 2017 for the ordinary and preferred shares of our investment in Sartorius AG, partially offset by lower investment income.

Our effective income tax rate was 18% and 36% for the six months ended June 30, 2017 and 2016, respectively. The effective tax rate for the first half of 2017 was lower primarily because of discrete tax benefits related to share-based compensation and the transfer of intangibles associated with our European reorganization.

Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate including Switzerland and Singapore have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35%.

Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes in the mix of earnings in the U.S. and jurisdictions with tax rates lower than the U.S. statutory rate, tax benefits from share-based compensation, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and tax credits.


33



Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade.  Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world.  Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price.  Gross margins are generally sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.  Also, additional liquidity is readily available via the sale of short-term investments and access to our domestic $200.0 million unsecured Credit Agreement, and to a lesser extent international lines of credit. Borrowings under the 2014 Credit Agreement are available on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of June 30, 2017, however $0.5 million was utilized for domestic standby letters of credit that reduced our borrowing availability.  The Credit Agreement matures in June 2019. In total under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had approximately $207.8 million available for borrowing and usage as of June 30, 2017, which was reduced by approximately $4.4 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and an acquisition of reasonable proportion to our existing total available capital.

At June 30, 2017, we had $712.9 million in cash, cash equivalents and short-term investments, of which approximately 31% was held in our foreign subsidiaries. We believe that our holdings of cash, cash equivalents and short-term investments in the U.S. and in our foreign subsidiaries are sufficient to meet both the current and long-term needs of our global operations. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows). Repatriation of overseas funds will result in additional U.S. federal and state income tax payments. In general, it is our practice and intention to indefinitely reinvest the cash generated by our foreign subsidiaries in our foreign subsidiaries' operations.

Demand for our products and services could change more dramatically than in previous years based on activity, funding, reimbursement constraints and support levels from government, universities, hospitals and private industry, including diagnostic laboratories.  The need for certain sovereign nations with large annual deficits to curtail spending could lead to slower growth of, or even a decline in, our business. Sovereign nations either delaying payment for goods and services or renegotiating their debts could impact our liquidity. As of June 30, 2017 and December 31, 2016, we had accounts receivable, net of an allowance for doubtful accounts, in Spain, Italy, Greece and Portugal of $39.9 million and $32.7 million, respectively. While economic growth is improving in some geographical locations, instability still exists in some of the developed nations, such as a less dependable rate of growth in the Chinese economy and in emerging markets, especially those oil producing countries that have been affected by a decline in oil prices, which may adversely affect our future cash flows.

34




Cash Flows from Operations

Net cash provided by operations was $6.2 million compared to $69.7 million for the six months ended June 30, 2017 and 2016, respectively.  The decrease in operating cash flows was primarily the net effect of:
•
more cash paid to suppliers to close open purchase orders received and related payables to minimize the transition for the third deployment of our ERP system that was implemented in April 2017, and an asset purchase for an early stage diagnostic device for $7.5 million,
•
lower cash received from customers in 2017 primarily due to the implementation of our current ERP deployment, a transitioning workforce, and there was higher cash received in 2016 that resulted from delays in the latter part of 2015 associated with the second deployment of the ERP system,
•
higher income tax payments in 2017 compared to 2016 as 2016 included refunds of $12.1 million of U.S. federal income taxes, and
•
higher net payments in 2017 compared to 2016 for forward foreign exchange contracts.

Cash Flows from Investing Activities

Net cash used in investing activities was $147.7 million compared to $110.3 million for the six months ended June 30, 2017 and 2016, respectively. The increase of payments for acquisitions and long-term investments was primarily due to more cash paid for the acquisition of RainDance Technologies, Inc. in February 2017 than the acquisition of a high performance analytical flow cytometer platform from Propel in January 2016. Capital expenditures were higher for the six months ended June 30, 2017 compared to the same period last year, reflecting the third phase of the ERP system that was completed in April 2017, in addition to more routine items included in capital expenditures listed below. Purchase of intangibles increased primarily due to a $3.9 million payment for an acquired technology and know-how to expand our product offerings. Purchases, sales and maturities of marketable securities and investments combined had an overall increase of $36.7 million primarily due to increases in maturities and lower purchases, slightly offset by lower security sales.

Our investment objective is to maintain liquidity to meet anticipated operational and other corporate requirements in which capital is preserved and increased through investing in low risk, high quality securities with commensurate returns, consistent with our risk tolerance level.

We continue to review possible acquisitions to expand both our Life Science and Clinical Diagnostics segments. We routinely meet with the principals or brokers of the subject companies.  We are currently in discussion and assessing a few possible acquisitions in which we expect our current reported cash and cash equivalents to be sufficient for any cash consideration required for these possible acquisitions. However, it is not certain at this time that any of these discussions involving material or significant acquisitions will advance to completion.

Capital expenditures totaled $65.0 million and $56.9 million for the six months ended June 30, 2017 and 2016, respectively.  Capital expenditures represent the addition and replacement of production machinery and research equipment, ongoing manufacturing and facility additions for expansion, regulatory, environmental and compliance. Also included in capital expenditures are investments in business systems and data communication upgrades and enhancements.  All periods include equipment placed with Clinical Diagnostics segment customers who then contract to purchase our reagents for use. As we continue to implement the remaining phases of the ERP platform, we expect capital expenditures to moderate in 2017. The current estimated future project cost for global implementation for the single instance ERP platform is projected to be $100 million to $130.0 million, and is estimated to take approximately the next three to four years to fully implement.

35



Cash Flows from Financing Activities

Net cash used in financing activities was $0.4 million compared to net cash provided by $3.3 million for the six months ended June 30, 2017 and 2016, respectively. This decrease for the six months ended June 30, 2017 was primarily due to a decrease in proceeds from the issuance of common stock, and repurchases of Bio-Rad's common stock as indicated below, slightly offset by lower payments of contingent consideration.

We have outstanding Senior Notes of $425 million, which are not due until 2020. We believe the current cash is sufficient to meet normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.

The Board of Directors has authorized the repurchase of up to $18.0 million of Bio-Rad's common stock, of which $2.3 million has yet to be repurchased as of June 30, 2017. During the second quarter of 2017, we made open market purchases of 4,000 shares of our Class A common stock. We made these purchases in order to obtain a tax deduction in some of our foreign entities associated with vesting restricted stock units. The Credit Agreement may limit our ability to repurchase our stock. In prior periods, we withheld 122 shares of our Class A common stock and 917 shares of our Class B common stock to satisfy tax obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of our stock.

Recent Accounting Standards Updates

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our condensed consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. In several foreign locations, we are statutorily required to provide a lump sum severance or termination indemnity to our employees and are currently evaluating the applicability of ASU 2017-07 to our situation.

In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. There was no impact of ASU 2017-04 on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.


36


In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principal on January 1, 2017, and made a policy election to account for forfeitures as they occur. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by $0.3 million, and increased Additional paid-in capital and Deferred tax assets by $0.4 million and $0.1 million, respectively, in the Condensed Consolidated Balance Sheet.


37


In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the condensed consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting principle on January 1, 2017, which did not have a material impact on our condensed consolidated financial statements.

38



In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We are in the process of assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.



Item 3. Quantitative and Qualitative Disclosures about Market Risk

During the six months ended June 30, 2017, there have been no material changes from the disclosures about market risk provided in our Annual Report on Form 10-K for the year ended December 31, 2016.


Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.



39


Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the CEO and CFO have concluded that, as of such date, our disclosure controls and procedures were effective to meet the objective for which they were designed and operate at the reasonable assurance level.

Changes to Internal Control Over Financial Reporting

During our quarter ended June 30, 2017, we launched our third deployment of the SAP enterprise resource planning system ("ERP") in Western Europe to support our billing, revenue, inventory management and purchase processes. The implementation of the ERP resulted primarily in changes to reports, interfaces and IT dependent controls. Therefore, we have modified the design and documentation of internal control processes and procedures relating to the new systems to enhance existing internal controls. The system changes were undertaken as an ongoing business initiative to integrate systems amongst our global operations and improve and enhance our internal control over financial reporting and were not undertaken in response to any actual or perceived deficiencies in our internal control over financial reporting.

Except as described in the previous paragraph, we identified no changes in internal control over financial reporting during our quarter ended June 30, 2017 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.


PART II – OTHER INFORMATION

Item 1. Legal Proceedings

See Note 12, “Legal Proceedings” in the Notes to Condensed Consolidated Financial Statements of Part I, Item 1 of this Quarterly Report on Form 10-Q.


Item 1A. Risk Factors

Our settlement with government agencies in connection with violations by us of the U.S. Foreign Corrupt Practices Act could have a material adverse effect on our business, results of operations and financial condition.

As previously disclosed, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) and consented to the entry of an Order by the SEC (SEC Order), effective November 3, 2014, which actions resolved both the DOJ and the SEC investigations into our violations of the U.S. Foreign Corrupt Practices Act (FCPA). Under the terms of the NPA and the SEC Order, we agreed to pay a financial penalty and certain amounts in disgorgement and interest as well as to compliance, reporting and cooperation obligations to be performed for two years. On October 28, 2016, the DOJ and SEC informed Bio-Rad that they did not intend to extend the NPA after it expired November 2, 2016.

Whether by virtue of disclosure of the NPA and the SEC Order or otherwise, we may be subject to investigations by foreign governments or further claims by third parties arising from conduct subject to the investigation or our other international operations. For additional information regarding further claims by third parties, see Note 12, “Legal Proceedings” in the Notes to Condensed Consolidated Financial Statements of Part I, Item 1 of this Quarterly Report on Form 10-Q. Many of our customers in our significant international operations are government agencies or state-owned or state-controlled universities, hospitals and laboratories. The disclosure of the NPA and the SEC Order could harm our reputation with these customers, which could materially adversely affect our business, results of operations and financial condition.


40


Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.

We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and during the first six months of 2017 our foreign subsidiaries generated 61% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements (including with respect to the invalidation of the U.S.-European Union safe harbor by the European Court of Justice in October 2015, compliance with the EU-U.S. Privacy Shield adopted by the European Commission in July 2016, and the requirements for compliance with the EU General Data Protection Regulation, which takes effect May 25, 2018), labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, export requirements, U.S. laws such as the FCPA and other U.S. federal laws and regulations established by the office of Foreign Asset Control, local laws such as the UK Bribery Act 2010 or other local laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers.

Given the high level of complexity of these laws, there is a risk that we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with our global policies and procedures.

Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. See also our risk factor regarding government regulations below.

The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively.

The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have merged, and some of our competitors have greater financial resources than we do and are less leveraged than we are, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition. 

We may not be able to grow our business because of our failure to develop new or improved products.

Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new product lines and extensions that integrate technological advances. In particular, we may not be able to keep up with changes in the clinical diagnostics industry, such as the trend toward molecular diagnostics or point-of-care tests. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new product lines and extensions successfully and in a timely manner, our business, results

41


of operations and financial condition will be adversely affected. We have experienced product launch delays in the past, and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition.

We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition.

As stated above, a significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies, such as the Swiss Franc, Brazilian Real and Russian Ruble, may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition.

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. For example, we experienced system implementation issues in our Clinical Diagnostics segment during our first deployment that impacted invoicing and caused an increase in accounts receivable. In our second deployment, we experienced delays in manufacturing and logistics, which adversely impacted our sales. We launched our third deployment in Western Europe in April 2017. We have experienced system implementation issues impacting the timing of payment of vendor invoices and resulting in delays in product availability and shipments. We also have experienced lower productivity levels related to the recent go-live of the ERP in Western Europe, which adversely impacted our sales during the second quarter of 2017. The third deployment was more complex than our prior deployments due to its scope. While we invested significant resources in planning, project management and training, additional and significant implementation issues may arise. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may continue to disrupt our operations and negatively impact our business, results of operations and financial condition.

Recent and planned changes to our organizational structure and executive management team could negatively impact our business.

We made significant changes to our organizational structure in 2014, 2015 and 2016, and we are continuing to make significant organizational changes in 2017. In 2014 and 2015, we functionalized our manufacturing and selling organizations globally and separated them from our marketing and research and development organizations. Specifically, we combined our international selling organization with our North American selling divisions into one global selling group and consolidated our manufacturing, procurement and logistics operations into one global supply chain group. We also created new management positions to head each of these groups. In addition, we appointed new executives to head each of our Life Science and Clinical Diagnostics segments, and we appointed a Chief Operating Officer. We also restructured our Life Science segment based on functional groups rather than product line divisions. In 2016, we began implementing the reorganization of the structure of our European organization. We continue to implement the reorganization of our European organization in 2017. These changes

42


may have unintended consequences, such as distraction of our management and employees, business disruption, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.

Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.

Maintaining effective internal control over financial reporting is necessary for us to produce reliable financial statements. We previously identified different material weaknesses in internal controls at December 31, 2013, December 31, 2012 and December 31, 2010, each of which has been remediated. We cannot assure you that additional material weaknesses in our internal control over financial reporting will not be identified in the future.

Such material weaknesses have adversely affected us in the past and could affect us in the future, and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to maintain new and more precise monitoring controls and improved detection and communication of financial misstatements across all levels of the organization could result in additional material weaknesses, result in material misstatements in our financial statements and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence, and could cause the trading price of our common stock to decline. For further information regarding our controls and procedures, see Part I, Item 4 of this Quarterly Report on Form 10-Q.

Breaches of our information systems could have material adverse effect on our business and results of operations.

Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our Web site. We also acquire and retain information about suppliers and employees in the normal course of business. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. Computer hackers may attempt to penetrate our or our vendors’ information systems and, if successful, misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our ERP implementation above and our information technology systems below.

Risks relating to intellectual property rights may negatively impact our business.

We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products.  However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us.  For instance, unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future.  Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important

43


to us, and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages to an infringed party.  Any of the foregoing matters could adversely impact our business, results of operations and financial condition.

Global economic conditions could continue to adversely affect our operations.

In recent years, we have been faced with very challenging global economic conditions. Further deterioration in the global economic environment may result in decreased demand for our products, increased competition, downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply in the future. We have also experienced delays in collecting receivables in certain countries in Western Europe, and we may experience similar delays in these and other countries or regions experiencing liquidity problems. As of June 30, 2017, we had accounts receivable, net of allowance for doubtful accounts, in Spain, Italy, Greece and Portugal of $39.9 million. In addition, a slowing of growth in the Chinese economy and in emerging markets, especially those oil-producing countries that have been affected by the decline in oil prices, could adversely affect our business, results of operations or financial condition. We also are monitoring developments following the United Kingdom's decision to leave the European Union to determine if there will be any potential impact on our business.

Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition.

Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies.  The capital spending programs of these institutions and companies have a significant effect on the demand for our products.  Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods.  If government funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected.
 
Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.

There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include:

•
The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices.  Consolidation among healthcare providers has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage.  In particular, there has been a consolidation of blood transfusion centers, as well as an industry decline in the number of blood transfusions. These industry trends and competitive forces place constraints on the levels of overall pricing, and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets.

•
Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers

44


for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Clinicians may decide not to order clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 will make significant changes to the way Medicare will pay for clinical laboratory services, which will further reduce reimbursement rates.

•
The PPACA has also imposed a 2.3% excise tax on the sales of certain medical devices in the U.S., which we are required to pay on most of our United States Clinical Diagnostic sales. However, the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), signed into law on December 18, 2015, includes a two year moratorium on the medical device excise tax during the period beginning on January 1, 2016, and ending on December 31, 2017.

To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the Protecting Access to Medicare Act of 2014, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected.  If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.

We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.

Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts.  The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.

The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Changes in the FDA’s review of certain clinical diagnostic products referred to as laboratory developed tests, which are tests developed by a single laboratory for use only in that laboratory, could affect some of our customers who use our Life Science instruments for laboratory developed tests. In the past, the FDA has chosen to not enforce applicable regulations and has not reviewed such tests for approval. However, the FDA has issued draft guidance that it may begin enforcing its medical device requirements, including premarket submission requirements, to such tests. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.

45



Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. For example, in April 2017 the European Parliament voted to enact final regulations that include broad changes to its regulations regarding in vitro diagnostic devices and medical devices, including stricter product labeling requirements, Russia has recently enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, reduced sales and potential fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Specifically, a resolution passed by Russia in February 2015 prohibited the procurement of certain types of medical devices by Russian state entities from foreign companies provided there are a sufficient number of Russian manufacturers submitting tenders. In December 2016, Russia continued its focus on import substitution by passing a resolution that added to the list of certain medical devices which participate in state procurement on a restricted basis. Such regulations could adversely affect our business, results of operations and financial condition.

We are also subject to government regulation of the use and handling of a number of materials and controlled substances.  The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.

We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.

As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. In order to be successful in these activities, we must, among other things:
•
assimilate the operations and personnel of acquired companies;
•
retain acquired business customers;
•
minimize potential disruption to our ongoing business;
•
retain key technical and management personnel;
•
integrate acquired companies into our strategic and financial plans;
•
accurately assess the value of target companies, products and technologies;
•
comply with new regulatory requirements;
•
harmonize standards, controls, procedures and policies;
•
minimize the impact to our relationships with our employees and customers; and
•
assess, document and remediate any deficiencies in disclosure controls and procedures and internal control over financial reporting.

The benefits of any acquisition may prove to be less than anticipated and may not outweigh the costs reported in our financial statements.  Completing any potential future acquisitions could cause significant diversion of our management’s time and resources.  If we acquire new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions, and any such acquisitions could adversely affect our business, results of operations and financial condition.

46



Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.

We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.

Lack of key personnel could hurt our business.

Our products are very technical in nature. In general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills.  In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job market in Northern California, where many of our employees are located, is very competitive. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business.

In some cases we rely on temporary personnel or consultants, and we may do so in the future. Such temporary personnel or consultants may lack the knowledge and/or specific skills necessary for our business, require time to train without benefiting us through extended employment and increase our costs. In addition, as noted above, our strategic initiatives, such as our internal restructuring and ERP implementation, may be burdensome and disruptive and lead to employee dissatisfaction and attrition.

A reduction or interruption in the supply of components and raw materials could adversely affect our manufacturing operations and related product sales.

The manufacture of many of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. In addition, due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. If our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner could be adversely affected, which would adversely affect our ability to sell our products.

If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed.

Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT systems could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory and collect accounts receivable.  Our IT systems also

47


allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service.  We may experience disruption of our IT systems due to redundancy issues with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency.

Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes.  We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business.  We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our ERP implementation and data security above and events beyond our control below.

Natural disasters, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.

We have significant manufacturing and distribution facilities, including in the western United States, France, Switzerland, Germany and Singapore.  In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years.  These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business.

Acts of terrorism, bioterrorism, violence or war could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. In particular, the political turmoil in Ukraine, along with the response of the Russian and U.S. governments to this situation, has the potential to impact our operations in Russia. Any of these events could adversely affect our business, results of operations and financial condition.

Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.

We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant.  We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal.  We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.

48



We may be subject to additional tax liabilities.

We are subject to income taxes in the United States and many foreign jurisdictions. We calculate our provision for income taxes in each jurisdiction in which we operate. Significant judgment is required in determining our worldwide provision for income taxes and in the ordinary course of business, there are many tax positions taken where the ultimate resolution is uncertain. We are subject to the examination of our tax positions in the United States and foreign jurisdictions. Taxing authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on our consolidated financial statements in the period or periods for which that determination is made. Changes in factors outside of our control, such as changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.

Our debt may restrict our future operations.

We have substantial debt and have the ability to incur additional debt. As of June 30, 2017, we had approximately $434.9 million of outstanding indebtedness. In addition, we have a revolving credit facility that provides for up to $200.0 million, $0.5 million of which has been utilized for domestic standby letters of credit. Our incurrence of substantial amounts of debt may have important consequences.  For instance, it could:

•
make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;
•
require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;
•
increase our vulnerability to general adverse economic and industry conditions;
•
limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;
•
place us at a competitive disadvantage compared with some of our competitors that have less debt; and
•
limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.

Our existing credit facility and the terms of our other debt instruments, including agreements we may enter in the future, contain or will contain covenants imposing significant restrictions on our business.  These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise.  These covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test.

Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions.  The breach of any of these restrictions could result in a default.  An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest. In addition, acceleration of our other indebtedness may cause us to be unable to make interest payments on our outstanding notes and repay the principal

49


amount of our outstanding notes or may cause the future subsidiary guarantors, if any, to be unable to make payments under the guarantees.

We are subject to healthcare fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.

We are subject to healthcare fraud and abuse regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example:

•
the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs;

•
U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;

•
the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;

•
the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and

•
state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.

We may incur losses in future periods due to write-downs in the value of financial instruments.
We have positions in a variety of financial instruments including asset backed securities and other similar instruments. Financial markets are quite volatile and the markets for these securities can be illiquid.  The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions or other market considerations.

50



Regulations related to “conflict minerals” could adversely impact our business.
As part of the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC adopted disclosure requirements regarding the use of certain minerals, known as conflict minerals, which are mined from the Democratic Republic of Congo (DRC) and adjoining countries, as well as procedures regarding a manufacturer's efforts to identify the sourcing of such minerals and metals produced from those minerals. In March and April 2017, the European Parliament and the European Council formally approved a conflict minerals regulation, and the requirements will become effective starting in January 2021. We have incurred, and will continue to incur, additional costs in order to comply with the SEC’s disclosure requirements. In addition, we might incur further costs due to possible changes to our products, processes, or sources of supply as a consequence of our due diligence activities. As our supply chain is complex, we may not be able to sufficiently verify the origins of the specified minerals used in our products through our due diligence procedures, which may harm our reputation. In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as “DRC conflict free”, which could place us at a competitive disadvantage if we do not do so. We filed our report for the calendar year 2016 with the SEC on May 10, 2017.

Risks related to our common stock
 
A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.
We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class.  When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors.

As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company.  The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.


Item 3. Defaults Upon Senior Securities

None.


Item 4. Mine Safety Disclosures

Not applicable.


Item 5. Other Information

None.

51





Item 6. Exhibits

(a)  Exhibits

The following documents are filed as part of this report:

Exhibit
No.
 
 
 
31.1
 
 
31.2
 
 
32.1
 
 
32.2
 
 
10.1
 
 
101.INS
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
 
 
101.SCH
XBRL Taxonomy Extension Schema Document
 
 
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
 
 
101.LAB
XBRL Taxonomy Extension Labels Linkbase Document

 
 
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
 
 


52



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.

BIO-RAD LABORATORIES, INC.
(Registrant)
 
 
 
 
Date:
August 7, 2017
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board,
 
 
 
President and Chief Executive Officer
 
 
 
 
Date:
August 7, 2017
 
/s/ Christine A. Tsingos
 
 
 
Christine A. Tsingos, Executive Vice President,
 
 
 
Chief Financial Officer

53
 EX-10.1 2 ex1017272017.htm EXHIBIT 10.1 FORM OF INDEMNIFICATION AGREEMENT Exhibit

Exhibit 10.1

INDEMNIFICATION AGREEMENT

This Indemnification Agreement (the “Agreement”) dated as of ____________, is by and between Bio-Rad Laboratories, Inc., a Delaware corporation (the “Company”), and ______________________ (the “Indemnitee”).

RECITALS

A.    The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and key employees, the significant increases in the cost of such insurance and the general reductions in the coverage of such insurance.

B.    The Company and Indemnitee further recognize the substantial increase in corporate litigation in general, subjecting directors, officers and key employees to expensive litigation risks at the same time as the availability and coverage of liability insurance has been severely limited.

C.    The Company and Indemnitee further recognize that it is standard for corporations to indemnify their officers and directors to the fullest extent available under the law.

D.    The Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, and to indemnify its directors, officers and key employees so as to provide them with the maximum protection permitted by law.

In consideration of the mutual promises made in this Agreement, and for other good and valuable consideration, receipt of which is hereby acknowledged, the Company and Indemnitee hereby agree as follows:

AGREEMENT

1.Indemnification.

(a)    Third Party Proceedings. The Company shall indemnify Indemnitee if Indemnitee was, is, or is threatened to be made a party to or a participant (as a witness or otherwise) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee while an officer or director or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement (if such settlement is approved in advance by the Company, which

1

approval shall not be unreasonably withheld) actually and reasonably incurred by Indemnitee in connection with such action, suit or proceeding if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe Indemnitee’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, or, with respect to any criminal action or proceeding, that Indemnitee had reasonable cause to believe that Indemnitee’s conduct was unlawful.

(b)    Proceedings By or in the Right of the Company. To the fullest extent permitted by law, the Company shall indemnify Indemnitee if Indemnitee was, is, or is threatened to be made a party to or a participant (as a witness or otherwise) in any threatened, pending or completed action or proceeding by or in the right of the Company or any subsidiary of the Company to procure a judgment in its favor by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee while an officer or director or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees) and amounts paid in settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld), in each case to the extent actually and reasonably incurred by Indemnitee in connection with the defense or settlement of such action or suit if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and its stockholders. Except as permitted by law, no indemnification shall be made in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudicated by court order or judgment to be liable to the Company in the performance of Indemnitee’s duty to the Company and its stockholders unless and only to the extent that the court in which such action or proceeding is or was pending shall determine upon application that, in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

(c)    Mandatory Payment of Expenses. To the extent that Indemnitee has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 1(a) or Section 1(b) or the defense of any claim, issue or matter therein, Indemnitee shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by Indemnitee in connection therewith.

2.No Employment Rights. Nothing contained in this Agreement is intended to create in Indemnitee any right to continued employment.


2


3.Expenses; Indemnification Procedure.

(a)    Advancement of Expenses. Except as otherwise provided in this Agreement, at the written request of Indemnitee, the Company shall advance all expenses incurred by Indemnitee in connection with the investigation, defense, settlement or appeal of any civil or criminal action, suit or proceeding referred to in Section l(a) or Section 1(b) hereof (including amounts actually paid in settlement of any such action, suit or proceeding). Indemnitee hereby undertakes to repay such amounts advanced only if, and to the extent that, it shall ultimately be determined that Indemnitee is not entitled to be indemnified by the Company as authorized hereby.

(b)    Notice/Cooperation by Indemnitee. Indemnitee shall, as a condition precedent to his or her right to be indemnified under this Agreement, give the Company notice in writing as soon as practicable of any claim made against Indemnitee for which indemnification will or could be sought under this Agreement. Notice to the Company shall be directed to the General Counsel of the Company and shall be given in accordance with the provisions of Section 12(d) below. In addition, Indemnitee shall give the Company such information and cooperation as it may reasonably require and as shall be within Indemnitee’s power.

(c)    Procedure. Any indemnification and advances provided for in Section 1 and this Section 3 shall be made no later than thirty (30) days after receipt of the written request of Indemnitee unless a determination is made within said thirty (30) day period that Indemnitee has not met the relevant standards for indemnification set forth in this Agreement. Such a determination shall be made, at the election of the Company’s board of directors, (i) by a majority vote of disinterested directors, even if less than a quorum, (ii) by a committee of disinterested directors designated by a majority vote of the disinterested directors, even if less than a quorum, or (iii) by independent legal counsel in a written opinion (which counsel shall be appointed by a quorum of the board of directors). For purposes of this section, disinterested directors are those members of the Company’s board of directors who are not parties to the proceeding in respect of which indemnification is being sought by Indemnitee.

If a claim under this Agreement, under any statute, or under any provision of the Company’s Certificate of Incorporation or Bylaws providing for indemnification, is not paid in full by the Company within thirty (30) days after a written request for payment thereof has first been received by the Company, Indemnitee may, but need not, at any time thereafter bring an action against the Company to recover the unpaid amount of the claim and, subject to Section 11 of this Agreement, Indemnitee shall also be entitled to be paid for the expenses (including attorneys’ fees) of bringing such action. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in connection with any action, suit or proceeding in advance of its final disposition) that Indemnitee has not met the standards of conduct which make it permissible under applicable law for the Company to indemnify Indemnitee for the amount claimed, but the burden of proving such defense shall be on the Company and Indemnitee shall be entitled to receive interim payments of expenses pursuant to

3


Section 3(a) unless and until such defense may be finally adjudicated by court order or judgment from which no further right of appeal exists. It is the parties’ intention that if the Company contests Indemnitee’s right to indemnification, the question of Indemnitee’s right to indemnification shall be for the court to decide, and neither the failure of the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its stockholders) to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct required by applicable law, nor an actual determination by the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its stockholders) that Indemnitee has not met such applicable standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct.

(d)    Notice to Insurers. If, at the time of the receipt of a notice of a claim pursuant to Section 3(b) hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.

(e)    Selection of Counsel. In the event the Company shall be obligated under Section 3(a) hereof to pay the expenses of any proceeding against Indemnitee, the Company will be entitled to participate therein at its own expense, and, except as otherwise provided below, the Company may assume the defense thereof, with counsel selected by the Company but satisfactory to Indemnitee. After notice from the Company to Indemnitee of its election to assume the defense of a proceeding, the Company will not be liable to Indemnitee under this Agreement for any expenses subsequently incurred by Indemnitee in connection with the defense thereof, other than as provided below. Indemnitee shall have the right to employ counsel in any proceeding, but the fees and expenses of such counsel incurred after notice from the Company of its assumption of the defense of the proceeding shall be at the expense of Indemnitee, unless (i) the employment of counsel by Indemnitee has been authorized by the Company, (ii) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of the defense of a proceeding or (iii) the Company shall not in fact have employed counsel to assume the defense of a proceeding, in each of which cases the fees and expenses of Indemnitee’s counsel shall be advanced by the Company. Notwithstanding the foregoing, the Company shall not be entitled to assume the defense of any proceeding brought by or in the right of the Company.

(f)    Settlement. The Company shall not be liable to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any proceeding effected without its written consent. The Company shall not settle any proceeding in any manner which would impose any penalty or limitation on Indemnitee without Indemnitee’s

4


written consent. Neither the Company nor Indemnitee will unreasonably withhold consent to any proposed settlement.

4.Additional Indemnification Rights; Nonexclusivity.

(a)    Scope. Notwithstanding any other provision of this Agreement, the Company hereby agrees to indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification is not specifically authorized by the other provisions of this Agreement, the Company’s Certificate of Incorporation, the Company’s Bylaws or by statute. In the event of any change, after the date of this Agreement, in any applicable law, statute, or rule which expands the right of a Delaware corporation to indemnify a member of its board of directors or an officer, such changes shall be deemed to be within the purview of Indemnitee’s rights and the Company’s obligations under this Agreement. In the event of any change in any applicable law, statute or rule which narrows the right of a Delaware corporation to indemnify a member of its board of directors or an officer, such changes, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement shall have no effect on this Agreement or the parties’ rights and obligations hereunder.

(b)    Nonexclusivity. The indemnification provided by this Agreement shall not be deemed exclusive of any rights to which Indemnitee may be entitled under the Company’s Certificate of Incorporation, its Bylaws, any agreement, any vote of stockholders or disinterested members of the Company’s Board of Directors, the General Corporation Law of the State of Delaware, or otherwise, both as to action in Indemnitee’s official capacity and as to action in another capacity while holding such office. The indemnification provided under this Agreement shall continue as to Indemnitee for any action taken or not taken while serving in an indemnified capacity even though he or she may have ceased to serve in any such capacity at the time of any action, suit or other covered proceeding.

5.Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties actually or reasonably incurred in the investigation, defense, appeal or settlement of any civil or criminal action, suit or proceeding, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines or penalties to which Indemnitee is entitled.

6.Mutual Acknowledgment. Both the Company and Indemnitee acknowledge that in certain instances, Federal law or public policy may override applicable state law and prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise. For example, the Company and Indemnitee acknowledge that the Securities and Exchange Commission (the “SEC”) has taken the position that indemnification is not permissible for liabilities arising under certain federal securities laws, and federal legislation prohibits indemnification for certain ERISA violations. Indemnitee understands and acknowledges that the Company has undertaken

5


or may be required in the future to undertake with the SEC to submit the question of indemnification to a court in certain circumstances for a determination of the Company’s right under public policy to indemnify Indemnitee.

7.Officer and Director Liability Insurance. The Company shall, from time to time, make the good faith determination whether or not it is practicable for the Company to obtain and maintain a policy or policies of insurance with reputable insurance companies providing the officers and directors of the Company with coverage for losses from wrongful acts, or to ensure the Company’s performance of its indemnification obligations under this Agreement. Among other considerations, the Company will weigh the costs of obtaining such insurance coverage against the protection afforded by such coverage. In all policies of director and officer liability insurance, Indemnitee shall be named as an insured in such a manner as to provide Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company’s directors, if Indemnitee is a director; or of the Company’s officers, if Indemnitee is not a director of the Company but is an officer; or of the Company’s key employees, if Indemnitee is not an officer or director but is a key employee. Notwithstanding the foregoing, the Company shall have no obligation to obtain or maintain such insurance if the Company determines in good faith that such insurance is not reasonably available, if the premium costs for such insurance are disproportionate to the amount of coverage provided, if the coverage provided by such insurance is limited by exclusions so as to provide an insufficient benefit, or if Indemnitee is covered by similar insurance maintained by a parent or subsidiary of the Company.

8.Severability. Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company’s inability, pursuant to court order, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. The provisions of this Agreement shall be severable as provided in this Section 8. If this Agreement or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify Indemnitee to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated, and the balance of this Agreement not so invalidated shall be enforceable in accordance with its terms.

9.Exceptions. Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement:

(a)    Claims Initiated by Indemnitee. To indemnify or advance expenses to Indemnitee with respect to proceedings or claims initiated or brought voluntarily by Indemnitee and not by way of defense, except with respect to proceedings brought to establish or enforce a right to indemnification under this Agreement or any other statute or law or otherwise as required under Section 145 of the Delaware General Corporation Law (unless a court of competent jurisdiction determines that each of the material assertions made by Indemnitee in such proceeding was not made in good faith or was

6


frivolous), but such indemnification or advancement of expenses may be provided by the Company in specific cases if the Board of Directors finds it to be appropriate;

(b)    Lack of Good Faith. To indemnify Indemnitee for any expenses incurred by Indemnitee resulting from Indemnitee’s conduct that is finally adjudged to have been willful misconduct, knowingly fraudulent or deliberately dishonest;

(c)    Insured Claims; Other Indemnity Provisions. To indemnify Indemnitee for expenses or liabilities of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) to the extent payment for such expenses or liabilities has been received by or on behalf of Indemnitee under any insurance policy or other indemnity provision; or

(d)    Claims under Section 16(b). To indemnify Indemnitee for expenses or the payment of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute or similar provisions of any federal, state or local statutory law; or
(e)    Final Determination. To make payment to Indemnitee pursuant to this Agreement if a court of competent jurisdiction finally determines that such payment hereunder is unlawful.

10.Construction of Certain Phrases.

(a)     For purposes of this Agreement, references to the “Company” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that if Indemnitee is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting or surviving corporation as Indemnitee would have with respect to such constituent corporation if its separate existence had continued.

(b)    For purposes of this Agreement, references to “other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to “serving at the request of the Company” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants, or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

7



11.Attorneys’ Fees. In the event that any action is instituted by Indemnitee under this Agreement to enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be paid all court costs and expenses, including reasonable attorneys’ fees, incurred by Indemnitee with respect to such action, unless as a part of such action, the court of competent jurisdiction determines that each of the material assertions made by Indemnitee as a basis for such action were not made in good faith or were frivolous. In the event of an action instituted by or in the name of the Company under this Agreement or to enforce or interpret any of the terms of this Agreement, Indemnitee shall be entitled to be paid all court costs and expenses, including attorneys’ fees, incurred by Indemnitee in defense of such action (including with respect to Indemnitee’s counterclaims and cross-claims made in such action), unless as a part of such action the court determines that each of Indemnitee’s material defenses to such action were made in bad faith or were frivolous.

12.Miscellaneous.

(a)    Governing Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflict of law.

(b)    Entire Agreement; Enforcement of Rights. This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter herein and merges all prior discussions between them. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.

(c)    Construction. This Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed in favor of or against any one of the parties hereto.

(d)    Notices. Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be deemed sufficient when delivered personally or sent by telegram or fax, or forty-eight (48) hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party to be notified at such party’s address as set forth below or as subsequently modified by written notice.

(e)    Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.


8


(f)    Successors and Assigns. This Agreement shall be binding upon the Company and its successors and assigns, and inure to the benefit of Indemnitee and Indemnitee’s heirs, legal representatives and assigns.

(g)    Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company to effectively bring suit to enforce such rights.

The parties hereto have executed this Agreement as of the day and year set forth on the first page of this Agreement.


BIO-RAD LABORATORIES, INC.
 
INDEMNITEE
a Delaware corporation
 
AGREED TO AND ACCEPTED
By:
 
 
By:
 
 
 
 
 
 
Name:
 
 
Name:
 
 
 
 
 
 
Title:
 
 
 
 
 
 
 
 
 
Address:
1000 Alfred Nobel Drive
 
Address:
 
 
Hercules, CA 94547
 
 
 
 



9

 EX-31.1 3 ex31163017.htm EXHIBIT 31.1 CEO SECTION 302 CERTIFICATION Exhibit


Exhibit 31.1

Certification of Chief Executive Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:
August 7, 2017
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board,
 
 
 
President and Chief Executive Officer



 EX-31.2 4 ex31263017.htm EXHIBIT 31.2 CFO SECTION 302 CERTIFICATION Exhibit


Exhibit 31.2

Certification of Chief Financial Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Christine A. Tsingos, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:
August 7, 2017
 
/s/ Christine A.Tsingos
 
 
 
Christine A. Tsingos
 
 
 
Executive Vice President,
 
 
 
Chief Financial Officer


 EX-32.1 5 ex32163017.htm EXHIBIT 32.1 CEO SECTION 906 CERTIFICATION Exhibit


Exhibit 32.1




Certification of Periodic Report


I, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
August 7, 2017
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board,
 
 
 
President and Chief Executive Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.


 EX-32.2 6 ex32263017.htm EXHIBIT 32.2 CFO SECTION 906 CERTIFICATION Exhibit


Exhibit 32.2




Certification of Periodic Report


I, Christine A. Tsingos, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:
August 7, 2017
 
/s/ Christine A. Tsingos
 
 
 
Christine A. Tsingos
 
 
 
Executive Vice President,
 
 
 
Chief Financial Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.



 EX-101.SCH 7 bio-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2113100 - Disclosure - 10. Income Taxes link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - 10. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - 11. Segment Information link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - 11. Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - 11. Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - 11. Segment Profit Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - 12. Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - 12. Legal Proceedings 12. Contingent Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - 13. Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - 13. Restructuring Costs (Notes) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - 13. Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - 1. Organization, Consolidation and Presentation of Financial Statements link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - 2. Acquisitions link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - 2. Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - 3. Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - 3. Available-for-Sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - 3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - 3. Fair Value Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - 3. Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - 3. Fair Value Measurements 3. Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - 3. Fair Value Measurements Fair Value Level Table (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - 3. Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - 3. Foreign Exchange Forward Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - 4. Intangible Assets, Goodwill and Other (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - 4. Intangible Assets, Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - 5. Product Warranty Liability link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - 5. Product Warranty Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - 5. Product Warranty Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - 6. Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - 6. Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - 6. Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - 8. Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - 8. Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - 8. Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - 9. Other Income and Expenses link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - 9. Other Income and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - 9. Other Income and Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets Parenthetical link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 bio-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 bio-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 bio-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Long-term Debt Long-term Debt [Text Block] Restructuring Costs [Abstract] Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Foreign Currency Gain (Loss) [Member] Foreign Currency Gain (Loss) [Member] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments [Member] Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Segment Reconciling Items [Member] Segment Reconciling Items [Member] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Research and Development Asset Acquired Other than Through Business Combination, Written-off Research and Development Asset Acquired Other than Through Business Combination, Written-off Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Fair Value Disclosures [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Measurement Basis [Axis] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying (Reported) Amount, Fair Value Disclosure [Member] Reported Value Measurement [Member] Estimate of Fair Value, Fair Value Disclosure [Member] Estimate of Fair Value Measurement [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Other Investments Other Investments Total long-term debt, excluding capital leases and current maturities Long-term Debt, Fair Value Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Statement, Business Segments [Axis] Segments [Axis] Segment [Domain] Segments [Domain] Life Science [Member] Life Sciences [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] All Other Segments [Member] Other Segments [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Net sales Revenue, Net Other Income and Expenses [Abstract] Other Income and Other Expense Disclosure Other Income and Other Expense Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Translation Adjustment [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Defined Benefit Plans Adjustment [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Accumulated Net Unrealized Investment Gain (Loss) [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Parent [Member] AOCI Attributable to Parent [Member] Reclassification Out of Accumulated Other Comprehensive Income [Axis] Reclassification Out of Accumulated Other Comprehensive Income [Domain] Reclassification Out Of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Selling, general and administrative expense Selling, General and Administrative Expense Other (income) expense, net Other Nonoperating Income (Expense) Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), before Reclassifications, before Tax Other Comprehensive Income (Loss), before Reclassifications, before Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Total other comprehensive income (loss) net of tax Other Comprehensive Income (Loss), Net of Tax Earnings Per Share [Abstract] Statement [Table] Scenario [Axis] Scenario, Unspecified [Domain] Statement [Line Items] Basic weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Effect of potentially dilutive stock options and restricted stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted weighted average common shares Weighted Average Number of Shares Outstanding, Diluted Anti-dilutive shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Loss Contingency, Information about Litigation Matters [Abstract] Legal Proceedings. Legal Matters and Contingencies [Text Block] Schedule of other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Acquired Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Customer Relationships [Member] Customer Relationships [Member] Know how [Member] Know How [Member] Know how [Member] Developed Technology Rights [Member] Developed Technology Rights [Member] Licensing Agreements [Member] Licensing Agreements [Member] Trade Names [Member] Trade Names [Member] Noncompete Agreements [Member] Noncompete Agreements [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Finite-lived Intangible Assets Acquired Finite-lived Intangible Assets Acquired Finite-Lived Intangible Assets, Net [Abstract] Average Remaining Life (years) Finite-Lived Intangible Assets, Remaining Amortization Period Purchase Price Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Carrying Amount Finite-Lived Intangible Assets, Net Amortization [Abstract] Amortization expense Amortization of Intangible Assets Organization, Consolidation and Presentation of Financial Statements [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Adjustments for New Accounting Pronouncement [Member] Adjustments for New Accounting Pronouncement [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Restricted Cash and Cash Equivalents, Current Restricted Cash and Cash Equivalents, Current Retained earnings Retained Earnings (Accumulated Deficit) Additional paid-in-capital Additional Paid in Capital Deferred Tax Assets, Gross Deferred Tax Assets, Gross New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Statement of Cash Flows [Abstract] Statement [Table] Statement, Scenario [Axis] Scenario, Unspecified [Domain] Statement [Line Items] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Cash received from customers Proceeds from Customers Cash paid to suppliers and employees Payments to Suppliers and Employees Interest paid, net Interest Paid, Net Income tax payments, net Income Taxes Paid, Net Investment proceeds and miscellaneous receipts, net Proceeds from Other Operating Activities Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Operating Activities (Payments for) proceeds from forward foreign exchange contracts, net Payments for (proceeds from) derivative instruments, operating activities Payments for (proceeds from) derivative instruments, operating activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Proceeds from dispositions of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Payments for acquisitions and long-term investments Payments to Acquire Assets, Investing Activities Payments for purchases of intangible assets Payments to Acquire Productive Assets Payments for purchases of intangible assets Payments to Acquire Intangible Assets Payments for purchases of marketable securities and investments Payments to Acquire Investments Proceeds from sales of marketable securities and investments Proceeds from Sale of Available-for-sale Securities Proceeds from maturities of marketable securities and investments Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net payments on line-of-credit arrangements and notes payable Proceeds from (Repayments of) Lines of Credit Payments on long-term borrowings Repayments of Long-term Debt Payments of contingent consideration Payments of contingent consideration Payments of contingent consideration Proceeds from issuance of common stock for shared-based compensation Proceeds from Issuance of Common Stock Payments for purchases of treasury stock Payments for Repurchase of Common Stock Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Adjustments to reconcile net income to net cash used in operating activities [Abstract] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments, Noncash Items, to Reconcile Net Income to Cash Used in Operating Activities [Abstract] Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Share-based compensation Share-based Compensation Losses (gains) on dispositions of securities Gain (Loss) on Sale of Securities, Net Changes in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability (Increase) decrease in accounts receivable Increase (Decrease) in Accounts Receivable Increase in inventories Increase (Decrease) in Inventories Increase in other current assets Increase (Decrease) in Other Current Assets Decrease in accounts payable and other current liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities (Decrease) increase in income taxes payable Increase (Decrease) in Income Taxes Payable (Decrease) increase in Deferred Income Taxes Increase (Decrease) in Deferred Income Taxes Net decrease/increase in other long-term assets/liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Document and Entity Information (Parenthetical) [Abstract] Document and Entity Information (Parenthetical) [Abstract] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Class A [Member] Common Class A [Member] Common Class B [Member] Common Class B [Member] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Segments [Axis] Segments [Domain] Life Science [Member] Clinical Diagnostics [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance [Member] Employee Severance [Member] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Cost of Goods, Total [Member] Cost of Goods, Total [Member] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve Restructuring Reserve Restructuring Charges Restructuring Charges Restructuring Reserve, Current Restructuring Reserve, Current Restructuring Reserve, Noncurrent Restructuring Reserve, Noncurrent Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment Payments for Restructuring Payments for Restructuring Restructuring Reserve, Foreign Currency Translation Gain (Loss) Restructuring Reserve, Foreign Currency Translation Gain (Loss) Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Long-term Investments [Member] Other Long-term Investments [Member] Short-term Investments [Member] Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Corporate Debt Securities [Member] Corporate Debt Securities [Member] Brokered certificates of deposit [Member] Interest-bearing Deposits [Member] Municipal obligations [Member] Municipal Bonds [Member] Asset-backed Securities [Member] Asset-backed Securities [Member] Marketable Equity Securities [Member] Equity Securities [Member] Available-for-sale Securities [Member] Available-for-sale Securities [Member] US Government Sponsored Agencies [Member] US Treasury and Government [Member] Foreign Government Obligations [Member] Foreign Government Debt Securities [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Disclosure Amortized Cost Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value Available-for-sale Securities Segment Information Segment Reporting Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill [Line Items] Goodwill Goodwill, Gross Accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Goodwill, net Goodwill Goodwill, Acquired During Period Goodwill, Acquired During Period Currency fluctuations Goodwill, Foreign Currency Translation Gain (Loss) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Schedule of financial assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Schedule of available-for-sale investments Available-for-sale Securities [Table Text Block] Summary of fair value of gross unrealized losses for investments with unrealized losses Schedule of Unrealized Loss on Investments [Table Text Block] Discussion of current derivative risk management Schedule of Derivative Instruments [Table Text Block] Summary of amortized cost and estimated fair value of debt securities by contractual maturity date Investments Classified by Contractual Maturity Date [Table Text Block] Estimated fair value of financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Balance Sheet Location [Axis] Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] RainDance Technologies, Inc. [Member] RainDance Technologies, Inc. [Member] RainDance Technologies, Inc. [Member] GnuBIO [Member] GnuBIO [Member] GnuBIO [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Business Combination, Consideration Transferred Business Combination, Consideration Transferred Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Goodwill Liabilities Assumed Business Combination, Consideration Transferred, Liabilities Incurred Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Price Change Debt Security Price Change Debt Security Price Change Debt Security Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Cost Method Investment, Percentage Owned Cost Method Investment, Percentage Owned Cost Method Investments, Percentage Owned Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Product Warranties Disclosures [Abstract] Movement in Standard Product Warranty Accrual [Roll Forward] Movement in Standard Product Warranty Accrual [Roll Forward] Accrual at beginning of period Standard and Extended Product Warranty Accrual Provision for warranty Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Actual warranty costs Standard and Extended Product Warranty Accrual, Decrease for Payments Accrual at end of period Goodwill and Intangible Assets Disclosure Goodwill and Intangible Assets Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Short-term Investments [Member] Other Investments [Member] Other Investments [Member] Municipal Obligations (Member) Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Commercial Paper [Member] Commercial Paper [Member] Foreign Time Deposits [Member] Bank Time Deposits [Member] Domestic time deposit [Member] Certificates of Deposit [Member] Money Market Funds [Member] Money Market Funds [Member] Cash Equivalents [Member] Cash Equivalents [Member] Fair Value by Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Restricted Investments, at Fair Value Restricted Investments, at Fair Value Available-for-sale Securities, Fair Value Disclosure Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Assets, Fair Value Disclosure Assets, Fair Value Disclosure Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Income Tax Disclosure [Abstract] Statutory Rate [Axis] Statutory Rate [Axis] Statutory Rate [Axis] Statutory Rate [Domain] Statutory Rate [Domain] Statutory Rate [Domain] U.S. Federal [Member] U.S. Federal [Member] U.S. Federal [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Statutory Rates Statutory Rates Statutory Rates Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Statement of Financial Position [Abstract] Common Class A [Member] Common Class B [Member] Treasury Class A [Member] Treasury Class-A [Member] Treasury Class A [Member] Treasury Class B [Member] Treasury Class B [Member] Treasury Class B [Member] ASSETS: Assets [Abstract] Cash and cash equivalents Short-term investments Short-term Investments Restricted investments Restricted Investments, Current Accounts receivable, net Accounts Receivable, Net, Current Inventories: Inventory, Net [Abstract] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Total inventories Inventory, Net Prepaid expenses Prepaid Expense, Current Other current assets Other Assets, Current Total current assets Assets, Current Property, plant and equipment, at cost Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill, net Purchased intangibles, net Intangible Assets, Net (Excluding Goodwill) Other investments Long-term Investments Other assets Other Assets Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities and Equity [Abstract] Accounts payable, accrued payroll and employee benefits Accounts Payable and Accrued Liabilities, Current Accrued payroll and employee benefits Employee-related Liabilities, Current Current maturities of long-term debt and notes payable Notes and Loans Payable, Current Income and other taxes payable Taxes Payable, Current Accrued royalties Accrued Royalties, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term debt, net of current maturities Long-term Debt and Capital Lease Obligations Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Deferred revenue Deferred Revenue, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock Common Stock, Value, Issued Additional paid-in capital Treasury Stock, Value Treasury Stock, Value Retained earnings Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Fair Value Measurements Fair Value Disclosures [Text Block] Product Warranty Liability Product Warranty Disclosure [Text Block] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Unsecured Debt [Member] Capital Lease Obligations [Member] Line of Credit [Member] Standby Letters of Credit [Member] Standby Letters of Credit [Member] Debt Instrument [Axis] Debt Instrument, Name [Domain] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Unsecured Debt Unsecured Debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Redemption Price, Percentage Debt Instrument, Redemption Price, Percentage Long-term debt Long-term Debt Long-term Debt and Capital Lease Obligations, Including Current Maturities Long-term Debt and Capital Lease Obligations, Including Current Maturities Debt and Capital Lease Obligations Debt and Capital Lease Obligations Less Current Maturities Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Face amount of debt sold Debt Instrument, Face Amount Line of credit maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Outstanding borrowings Long-term Line of Credit Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Restructuring and Related Costs [Table Text Block] Restructuring and Related Costs [Table Text Block] 12. Legal Proceedings [Abstract] 12. Legal Proceedings [Abstract] Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Litigation Settlement Interest Litigation Settlement Interest Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Changes to goodwill by segment Schedule of Goodwill [Table Text Block] Schedule of identifiable purchased intangible assets with definite lives Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Finite-lived Intangible Assets Amortization Expense [Table Text Block] Finite-lived Intangible Assets Amortization Expense [Table Text Block] Income Statement [Abstract] Cost of goods sold Cost of Goods Sold Gross profit Gross Profit Selling, general and administrative expense Research and Development Expense Research and Development Expense Asset Impairment Charges Asset Impairment Charges Segment profit (loss) Operating Income (Loss) Interest expense Interest Expense Foreign exchange losses, net Foreign Currency Transaction Gain (Loss), before Tax Income before income taxes Provision for income taxes Income Tax Expense (Benefit) Net income including noncontrolling interests Net income attributable to Bio-Rad Net Income (Loss) Attributable to Parent Basic earnings per share: Earnings Per Share, Basic [Abstract] Net income per share basic attributable to Bio-Rad Earnings Per Share, Basic Weighted average common shares - basic Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Net income per share diluted attributable to Bio-Rad Earnings Per Share, Diluted Weighted average common shares - diluted Balance Sheet Related Disclosures [Abstract] Common Stock, Shares, Issued Common Stock, Shares, Issued Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Treasury Stock, Shares Treasury Stock, Shares Mature in less than one year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis Mature in one to five years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis Mature in more than five years Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Amortized Cost Basis Total Amortized Cost Available-for-sale Debt Securities, Amortized Cost Basis Mature in less than one year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Mature in one to five years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Mature in more than five years Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value Estimated Fair Value Available-for-sale Securities, Debt Securities Interest and investment income Investment Income, Interest and Dividend Net realized loss (gain) on investments Realized Investment Gains (Losses) Other (income) expense, net Earnings Per Share Earnings Per Share [Text Block] Derivative [Table] Derivative [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Notional value Derivative, Notional Amount Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Contingent Consideration by Type [Domain] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Market Price of Risk [Member] Market Price of Risk [Member] Market Price of Risk [Member] Projected Volatility of Growth Rate [Member] Projected Volatility of Sales [Member] [Member] Projected Volatility of Sales [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] CellSorter [Member] CellSorter [Member] CellSorter [Member] [Member] Fair Value Inputs, Entity Credit Risk Fair Value Inputs, Discount Rate Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Contingent consideration milestone payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements (Decrease) increase in fair value of contingent consideration included in SGA Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Business Acquisition, Contingent Consideration, Potential Percentage Payout Business Acquisition, Contingent Consideration, Potential Percentage Payout business acquisition contingent consideration percentage payout Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Information regarding industry segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Reconciliation of segment profit to consolidated income before taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Income Taxes Income Tax Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Net Income (Loss) Attributable to Parent Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent Net unrealized holding gains (losses) on available-for-sale investments net of tax expense Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Organization, Consolidation and Presentation of Financial Statements Disclosure Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Components of warranty accrual Schedule of Product Warranty Liability [Table Text Block] EX-101.PRE 11 bio-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 a10q63017_htm.xml IDEA: XBRL DOCUMENT 0000012208 2017-01-01 2017-06-30 0000012208 us-gaap:CommonClassBMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 bio:TreasuryClassAMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommonClassBMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 bio:TreasuryClassBMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 2016-04-01 2016-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 2017-04-01 2017-06-30 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2017-01-01 2017-06-30 0000012208 bio:CellsorterMember 2017-01-01 2017-06-30 0000012208 bio:GnuBIOMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2017-06-30 0000012208 bio:CellsorterMember 2012-09-30 2016-09-30 0000012208 2016-01-01 2016-06-30 0000012208 bio:CellsorterMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2017-06-30 0000012208 bio:CellsorterMember 2012-09-30 0000012208 bio:GnuBIOMember 2014-04-10 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2017-06-30 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-06-30 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 2016-03-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-06-30 0000012208 2015-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0000012208 us-gaap:TradeNamesMember 2016-12-31 0000012208 bio:KnowHowMember 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2017-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember 2017-06-30 0000012208 bio:KnowHowMember 2017-06-30 0000012208 us-gaap:LicensingAgreementsMember 2017-06-30 0000012208 us-gaap:NewAccountingPronouncementMember 2017-01-01 0000012208 us-gaap:NoncompeteAgreementsMember 2017-06-30 0000012208 us-gaap:TradeNamesMember 2017-06-30 0000012208 bio:ClinicalDiagnosticsMember 2017-01-01 2017-06-30 0000012208 bio:LifeScienceMember 2016-12-31 0000012208 bio:LifeScienceMember 2017-01-01 2017-06-30 0000012208 bio:LifeScienceMember 2017-06-30 0000012208 bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-06-30 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassAMember 2017-07-27 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2017-06-30 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 bio:RainDanceTechnologiesInc.Member 2017-01-01 2017-03-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-06 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2017-04-01 2017-06-30 0000012208 us-gaap:LineOfCreditMember 2017-06-30 0000012208 us-gaap:StandbyLettersOfCreditMember 2017-06-30 0000012208 us-gaap:DeferredTaxAssetDomain bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2016-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2017-06-30 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2016-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2017-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000012208 bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-01 2016-03-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-04-01 2016-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-04-01 2016-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-04-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-04-01 2017-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-06-30 0000012208 bio:USFederalMember 2017-04-01 2017-06-30 0000012208 bio:USFederalMember 2016-01-01 2016-06-30 0000012208 bio:USFederalMember 2017-01-01 2017-06-30 0000012208 bio:USFederalMember 2016-04-01 2016-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 bio:LifeScienceMember 2016-01-01 2016-06-30 0000012208 bio:ClinicalDiagnosticsMember 2016-01-01 2016-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-04-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2016-04-01 2016-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-04-01 2017-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:OperatingSegmentsMember 2017-01-01 2017-06-30 0000012208 us-gaap:OperatingSegmentsMember 2016-04-01 2016-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2017-04-01 2017-06-30 0000012208 us-gaap:OperatingSegmentsMember 2016-01-01 2016-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-06-30 0000012208 us-gaap:CorporateNonSegmentMember 2016-04-01 2016-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-04-01 2016-06-30 0000012208 us-gaap:OperatingSegmentsMember 2017-04-01 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2016-04-01 2016-06-30 0000012208 bio:ClinicalDiagnosticsMember 2016-04-01 2016-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2017-04-01 2017-06-30 0000012208 bio:LifeScienceMember 2017-04-01 2017-06-30 0000012208 bio:ClinicalDiagnosticsMember 2017-04-01 2017-06-30 0000012208 bio:LifeScienceMember 2016-04-01 2016-06-30 0000012208 us-gaap:CostOfGoodsTotalMember 2017-04-01 2017-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-06-30 0000012208 us-gaap:CostOfGoodsTotalMember 2017-01-01 2017-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-04-01 2017-06-30 0000012208 us-gaap:CommonClassBMember 2017-07-27 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:EmployeeSeveranceMember 2017-01-01 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000012208 bio:TreasuryClassAMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-06-30 0000012208 us-gaap:CommonClassAMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-06-30 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 bio:TreasuryClassBMember 2017-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:ProjectedVolatilityOfSalesMemberMember 2017-01-01 2017-06-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:MarketPriceOfRiskMember 2017-01-01 2017-06-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2017-01-01 2017-06-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2017-06-30 0000012208 us-gaap:CommonClassAMember 2016-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2017-01-01 2017-06-30 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2017-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 iso4217:USD shares iso4217:USD pure shares 0.35 0.35 0.35 false --12-31 Q2 2017 0000012208 Yes Large Accelerated Filer BIO RAD LABORATORIES INC No Yes 24454048 5123883 24500249 5125094 24453926 5122966 24496127 5124177 P9Y P1Y P8Y P1Y P12Y P3Y P9Y P1Y P9Y P2Y P0Y P0Y P8Y P4Y P9Y P1Y P8Y P1Y P12Y P2Y P14Y P2Y P9Y P2Y P0Y P0Y P7Y P4Y 0 122 917 4122 917 10-Q 2017-06-30 24528198 5109777 321584000 456264000 391268000 383176000 4560000 4560000 392842000 372348000 115043000 116540000 133055000 125982000 332483000 282439000 580581000 524961000 125655000 91014000 10038000 12201000 1826528000 1844524000 1277970000 1227388000 774641000 738774000 503329000 488614000 530287000 477115000 184819000 161609000 1040959000 830790000 57537000 47852000 4143459000 3850504000 277566000 296473000 505000 334000 33308000 28124000 143731000 146391000 455110000 471322000 434386000 434186000 294843000 222919000 148123000 135318000 1332462000 1263745000 2000 2000 1000 1000 347658000 332911000 895000 12000 89000 89000 1853372000 1836180000 610948000 417766000 2810997000 2586759000 4143459000 3850504000 504666000 516777000 1004717000 987974000 231367000 236545000 461431000 443713000 273299000 280232000 543286000 544261000 213027000 205536000 407967000 395252000 62623000 49811000 112111000 98397000 0 2360000 0 2360000 -2351000 22525000 23208000 48252000 5770000 5632000 10811000 11212000 -2516000 -1237000 -4305000 -2366000 11757000 11208000 13175000 12385000 1120000 26864000 21267000 47059000 -3915000 8850000 3819000 16769000 5035000 18014000 17448000 30290000 0.17 0.61 0.59 1.03 29613000 29398000 29597000 29381000 0.17 0.61 0.58 1.03 30006000 29589000 29962000 29549000 5035000 18014000 17448000 30290000 41679000 -18424000 60522000 19512000 1938000 -535000 2053000 105000 54564000 62109000 134713000 58015000 94305000 44220000 193182000 77422000 99340000 62234000 210630000 107712000 999779000 1020149000 970116000 935587000 10315000 10911000 19066000 11085000 13947000 12810000 0 75000 8029000 -5594000 6200000 69707000 64951000 56865000 21000 21000 73573000 11477000 3920000 6000 142993000 148423000 39362000 42386000 98379000 64036000 -147675000 -110328000 -36000 0 149000 156000 3105000 3500000 3778000 6875000 883000 0 0 75000 -395000 3294000 7190000 -1571000 -134680000 -38898000 456264000 457549000 321584000 418651000 17448000 30290000 70688000 71668000 10579000 9407000 -310000 66000 0 75000 -8700000 -1873000 1849000 -32067000 37870000 50979000 14878000 2561000 -24160000 -32564000 -13208000 11000 3057000 -4060000 -10897000 -10322000 6200000 69707000 1.<span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">BASIS OF PRESENTATION AND USE OF ESTIMATES</span><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Basis of Presentation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Use of Estimates</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Recent Accounting Standards Updates</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our condensed consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. In several foreign locations, we are statutorily required to provide a lump sum severance or termination indemnity to our employees and are currently evaluating the applicability of ASU 2017-07 to our situation. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. There was no impact of ASU 2017-04 on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs.</span><span> </span><span style="font-size:11pt;">Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. </span><span> </span><span style="font-size:11pt;">ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principal on January 1, 2017, and made a policy election to account for forfeitures as they occur. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, and increased Additional paid-in capital and Deferred tax assets by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, in the Condensed Consolidated Balance Sheet. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our condensed consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-size:11pt;">In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. </span><span style="font-size:12pt;"> </span><span style="font-size:11pt;">For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the condensed consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-size:11pt;">In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-size:11pt;">principle on January 1, 2017, which did not have a material impact on our condensed consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-size:11pt;">In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We are in the process of assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.</span> <span style="font-size:11pt;">In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our condensed consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. In several foreign locations, we are statutorily required to provide a lump sum severance or termination indemnity to our employees and are currently evaluating the applicability of ASU 2017-07 to our situation. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. There was no impact of ASU 2017-04 on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs.</span><span> </span><span style="font-size:11pt;">Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. </span><span> </span><span style="font-size:11pt;">ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principal on January 1, 2017, and made a policy election to account for forfeitures as they occur. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, and increased Additional paid-in capital and Deferred tax assets by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, in the Condensed Consolidated Balance Sheet. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our condensed consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-size:11pt;">In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. </span><span style="font-size:12pt;"> </span><span style="font-size:11pt;">For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the condensed consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-size:11pt;">In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-size:11pt;">principle on January 1, 2017, which did not have a material impact on our condensed consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-size:11pt;">In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We are in the process of assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.</span> -300000 400000 100000 ACQUISITIONS<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">RainDance Technologies, Inc.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$76.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> including certain assumed net liabilities. Cash payments at closing were </span><span style="font-family:inherit;font-size:11pt;"><span>$72.8 million</span></span><span style="font-family:inherit;font-size:11pt;">. In addition, we had a cash payment of </span><span style="font-family:inherit;font-size:11pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> for a one-time expense associated with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The preliminary allocation of the payments were </span><span style="font-family:inherit;font-size:11pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the one-time expense, </span><span style="font-family:inherit;font-size:11pt;"><span>$35.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> to purchased intangibles consisting primarily of a large patent and license portfolio, limited know how and customer relationships, </span><span style="font-family:inherit;font-size:11pt;"><span>$3.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> to assumed net liabilities, and </span><span style="font-family:inherit;font-size:11pt;"><span>$36.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> to goodwill. We recorded a deferred tax liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$12.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to the purchased intangibles and a deferred tax asset of </span><span style="font-family:inherit;font-size:11pt;"><span>$18.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to the acquired net operating losses. The purchase price allocation is preliminary as additional time is required to complete the valuation of the intangibles. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers with solutions for a wide range of nucleic acid detection applications. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Propel Labs, Inc.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair value of the consideration as of the acquisition date was </span><span style="font-family:inherit;font-size:11pt;"><span>$32.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, which included </span><span style="font-family:inherit;font-size:11pt;"><span>$9.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> paid in cash at the closing date and </span><span style="font-family:inherit;font-size:11pt;"><span>$23.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> in contingent consideration potentially payable to Propel. The amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, and was recognized at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$26.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> (see Note 3, "Fair Value Measurements").</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair values of the net assets acquired from Propel as of the acquisition date were determined to be </span><span style="font-family:inherit;font-size:11pt;"><span>$32.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> of definite-lived intangible assets and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill. The goodwill related to this acquisition will be deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>In addition, Bio-Rad contracted with Propel to provide development services concurrent with and included in the purchase agreement. Bio-Rad is receiving future manufacturing, engineering and marketing support from Propel on which payments will be made upon the successful completion of all contracted services. As a result, these services are not included in the total purchase consideration and a majority will be expensed in future periods. 76600000 72800000 10000000.0 10000000.0 35000000.0 -3800000 36200000 12900000 18300000 32800000 9500000 23300000 26700000 32700000 100000 3.<span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">FAIR VALUE MEASUREMENTS</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1: Quoted prices in active markets for identical instruments</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>980.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>980.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (b)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>980.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>352.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,332.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,001.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>367.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,369.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (b)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>347.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>790.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,173.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>391.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>941.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,332.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(e)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2012, we recognized a contingent consideration liability for certain milestones of </span><span style="font-family:inherit;font-size:11pt;"><span>$44.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon our acquisition of a cell sorting system from Propel. Since 2012, we have paid </span><span style="font-family:inherit;font-size:11pt;"><span>$32.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon reaching the milestones and have reduced the valuation of the milestones by </span><span style="font-family:inherit;font-size:11pt;"><span>$12.6 million</span></span><span style="font-family:inherit;font-size:11pt;">. The remaining liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> was paid in </span><span style="font-size:11pt;">February 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from </span><span style="font-family:inherit;font-size:11pt;"><span>39%</span></span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> for the calendar years </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> through </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;">. The sales milestones could potentially range from </span><span style="font-family:inherit;font-size:11pt;"><span>$0</span></span><span style="font-family:inherit;font-size:11pt;"> to an unlimited amount through </span><span style="font-family:inherit;font-size:11pt;">December 31, 2020</span><span style="font-family:inherit;font-size:11pt;">. The contingent consideration was accrued at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$26.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Cell sorting system:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Analytical flow cytometer platform:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides quantitative information about Level 3 inputs for fair value measurement of our</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">analytical flow cytometer platform</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:27%;"/><td style="width:26%;"/><td style="width:31%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of debt</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at </span><span style="font-family:inherit;font-size:11pt;"><span>$10.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The contingent </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">consideration was revalued to a fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of December 31, 2016 and was reversed to selling, general and administrative expenses during the first quarter of 2017 due to reaching a favorable outcome with GnuBIO, Inc. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">To estimate the fair value of Level 2 debt securities as of </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, our primary pricing provider uses S&amp;P Capital IQ as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is S&amp;P Capital IQ as the primary pricing source and then our custodian as the secondary pricing source. If S&amp;P Capital IQ does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For commercial paper as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our pricing provider performs daily reasonableness testing of the S&amp;P Capital IQ prices. Price changes of </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> or greater are investigated and resolved. In addition, we perform a quarterly testing of the S&amp;P Capital IQ prices to custodian reported prices. Price differences outside a tolerable variance of approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>1%</span></span><span style="font-family:inherit;font-size:11pt;"> are investigated and resolved.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>384.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>391.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>886.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>940.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>886.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>941.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>439.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>894.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,332.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>83.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>380.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>681.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>164.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>160.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> or at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of our forward foreign exchange contracts (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in July through September 2017 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in July through September 2017 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>327.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of the amortized cost and estimated fair value of our debt securities at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>144.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>144.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>352.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>352.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of financial instruments that are not recognized at fair value in the Condensed Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which have fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>93.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,265.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>984.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>456.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>454.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>35%</span></span><span style="font-family:inherit;font-size:11pt;"> of the outstanding voting shares (excluding treasury shares) of Sartorius as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;">.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ Board of Directors, nor do we have the ability to exercise significant </span></div>influence over the operating and financial policies of Sartorius.  We account for this investment using the cost method.  The carrying value of this investment is included in Other investments in our Condensed Consolidated Balance Sheets. As the stock is thinly traded and in conjunction with the valuation method discussed above, we have classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock. <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>980.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>980.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (b)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>980.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>352.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,332.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,001.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>367.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,369.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (b)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>347.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>790.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,173.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>391.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>941.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,332.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(e)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0 15200000 0 15200000 12400000 0 0 12400000 4600000 0 0 4600000 17000000.0 15200000 0 32200000 4600000 0 0 4600000 0 201700000 0 201700000 0 72100000 0 72100000 0 3000000.0 0 3000000.0 0 3600000 0 3600000 0 13800000 0 13800000 980100000 0 0 980100000 0 58100000 0 58100000 980100000 352300000 0 1332400000 0 400000 0 400000 1001700000 367900000 0 1369600000 0 1000000.0 0 1000000.0 0 0 26700000 26700000 0 1000000.0 26700000 27700000 0 14100000 0 14100000 11800000 0 0 11800000 0 20000000.0 0 20000000.0 0 1100000 0 1100000 5900000 0 0 5900000 17700000 35200000 0 52900000 4600000 0 0 4600000 0 179400000 0 179400000 0 82500000 0 82500000 0 4400000 0 4400000 0 3600000 0 3600000 0 15400000 0 15400000 767800000 0 0 767800000 0 62500000 0 62500000 767800000 347800000 0 1115600000 0 600000 0 600000 790100000 383600000 0 1173700000 0 1300000 0 1300000 0 0 38500000 38500000 0 1300000 38500000 39800000 391300000 383200000 941100000 732400000 1332400000 1115600000 3200000 14500000 23500000 24000000.0 26700000 38500000 44600000 32000000.0 12600000 3100000 0.39 0.20 0 26700000 The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Cell sorting system:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Analytical flow cytometer platform:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 28500000 3100000 1300000 26700000 <span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides quantitative information about Level 3 inputs for fair value measurement of our</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">analytical flow cytometer platform</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span><span style="font-family:inherit;font-size:11pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:27%;"/><td style="width:26%;"/><td style="width:31%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of debt</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 0.105 0.043 10700000 10000000.0 0.05 0.01 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>384.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>391.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>886.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>940.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>886.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>941.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>439.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>894.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,332.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>83.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>380.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>681.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 201600000 400000 300000 201700000 3600000 0 0 3600000 13800000 0 0 13800000 57900000 100000 100000 57900000 72400000 100000 400000 72100000 3000000.0 0 0 3000000.0 32500000 7000000.0 300000 39200000 384800000 7600000 1100000 391300000 54500000 886400000 0 940900000 200000 0 0 200000 54700000 886400000 0 941100000 439500000 894000000.0 1100000 1332400000 179700000 200000 500000 179400000 3600000 0 0 3600000 15500000 0 100000 15400000 62200000 100000 100000 62200000 83100000 100000 700000 82500000 4400000 0 0 4400000 32400000 3700000 400000 35700000 380900000 4100000 1800000 383200000 54500000 677600000 0 732100000 300000 0 0 300000 54800000 677600000 0 732400000 435700000 681700000 1800000 1115600000 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>164.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>160.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 8100000 11800000 164800000 160500000 300000 300000 800000 1500000 The following is a summary of our forward foreign exchange contracts (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in July through September 2017 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in July through September 2017 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>327.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 76800000 200000 327000000.0 400000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of the amortized cost and estimated fair value of our debt securities at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>144.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>144.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>352.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>352.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 156200000 156200000 144900000 144900000 51400000 51200000 352500000 352300000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>93.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,265.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>984.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>456.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>454.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div> 93700000 1265800000 92800000 984200000 422800000 456700000 422500000 454200000 0.35 GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to goodwill by segment were as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balances as of January 1, 2017:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>311.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>518.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated impairment losses</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(41.7</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>297.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisitions</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency fluctuations</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balances as of June 30, 2017:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>243.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>572.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated impairment losses</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(41.7</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>313.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>530.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions), we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$36.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill and </span><span style="font-family:inherit;font-size:11pt;"><span>$35.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> for licenses.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>90.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(59.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>190.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(149.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>129.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(63.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-14</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(33.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4-7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>496.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(311.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>184.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(52.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>182.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(136.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>125.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(56.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(30.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>443.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(281.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>161.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization expense related to purchased intangible assets is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> Changes to goodwill by segment were as follows (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balances as of January 1, 2017:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>311.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>518.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated impairment losses</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(41.7</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>297.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisitions</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency fluctuations</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balances as of June 30, 2017:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>243.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>572.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated impairment losses</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(41.7</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>313.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>530.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions), we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$36.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill and </span><span style="font-family:inherit;font-size:11pt;"><span>$35.0 million</span></span> for licenses. 207100000 311700000 518800000 27200000 14500000 41700000 179900000 297200000 477100000 36200000 0 36200000 400000 16600000 17000000.0 243700000 328300000 572000000.0 27200000 14500000 41700000 216500000 313800000 530300000 36200000 35000000.0 Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>90.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(59.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>190.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(149.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>129.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(63.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-14</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(33.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4-7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>496.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(311.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>184.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(52.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>182.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(136.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>125.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(56.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(30.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>443.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(281.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>161.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 90000000.0 59500000 30500000 190200000 149200000 41000000.0 129800000 63300000 66500000 74800000 33900000 40900000 3600000 2700000 900000 7900000 2900000 5000000.0 496300000 311500000 184800000 84400000 52800000 31600000 182600000 136900000 45700000 125900000 56300000 69600000 39000000.0 30600000 8400000 3500000 2500000 1000000.0 7800000 2500000 5300000 443200000 281600000 161600000 Amortization expense related to purchased intangible assets is as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 8700000 9600000 15600000 19000000.0 5.<span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">PRODUCT WARRANTY LIABILITY</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.8</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.8</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 17600000 13900000 13800000 17700000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">6.    LONG-TERM DEBT</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The principal components of long-term debt are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020 principal amount</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.8</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.9</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Senior Notes due 2020</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2010, Bio-Rad sold </span><span style="font-family:inherit;font-size:11pt;"><span>$425.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> principal amount of Senior Notes due 2020 (</span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes).  The sale yielded net cash proceeds of </span><span style="font-family:inherit;font-size:11pt;"><span>$422.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at an effective rate of </span><span style="font-family:inherit;font-size:11pt;"><span>4.946%</span></span><span style="font-family:inherit;font-size:11pt;">.  The </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes pay a fixed rate of interest of </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> per year.  We have the option to redeem any or all of the </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes at any time at a redemption price of </span><span style="font-family:inherit;font-size:11pt;"><span>100%</span></span><span style="font-family:inherit;font-size:11pt;"> of the principal amount (plus a specified make-whole premium as defined in the indenture governing the </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the </span><span style="font-family:inherit;font-size:11pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Credit Agreement</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2014, Bio-Rad entered into a </span><span style="font-family:inherit;font-size:11pt;color:#000000;font-style:normal;text-decoration:none;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> or </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, however </span><span style="font-family:inherit;font-size:11pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> was utilized for domestic standby letters of credit that reduced our borrowing availability as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;">. The Credit Agreement matures in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 2019</span><span style="font-family:inherit;font-size:11pt;">. If we had borrowed against our Credit Agreement, the borrowing rate would have been </span><span style="font-family:inherit;font-size:11pt;"><span>2.55%</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span>. The principal components of long-term debt are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020 principal amount</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.8</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.9</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c1ffba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c1ffba;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 425000000.0 425000000.0 2200000 2500000 422800000 422500000 12100000 12000000.0 434900000 434500000 500000 300000 434400000 434200000 425000000.0 0.04875 422600000 0.04946 0.04875 0.04875 0.04875 1 0.04875 0.04875 0.04875 200000000.0 500000 0.0255 7.    <span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ACCUMULATED OTHER COMPREHENSIVE INCOME</span><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2017:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of June 30, 2017:</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>569.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>610.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2016:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>369.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of June 30, 2016:</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>459.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:35%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="17" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes impact (in millions):</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding (losses) gains on available-for-sale investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reclassification adjustments are calculated using the specific identification method. Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2017:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of June 30, 2017:</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>569.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>610.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2016:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>369.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of June 30, 2016:</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>459.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1300000 -18600000 435000000.0 417700000 60500000 -2500000 213200000 271200000 0 0 0 0 0 -500000 78500000 78000000.0 60500000 -2000000.0 134700000 193200000 61800000 -20600000 569700000 610900000 33700000 -20700000 369100000 382100000 19500000 -600000 92300000 111200000 0 -600000 500000 -100000 0 100000 33800000 33900000 19500000 -100000 58000000.0 77400000 53200000 -20800000 427100000 459500000 The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:35%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="17" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes impact (in millions):</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding (losses) gains on available-for-sale investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reclassification adjustments are calculated using the specific identification method. -200000 300000 0 600000 -200000 500000 0 500000 8.    EARNINGS PER SHARE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,613</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,398</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,597</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,381</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-18px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options and restricted stock awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,589</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,962</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive shares</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,613</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,398</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,597</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,381</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-18px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options and restricted stock awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,589</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,962</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive shares</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 29613000 29398000 29597000 29381000 393000 191000 365000 168000 30006000 29589000 29962000 29549000 0 75000 15000 74000 9.    OTHER INCOME AND EXPENSE, NET<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net includes the following components (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized loss (gain) on investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> Other (income) expense, net includes the following components (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized loss (gain) on investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div> 12000000.0 10600000 13100000 11900000 -200000 600000 100000 500000 11800000 11200000 13200000 12400000 10.    INCOME TAXES<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our effective income tax rate was </span><span style="font-family:inherit;font-size:11pt;"><span>(350)%</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>33%</span></span><span style="font-family:inherit;font-size:11pt;"> for the </span><span style="font-size:11pt;">three</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively. Our effective income tax rate was </span><span style="font-family:inherit;font-size:11pt;"><span>18%</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>36%</span></span><span style="font-family:inherit;font-size:11pt;"> for the </span><span style="font-size:11pt;">first half of</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively. </span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">The effective tax rate for the second quarter of 2017 was unusually low because of discrete tax benefits related to share-based compensation and the transfer of intangibles associated with our European reorganization, combined with low earnings before tax.</span><span style="font-family:inherit;font-size:11pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:11pt;">The effective tax rate for the first half of 2017 was lower primarily due to the second quarter discrete tax benefits.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate including Switzerland and Singapore have statutory tax rates that are significantly lower than the U.S. statutory tax rate of </span><span style="font-family:inherit;font-size:11pt;"><span>35%</span></span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">As of June 30, 2017, based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$3.5 million</span></span>. Substantially all such amounts will favorably impact our effective income tax rate. -3.50 0.33 0.18 0.36 0.35 3500000 SEGMENT INFORMATION<div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments for the three months ended </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> is as follows (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>322.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>180.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>333.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net (loss) profit</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(23.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments for the six months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> is as follows (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>353.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>644.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>345.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>635.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net (loss) profit</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(41.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment.  During the second quarter of 2017, our Clinical Diagnostics segment had an asset purchase for an early stage device for </span><span style="font-family:inherit;font-size:11pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> that was recorded in Research and development expense. See Note 13 for a discussion of restructuring costs. The following reconciles total segment profit to consolidated income before taxes (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment (loss) profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency exchange losses, net</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> Information regarding industry segments for the three months ended <span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> is as follows (in millions):</span><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>322.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>180.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>333.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net (loss) profit</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(23.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments for the six months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> is as follows (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>353.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>644.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>345.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>635.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net (loss) profit</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(41.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><br/> 179400000 322100000 3200000 180000000.0 333700000 3100000 -23000000.0 17900000 200000 -5100000 23900000 -300000 353600000 644400000 6700000 345800000 635400000 6800000 -41800000 58900000 400000 -8400000 48600000 100000 7500000 The following reconciles total segment profit to consolidated income before taxes (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment (loss) profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency exchange losses, net</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -4900000 18500000 17500000 40300000 -2500000 -1200000 -4300000 -2400000 -3300000 -1600000 -5100000 -3200000 11800000 11200000 13200000 12400000 1100000 26900000 21300000 47100000 12.    LEGAL PROCEEDINGS<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our then current directors and one former director. We were also named as a nominal defendant. In the complaint, the plaintiff alleged that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors had been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff sought an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it was not in the best interests of the </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption was City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our then current directors and one former director. We were named as a nominal defendant in the complaints. The complaints alleged that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs asserted claims for breach of fiduciary duty and unjust enrichment and requested an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that set forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement included the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants did not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. The Court held a hearing for final approval of the settlement on March 2, 2017, and the Court approved the settlement.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded </span><span style="font-family:inherit;font-size:11pt;"><span>$10.92 million</span></span><span style="font-family:inherit;font-size:11pt;">, plus prejudgment interest of </span><span style="font-family:inherit;font-size:11pt;"><span>$141,608</span></span><span style="font-family:inherit;font-size:11pt;">, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleges that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. We are cooperating with the District and are investigating the allegations. No formal proceeding has been initiated by the District.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 10920000 141608 13.    RESTRUCTURING COSTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For the </span><span style="font-size:11pt;">three</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-size:11pt;">six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;">, we recorded less than </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to restructuring actions that include the elimination or relocation of various positions. These actions are generally intended to streamline and focus our efforts and more properly align our cost structure with projected future revenue streams.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity of our restructuring reserves for severance (in millions): </span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:40%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation losses</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance at June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">In May, 2016, management announced that it will take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded less than </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of adjustments in restructuring charges related to severance and other employee benefits for the </span><span style="font-size:11pt;">three</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-size:11pt;">six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;">. The liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$7.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span><span style="font-family:inherit;font-size:11pt;"> encompassed a short-term liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> and a long-term liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, and is anticipated to be paid through 2019. The amounts recorded were reflected in Cost of goods sold of less than </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.2) million</span></span><span style="font-family:inherit;font-size:11pt;">, and in Selling, general and administrative expense of less than </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Condensed Consolidated Statements of Income for the </span><span style="font-size:11pt;">three</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-size:11pt;">six</span><span style="font-family:inherit;font-size:11pt;"> months ended </span><span style="font-family:inherit;font-size:11pt;">June 30, 2017</span>, respectively. The amounts adjusted were primarily due to employees finding other positions within Bio-Rad or leaving prematurely. 100000 The following table summarizes the activity of our restructuring reserves for severance (in millions): <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:40%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation losses</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance at June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 3200000 5800000 9000000.0 0 0 0 0 0 0 700000 1200000 1900000 -300000 -400000 -700000 2800000 5000000.0 7800000 100000 7800000 5200000 2600000 100000 -200000 100000 200000 Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2017 December 31, 2016Short-term investments$391.3 $383.2Other investments941.1 732.4Total$1,332.4 $1,115.6 Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2017 December 31, 2016Other current liabilities$3.2 $14.5Other long-term liabilities23.5 24.0   Total$26.7 $38.5 Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. XML 13 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2017
Jul. 27, 2017
Entity Registrant Name BIO RAD LABORATORIES INC  
Entity Central Index Key 0000012208  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Jun. 30, 2017  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Well-known Seasoned Issuer Yes  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Common Class A [Member]    
Entity Common Stock, Shares Outstanding   24,528,198
Common Class B [Member]    
Entity Common Stock, Shares Outstanding   5,109,777
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
ASSETS:    
Cash and cash equivalents $ 321,584 $ 456,264
Short-term investments 391,268 383,176
Restricted investments 4,560 4,560
Accounts receivable, net 392,842 372,348
Inventories:    
Raw materials 115,043 116,540
Work in process 133,055 125,982
Finished goods 332,483 282,439
Total inventories 580,581 524,961
Prepaid expenses 125,655 91,014
Other current assets 10,038 12,201
Total current assets 1,826,528 1,844,524
Property, plant and equipment, at cost 1,277,970 1,227,388
Less: accumulated depreciation and amortization (774,641) (738,774)
Property, plant and equipment, net 503,329 488,614
Goodwill, net 530,287 477,115
Purchased intangibles, net 184,819 161,609
Other investments 1,040,959 830,790
Other assets 57,537 47,852
Total assets 4,143,459 3,850,504
LIABILITIES AND STOCKHOLDERS' EQUITY:    
Accounts payable, accrued payroll and employee benefits 277,566 296,473
Current maturities of long-term debt and notes payable 505 334
Income and other taxes payable 33,308 28,124
Other current liabilities 143,731 146,391
Total current liabilities 455,110 471,322
Long-term debt, net of current maturities 434,386 434,186
Deferred income taxes 294,843 222,919
Other long-term liabilities 148,123 135,318
Total liabilities 1,332,462 1,263,745
Stockholders' equity:    
Additional paid-in capital 347,658 332,911
Retained earnings 1,853,372 1,836,180
Accumulated other comprehensive income 610,948 417,766
Total stockholders' equity 2,810,997 2,586,759
Total liabilities and stockholders' equity 4,143,459 3,850,504
Common Class A [Member]    
Stockholders' equity:    
Common stock 2 2
Common Class B [Member]    
Stockholders' equity:    
Common stock 1 1
Treasury Class A [Member]    
Stockholders' equity:    
Treasury Stock, Value (895) (12)
Treasury Class B [Member]    
Stockholders' equity:    
Treasury Stock, Value $ (89) $ (89)
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets Parenthetical - shares
Jun. 30, 2017
Dec. 31, 2016
Common Class A [Member]    
Common Stock, Shares, Issued 24,500,249 24,454,048
Common Stock, Shares, Outstanding 24,496,127 24,453,926
Common Class B [Member]    
Common Stock, Shares, Issued 5,125,094 5,123,883
Common Stock, Shares, Outstanding 5,124,177 5,122,966
Treasury Class A [Member]    
Treasury Stock, Shares 4,122 122
Treasury Class B [Member]    
Treasury Stock, Shares 917 917
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Net sales $ 504,666 $ 516,777 $ 1,004,717 $ 987,974
Cost of goods sold 231,367 236,545 461,431 443,713
Gross profit 273,299 280,232 543,286 544,261
Selling, general and administrative expense 213,027 205,536 407,967 395,252
Research and Development Expense 62,623 49,811 112,111 98,397
Asset Impairment Charges 0 2,360 0 2,360
Segment profit (loss) (2,351) 22,525 23,208 48,252
Interest expense 5,770 5,632 10,811 11,212
Foreign exchange losses, net 2,516 1,237 4,305 2,366
Other (income) expense, net (11,757) (11,208) (13,175) (12,385)
Income before income taxes 1,120 26,864 21,267 47,059
Provision for income taxes 3,915 (8,850) (3,819) (16,769)
Net income including noncontrolling interests     17,448 30,290
Net income attributable to Bio-Rad $ 5,035 $ 18,014 $ 17,448 $ 30,290
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 0.17 $ 0.61 $ 0.59 $ 1.03
Weighted average common shares - basic 29,613 29,398 29,597 29,381
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 0.17 $ 0.61 $ 0.58 $ 1.03
Weighted average common shares - diluted 30,006 29,589 29,962 29,549
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Net Income (Loss) Attributable to Parent $ 5,035 $ 18,014 $ 17,448 $ 30,290
Foreign currency translation adjustments 41,679 (18,424) 60,522 19,512
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent (1,938) 535 (2,053) (105)
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense 54,564 62,109 134,713 58,015
Total other comprehensive income (loss) net of tax 94,305 44,220 193,182 77,422
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ 99,340 $ 62,234 $ 210,630 $ 107,712
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Cash flows from operating activities:    
Cash received from customers $ 999,779 $ 1,020,149
Cash paid to suppliers and employees (970,116) (935,587)
Interest paid, net (10,315) (10,911)
Income tax payments, net (19,066) (11,085)
Investment proceeds and miscellaneous receipts, net 13,947 12,810
Excess tax benefits from share-based compensation 0 (75)
(Payments for) proceeds from forward foreign exchange contracts, net (8,029) 5,594
Net cash provided by operating activities 6,200 69,707
Cash flows from investing activities:    
Capital expenditures (64,951) (56,865)
Proceeds from dispositions of property, plant and equipment 21 21
Payments for acquisitions and long-term investments (73,573) (11,477)
Payments for purchases of intangible assets (3,920) (6)
Payments for purchases of marketable securities and investments (142,993) (148,423)
Proceeds from sales of marketable securities and investments 39,362 42,386
Proceeds from maturities of marketable securities and investments 98,379 64,036
Net cash used in investing activities (147,675) (110,328)
Cash flows from financing activities:    
Net payments on line-of-credit arrangements and notes payable (36) 0
Payments on long-term borrowings (149) (156)
Payments of contingent consideration (3,105) (3,500)
Proceeds from issuance of common stock for shared-based compensation 3,778 6,875
Payments for purchases of treasury stock 883 0
Excess tax benefits from share-based compensation 0 75
Net cash (used in) provided by financing activities (395) 3,294
Effect of foreign exchange rate changes on cash 7,190 (1,571)
Net decrease in cash and cash equivalents (134,680) (38,898)
Cash and cash equivalents at beginning of period 456,264 457,549
Cash and cash equivalents at end of period 321,584  
Adjustments to reconcile net income to net cash used in operating activities [Abstract]    
Net income 17,448 30,290
Adjustments, Noncash Items, to Reconcile Net Income to Cash Used in Operating Activities [Abstract]    
Depreciation and amortization 70,688 71,668
Share-based compensation 10,579 9,407
Losses (gains) on dispositions of securities 310 (66)
Excess tax benefits from share-based compensation 0 (75)
Changes in fair value of contingent consideration (8,700) (1,873)
(Increase) decrease in accounts receivable (1,849) 32,067
Increase in inventories (37,870) (50,979)
Increase in other current assets (14,878) (2,561)
Decrease in accounts payable and other current liabilities (24,160) (32,564)
(Decrease) increase in income taxes payable (13,208) 11
(Decrease) increase in Deferred Income Taxes (3,057) 4,060
Net decrease/increase in other long-term assets/liabilities 10,897 10,322
Net cash provided by operating activities $ 6,200 $ 69,707
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
1. Organization, Consolidation and Presentation of Financial Statements
 6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure 1.BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2016.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.

Recent Accounting Standards Updates

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our condensed consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for
capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. In several foreign locations, we are statutorily required to provide a lump sum severance or termination indemnity to our employees and are currently evaluating the applicability of ASU 2017-07 to our situation.

In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. There was no impact of ASU 2017-04 on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the
carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principal on January 1, 2017, and made a policy election to account for forfeitures as they occur. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by $0.3 million, and increased Additional paid-in capital and Deferred tax assets by $0.4 million and $0.1 million, respectively, in the Condensed Consolidated Balance Sheet.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the condensed consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting
principle on January 1, 2017, which did not have a material impact on our condensed consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We are in the process of assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
2. Acquisitions
 6 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
Business Combination Disclosure [Text Block] ACQUISITIONS

RainDance Technologies, Inc.
In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $76.6 million including certain assumed net liabilities. Cash payments at closing were $72.8 million. In addition, we had a cash payment of $10.0 million for a one-time expense associated with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.
The preliminary allocation of the payments were $10.0 million for the one-time expense, $35.0 million to purchased intangibles consisting primarily of a large patent and license portfolio, limited know how and customer relationships, $3.8 million to assumed net liabilities, and $36.2 million to goodwill. We recorded a deferred tax liability of $12.9 million related to the purchased intangibles and a deferred tax asset of $18.3 million related to the acquired net operating losses. The purchase price allocation is preliminary as additional time is required to complete the valuation of the intangibles.
RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers with solutions for a wide range of nucleic acid detection applications.

Propel Labs, Inc.

In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date.

The fair value of the consideration as of the acquisition date was $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel. The amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, and was recognized at its estimated fair value of $26.7 million as of June 30, 2017 (see Note 3, "Fair Value Measurements").

The fair values of the net assets acquired from Propel as of the acquisition date were determined to be $32.7 million of definite-lived intangible assets and $0.1 million of goodwill. The goodwill related to this acquisition will be deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology.

In addition, Bio-Rad contracted with Propel to provide development services concurrent with and included in the purchase agreement. Bio-Rad is receiving future manufacturing, engineering and marketing support from Propel on which payments will be made upon the successful completion of all contracted services. As a result, these services are not included in the total purchase consideration and a majority will be expensed in future periods.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Fair Value Measurements
 6 Months Ended
Jun. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value Measurements 3.FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2017 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
15.2

 
$
—

 
$
15.2

Foreign time deposits
12.4

 
—

 
—

 
12.4

Money market funds
4.6

 
—

 
—

 
4.6

Total cash equivalents (a)
17.0

 
15.2

 
—

 
32.2

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
201.7

 
—

 
201.7

U.S. government sponsored agencies
—

 
72.1

 
—

 
72.1

Foreign government obligations
—

 
3.0

 
—

 
3.0

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
13.8

 
—

 
13.8

Marketable equity securities
980.1

 
—

 
—

 
980.1

Asset-backed securities
—

 
58.1

 
—

 
58.1

Total available-for-sale investments (b)
980.1

 
352.3

 
—

 
1,332.4

Forward foreign exchange contracts (c)
—

 
0.4

 
—

 
0.4

Total financial assets carried at fair value
$
1,001.7

 
$
367.9

 
$
—

 
$
1,369.6

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.0

 
$
—

 
$
1.0

Contingent consideration (e)
—

 
—

 
26.7

 
26.7

Total financial liabilities carried at fair value
$
—

 
$
1.0

 
$
26.7

 
$
27.7



Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
14.1

 
$
—

 
$
14.1

Foreign time deposits
11.8

 
—

 
—

 
11.8

Domestic time deposits
—

 
20.0

 
—

 
20.0

U.S. government sponsored agencies
—

 
1.1

 
—

 
1.1

Money market funds
5.9

 
—

 
—

 
5.9

Total cash equivalents (a)
17.7

 
35.2

 
—

 
52.9

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
179.4

 
—

 
179.4

U.S. government sponsored agencies
—

 
82.5

 
—

 
82.5

Foreign government obligations
—

 
4.4

 
—

 
4.4

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
15.4

 
—

 
15.4

Marketable equity securities
767.8

 
—

 
—

 
767.8

Asset-backed securities
—

 
62.5

 
—

 
62.5

Total available-for-sale investments (b)
767.8

 
347.8

 
—

 
1,115.6

Forward foreign exchange contracts (c)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
790.1

 
$
383.6

 
$
—

 
$
1,173.7

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.3

 
$
—

 
$
1.3

Contingent consideration (e)
—

 
—

 
38.5

 
38.5

Total financial liabilities carried at fair value
$
—

 
$
1.3

 
$
38.5

 
$
39.8


(a)
Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

(b)
Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30,
2017
 
December 31, 2016
Short-term investments
$
391.3

 
$
383.2

Other investments
941.1

 
732.4

Total
$
1,332.4

 
$
1,115.6



(c)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.

(d)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.

(e)
Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
June 30, 2017
 
December 31, 2016
Other current liabilities
$
3.2

 
$
14.5

Other long-term liabilities
23.5

 
24.0

   Total
$
26.7

 
$
38.5



In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a cell sorting system from Propel. Since 2012, we have paid $32.0 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million. The remaining liability of $3.1 million was paid in February 2017.

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount through December 31, 2020. The contingent consideration was accrued at its estimated fair value of $26.7 million as of June 30, 2017.

The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):

January 1, 2017
$
28.5

Cell sorting system:
 
Payment of sales milestone
(3.1
)
 
 
Analytical flow cytometer platform:
 
Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense
1.3

June 30, 2017
$
26.7



The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of June 30, 2017. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
 
 
 
 
Valuation Technique
Unobservable Input
 
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
10.5
%
 
 
Cost of debt
4.3
%
 
 
 
 



In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The contingent
consideration was revalued to a fair value of $10.0 million as of December 31, 2016 and was reversed to selling, general and administrative expenses during the first quarter of 2017 due to reaching a favorable outcome with GnuBIO, Inc.

To estimate the fair value of Level 2 debt securities as of June 30, 2017 and December 31, 2016, our primary pricing provider uses S&P Capital IQ as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is S&P Capital IQ as the primary pricing source and then our custodian as the secondary pricing source. If S&P Capital IQ does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing.

For commercial paper as of June 30, 2017 and December 31, 2016, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par.

Our pricing provider performs daily reasonableness testing of the S&P Capital IQ prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the S&P Capital IQ prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
June 30, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
201.6

 
$
0.4

 
$
(0.3
)
 
$
201.7

Brokered certificates of deposit
3.6

 
—

 
—

 
3.6

Municipal obligations
13.8

 
—

 
—

 
13.8

Asset-backed securities
57.9

 
0.1

 
(0.1
)
 
57.9

U.S. government sponsored agencies
72.4

 
0.1

 
(0.4
)
 
72.1

Foreign government obligations
3.0

 
—

 
—

 
3.0

Marketable equity securities
32.5

 
7.0

 
(0.3
)
 
39.2

 
384.8

 
7.6

 
(1.1
)
 
391.3

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
886.4

 
—

 
940.9

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
886.4

 
—

 
941.1

Total
$
439.5

 
$
894.0

 
$
(1.1
)
 
$
1,332.4



 
December 31, 2016
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
179.7

 
$
0.2

 
$
(0.5
)
 
$
179.4

Brokered certificates of deposit
3.6

 
—

 
—

 
3.6

Municipal obligations
15.5

 
—

 
(0.1
)
 
15.4

Asset-backed securities
62.2

 
0.1

 
(0.1
)
 
62.2

U.S. government sponsored agencies
83.1

 
0.1

 
(0.7
)
 
82.5

Foreign government obligations
4.4

 
—

 
—

 
4.4

Marketable equity securities
32.4

 
3.7

 
(0.4
)
 
35.7

 
380.9

 
4.1

 
(1.8
)
 
383.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
677.6

 
—

 
732.1

Asset-backed securities
0.3

 
—

 
—

 
0.3

 
54.8

 
677.6

 
—

 
732.4

Total
$
435.7

 
$
681.7

 
$
(1.8
)
 
$
1,115.6



The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares.

The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
June 30,
2017
 
December 31, 2016
Fair value of investments in a loss position 12 months or more
$
8.1

 
$
11.8

Fair value of investments in a loss position less than 12 months
$
164.8

 
$
160.5

Gross unrealized losses for investments in a loss position 12 months or more
$
0.3

 
$
0.3

Gross unrealized losses for investments in a loss position less than 12 months
$
0.8

 
$
1.5



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at June 30, 2017 or at December 31, 2016.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of June 30, 2017 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income.

The following is a summary of our forward foreign exchange contracts (in millions):
 
June 30,
 
2017
Contracts maturing in July through September 2017 to sell foreign currency:
 
Notional value
$
76.8

Unrealized loss
$
0.2

Contracts maturing in July through September 2017 to purchase foreign currency:
 
Notional value
$
327.0

Unrealized loss
$
0.4



The following is a summary of the amortized cost and estimated fair value of our debt securities at June 30, 2017 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
156.2

 
$
156.2

Mature in one to five years
144.9

 
144.9

Mature in more than five years
51.4

 
51.2

Total
$
352.5

 
$
352.3



The estimated fair value of financial instruments that are not recognized at fair value in the Condensed Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which have fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):

 
June 30, 2017
 
December 31, 2016
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
93.7

 
$
1,265.8

 
2
 
$
92.8

 
$
984.2

 
2
Total long-term debt, excluding leases and current maturities
$
422.8

 
$
456.7

 
2
 
$
422.5

 
$
454.2

 
2


We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over 35% of the outstanding voting shares (excluding treasury shares) of Sartorius as of June 30, 2017.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ Board of Directors, nor do we have the ability to exercise significant
influence over the operating and financial policies of Sartorius.  We account for this investment using the cost method.  The carrying value of this investment is included in Other investments in our Condensed Consolidated Balance Sheets. As the stock is thinly traded and in conjunction with the valuation method discussed above, we have classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
4. Intangible Assets, Goodwill and Other
 6 Months Ended
Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1, 2017:
 
 
 
 
 
Goodwill
$
207.1

 
$
311.7

 
$
518.8

Accumulated impairment losses
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
179.9

 
297.2

 
477.1

 
 
 
 
 
 
Acquisitions
36.2

 
—

 
36.2

Currency fluctuations
0.4

 
16.6

 
17.0

 
 
 
 
 
 
Balances as of June 30, 2017:
 
 
 
 
 
Goodwill
243.7

 
328.3

 
572.0

Accumulated impairment losses
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
$
216.5

 
$
313.8

 
$
530.3



In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions), we recorded $36.2 million of goodwill and $35.0 million for licenses.

Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
June 30, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
90.0

 
$
(59.5
)
 
$
30.5

Know how
1-9
 
190.2

 
(149.2
)
 
41.0

Developed product technology
2-12
 
129.8

 
(63.3
)
 
66.5

Licenses
2-14
 
74.8

 
(33.9
)
 
40.9

Tradenames
4-7
 
3.6

 
(2.7
)
 
0.9

Covenants not to compete
2-9
 
7.9

 
(2.9
)
 
5.0

     Total definite-lived intangible assets
 
 
$
496.3

 
$
(311.5
)
 
$
184.8


 
December 31, 2016
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
84.4

 
$
(52.8
)
 
$
31.6

Know how
1-9
 
182.6

 
(136.9
)
 
45.7

Developed product technology
3-12
 
125.9

 
(56.3
)
 
69.6

Licenses
1-9
 
39.0

 
(30.6
)
 
8.4

Tradenames
4-8
 
3.5

 
(2.5
)
 
1.0

Covenants not to compete
2-9
 
7.8

 
(2.5
)
 
5.3

     Total definite-lived intangible assets
 
 
$
443.2

 
$
(281.6
)
 
$
161.6



Amortization expense related to purchased intangible assets is as follows (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
Amortization expense
$
8.7

 
$
9.6

 
$
15.6

 
$
19.0
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
5. Product Warranty Liability
 6 Months Ended
Jun. 30, 2017
Product Warranties Disclosures [Abstract]  
Product Warranty Liability 5.PRODUCT WARRANTY LIABILITY

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):

January 1, 2017
$
17.6

Provision for warranty
13.9

Actual warranty costs
(13.8
)
June 30, 2017
$
17.7
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
6. Long-Term Debt
 6 Months Ended
Jun. 30, 2017
Debt Disclosure [Abstract]  
Long-term Debt
6.    LONG-TERM DEBT

The principal components of long-term debt are as follows (in millions):

 
June 30,
2017
 
December 31, 2016
4.875% Senior Notes due 2020 principal amount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(2.2
)
 
(2.5
)
Long-term debt less unamortized discount and debt issuance costs
422.8

 
422.5

Capital leases and other debt
12.1

 
12.0

 
434.9

 
434.5

Less current maturities
(0.5
)
 
(0.3
)
Long-term debt
$
434.4

 
$
434.2




Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.

Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of June 30, 2017 or December 31, 2016, however $0.5 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of June 30, 2017. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the borrowing rate would have been 2.55% at June 30, 2017.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of June 30, 2017.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)
 6 Months Ended
Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Stockholders' Equity Note Disclosure [Text Block] 7.    ACCUMULATED OTHER COMPREHENSIVE INCOME

Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2017:
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
60.5

(2.5
)
213.2

271.2

Amounts reclassified from Accumulated other comprehensive income
—

—

—

—

Income tax effects
—

0.5

(78.5
)
(78.0
)
Other comprehensive income (loss), net of income taxes
60.5

(2.0
)
134.7

193.2

Balances as of June 30, 2017:
$
61.8

$
(20.6
)
$
569.7

$
610.9


 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2016:
$
33.7

$
(20.7
)
$
369.1

$
382.1

Other comprehensive income (loss), before reclassifications
19.5

(0.6
)
92.3

111.2

Amounts reclassified from Accumulated other comprehensive income
—

0.6

(0.5
)
0.1

Income tax effects
—

(0.1
)
(33.8
)
(33.9
)
Other comprehensive income (loss), net of income taxes
19.5

(0.1
)
58.0

77.4

Balances as of June 30, 2016:
$
53.2

$
(20.8
)
$
427.1

$
459.5



The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:

 
Income before taxes impact (in millions):
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
 
June 30,
 
June 30,
 
 
Components of Comprehensive income
 
2017
 
2016
 
2017
 
2016
 
Location
Amortization of foreign other post-employment benefit items
 
$
0.2

 
$
(0.3
)
 
$
—

 
$
(0.6
)
 
Selling, general and administrative expense
Net holding (losses) gains on available-for-sale investments
 
$
(0.2
)
 
$
0.5

 
$
—

 
$
0.5

 
Other (income) expense, net

Reclassification adjustments are calculated using the specific identification method.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
8. Earnings Per Share
 6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Earnings Per Share 8.    EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Basic weighted average shares outstanding
29,613

 
29,398

 
29,597

 
29,381

Effect of potentially dilutive stock options and restricted stock awards
393

 
191

 
365

 
168

Diluted weighted average common shares
30,006

 
29,589

 
29,962

 
29,549

Anti-dilutive shares
—

 
75

 
15

 
74
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
9. Other Income and Expenses
 6 Months Ended
Jun. 30, 2017
Other Income and Expenses [Abstract]  
Other Income and Other Expense Disclosure 9.    OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Interest and investment income
$
(12.0
)
 
$
(10.6
)
 
$
(13.1
)
 
$
(11.9
)
Net realized loss (gain) on investments
0.2

 
(0.6
)
 
(0.1
)
 
(0.5
)
Other (income) expense, net
$
(11.8
)
 
$
(11.2
)
 
$
(13.2
)
 
$
(12.4
)
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
10. Income Taxes
 6 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]  
Income Taxes 10.    INCOME TAXES
 
Our effective income tax rate was (350)% and 33% for the three months ended June 30, 2017 and 2016, respectively. Our effective income tax rate was 18% and 36% for the first half of 2017 and 2016, respectively. The effective tax rate for the second quarter of 2017 was unusually low because of discrete tax benefits related to share-based compensation and the transfer of intangibles associated with our European reorganization, combined with low earnings before tax. The effective tax rate for the first half of 2017 was lower primarily due to the second quarter discrete tax benefits.
  
Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate including Switzerland and Singapore have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35%.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

As of June 30, 2017, based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $3.5 million. Substantially all such amounts will favorably impact our effective income tax rate.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
11. Segment Information
 6 Months Ended
Jun. 30, 2017
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION

Information regarding industry segments for the three months ended June 30, 2017 and 2016 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2017
$
179.4

 
$
322.1

 
$
3.2

 
2016
$
180.0

 
$
333.7

 
$
3.1

 
 
 
 
 
 
 
Segment net (loss) profit
2017
$
(23.0
)
 
$
17.9

 
$
0.2

 
2016
$
(5.1
)
 
$
23.9

 
$
(0.3
)


Information regarding industry segments for the six months ended June 30, 2017 and 2016 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2017
$
353.6

 
$
644.4

 
$
6.7

 
2016
$
345.8

 
$
635.4

 
$
6.8

 
 
 
 
 
 
 
Segment net (loss) profit
2017
$
(41.8
)
 
$
58.9

 
$
0.4

 
2016
$
(8.4
)
 
$
48.6

 
$
0.1



Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment.  During the second quarter of 2017, our Clinical Diagnostics segment had an asset purchase for an early stage device for $7.5 million that was recorded in Research and development expense. See Note 13 for a discussion of restructuring costs. The following reconciles total segment profit to consolidated income before taxes (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Total segment (loss) profit
$
(4.9
)
 
$
18.5

 
$
17.5

 
$
40.3

Foreign currency exchange losses, net
(2.5
)
 
(1.2
)
 
(4.3
)
 
(2.4
)
Net corporate operating, interest and other expense not allocated to segments
(3.3
)
 
(1.6
)
 
(5.1
)
 
(3.2
)
Other income (expense), net
11.8

 
11.2

 
13.2

 
12.4

Consolidated income before income taxes
$
1.1

 
$
26.9

 
$
21.3

 
$
47.1
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
12. Legal Proceedings
 6 Months Ended
Jun. 30, 2017
Loss Contingency, Information about Litigation Matters [Abstract]  
Legal Proceedings. 12.    LEGAL PROCEEDINGS

On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our then current directors and one former director. We were also named as a nominal defendant. In the complaint, the plaintiff alleged that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors had been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff sought an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it was not in the best interests of the
Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption was City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”.

On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our then current directors and one former director. We were named as a nominal defendant in the complaints. The complaints alleged that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs asserted claims for breach of fiduciary duty and unjust enrichment and requested an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.

The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that set forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement included the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants did not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. The Court held a hearing for final approval of the settlement on March 2, 2017, and the Court approved the settlement.

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.

Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleges that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. We are cooperating with the District and are investigating the allegations. No formal proceeding has been initiated by the District.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
13. Restructuring Costs (Notes)
 6 Months Ended
Jun. 30, 2017
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] 13.    RESTRUCTURING COSTS

For the three and six months ended June 30, 2017, we recorded less than $0.1 million related to restructuring actions that include the elimination or relocation of various positions. These actions are generally intended to streamline and focus our efforts and more properly align our cost structure with projected future revenue streams.
 
The following table summarizes the activity of our restructuring reserves for severance (in millions):
 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance at December 31, 2016
 
$
3.2

 
$
5.8

 
$
9.0

Charged to expense
 
—

 
—

 
—

Adjustment to expense
 
—

 
—

 
—

Cash payments
 
(0.7
)
 
(1.2
)
 
(1.9
)
Foreign currency translation losses
 
0.3

 
0.4

 
0.7

Balance at June 30, 2017
 
$
2.8

 
$
5.0

 
$
7.8



In May, 2016, management announced that it will take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded less than $0.1 million of adjustments in restructuring charges related to severance and other employee benefits for the three and six months ended June 30, 2017. The liability of $7.8 million as of June 30, 2017 encompassed a short-term liability of $5.2 million and a long-term liability of $2.6 million, and is anticipated to be paid through 2019. The amounts recorded were reflected in Cost of goods sold of less than $0.1 million and $(0.2) million, and in Selling, general and administrative expense of less than $0.1 million and $0.2 million in the Condensed Consolidated Statements of Income for the three and six months ended June 30, 2017, respectively. The amounts adjusted were primarily due to employees finding other positions within Bio-Rad or leaving prematurely.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies)
 6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
New Accounting Pronouncements, Policy [Policy Text Block] In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our condensed consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for
capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. In several foreign locations, we are statutorily required to provide a lump sum severance or termination indemnity to our employees and are currently evaluating the applicability of ASU 2017-07 to our situation.

In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. There was no impact of ASU 2017-04 on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the
carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principal on January 1, 2017, and made a policy election to account for forfeitures as they occur. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by $0.3 million, and increased Additional paid-in capital and Deferred tax assets by $0.4 million and $0.1 million, respectively, in the Condensed Consolidated Balance Sheet.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the condensed consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting
principle on January 1, 2017, which did not have a material impact on our condensed consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We are in the process of assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2017
Fair Value Disclosures [Abstract]  
Schedule of financial assets and liabilities carried at fair value on a recurring basis
Financial assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2017 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
15.2

 
$
—

 
$
15.2

Foreign time deposits
12.4

 
—

 
—

 
12.4

Money market funds
4.6

 
—

 
—

 
4.6

Total cash equivalents (a)
17.0

 
15.2

 
—

 
32.2

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
201.7

 
—

 
201.7

U.S. government sponsored agencies
—

 
72.1

 
—

 
72.1

Foreign government obligations
—

 
3.0

 
—

 
3.0

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
13.8

 
—

 
13.8

Marketable equity securities
980.1

 
—

 
—

 
980.1

Asset-backed securities
—

 
58.1

 
—

 
58.1

Total available-for-sale investments (b)
980.1

 
352.3

 
—

 
1,332.4

Forward foreign exchange contracts (c)
—

 
0.4

 
—

 
0.4

Total financial assets carried at fair value
$
1,001.7

 
$
367.9

 
$
—

 
$
1,369.6

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.0

 
$
—

 
$
1.0

Contingent consideration (e)
—

 
—

 
26.7

 
26.7

Total financial liabilities carried at fair value
$
—

 
$
1.0

 
$
26.7

 
$
27.7



Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
14.1

 
$
—

 
$
14.1

Foreign time deposits
11.8

 
—

 
—

 
11.8

Domestic time deposits
—

 
20.0

 
—

 
20.0

U.S. government sponsored agencies
—

 
1.1

 
—

 
1.1

Money market funds
5.9

 
—

 
—

 
5.9

Total cash equivalents (a)
17.7

 
35.2

 
—

 
52.9

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
179.4

 
—

 
179.4

U.S. government sponsored agencies
—

 
82.5

 
—

 
82.5

Foreign government obligations
—

 
4.4

 
—

 
4.4

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
15.4

 
—

 
15.4

Marketable equity securities
767.8

 
—

 
—

 
767.8

Asset-backed securities
—

 
62.5

 
—

 
62.5

Total available-for-sale investments (b)
767.8

 
347.8

 
—

 
1,115.6

Forward foreign exchange contracts (c)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
790.1

 
$
383.6

 
$
—

 
$
1,173.7

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.3

 
$
—

 
$
1.3

Contingent consideration (e)
—

 
—

 
38.5

 
38.5

Total financial liabilities carried at fair value
$
—

 
$
1.3

 
$
38.5

 
$
39.8


(a)
Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

(b)
Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30,
2017
 
December 31, 2016
Short-term investments
$
391.3

 
$
383.2

Other investments
941.1

 
732.4

Total
$
1,332.4

 
$
1,115.6



(c)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.

(d)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.

(e)
Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
June 30, 2017
 
December 31, 2016
Other current liabilities
$
3.2

 
$
14.5

Other long-term liabilities
23.5

 
24.0

   Total
$
26.7

 
$
38.5
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):

January 1, 2017
$
28.5

Cell sorting system:
 
Payment of sales milestone
(3.1
)
 
 
Analytical flow cytometer platform:
 
Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense
1.3

June 30, 2017
$
26.7
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of June 30, 2017. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
 
 
 
 
Valuation Technique
Unobservable Input
 
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
10.5
%
 
 
Cost of debt
4.3
%
 
 
 
 
Schedule of available-for-sale investments
Available-for-sale investments consist of the following (in millions):

 
June 30, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
201.6

 
$
0.4

 
$
(0.3
)
 
$
201.7

Brokered certificates of deposit
3.6

 
—

 
—

 
3.6

Municipal obligations
13.8

 
—

 
—

 
13.8

Asset-backed securities
57.9

 
0.1

 
(0.1
)
 
57.9

U.S. government sponsored agencies
72.4

 
0.1

 
(0.4
)
 
72.1

Foreign government obligations
3.0

 
—

 
—

 
3.0

Marketable equity securities
32.5

 
7.0

 
(0.3
)
 
39.2

 
384.8

 
7.6

 
(1.1
)
 
391.3

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
886.4

 
—

 
940.9

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
886.4

 
—

 
941.1

Total
$
439.5

 
$
894.0

 
$
(1.1
)
 
$
1,332.4



 
December 31, 2016
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
179.7

 
$
0.2

 
$
(0.5
)
 
$
179.4

Brokered certificates of deposit
3.6

 
—

 
—

 
3.6

Municipal obligations
15.5

 
—

 
(0.1
)
 
15.4

Asset-backed securities
62.2

 
0.1

 
(0.1
)
 
62.2

U.S. government sponsored agencies
83.1

 
0.1

 
(0.7
)
 
82.5

Foreign government obligations
4.4

 
—

 
—

 
4.4

Marketable equity securities
32.4

 
3.7

 
(0.4
)
 
35.7

 
380.9

 
4.1

 
(1.8
)
 
383.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
677.6

 
—

 
732.1

Asset-backed securities
0.3

 
—

 
—

 
0.3

 
54.8

 
677.6

 
—

 
732.4

Total
$
435.7

 
$
681.7

 
$
(1.8
)
 
$
1,115.6
Summary of fair value of gross unrealized losses for investments with unrealized losses The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
June 30,
2017
 
December 31, 2016
Fair value of investments in a loss position 12 months or more
$
8.1

 
$
11.8

Fair value of investments in a loss position less than 12 months
$
164.8

 
$
160.5

Gross unrealized losses for investments in a loss position 12 months or more
$
0.3

 
$
0.3

Gross unrealized losses for investments in a loss position less than 12 months
$
0.8

 
$
1.5
Discussion of current derivative risk management The following is a summary of our forward foreign exchange contracts (in millions):
 
June 30,
 
2017
Contracts maturing in July through September 2017 to sell foreign currency:
 
Notional value
$
76.8

Unrealized loss
$
0.2

Contracts maturing in July through September 2017 to purchase foreign currency:
 
Notional value
$
327.0

Unrealized loss
$
0.4
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date
The following is a summary of the amortized cost and estimated fair value of our debt securities at June 30, 2017 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
156.2

 
$
156.2

Mature in one to five years
144.9

 
144.9

Mature in more than five years
51.4

 
51.2

Total
$
352.5

 
$
352.3
Estimated fair value of financial instruments
The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):

 
June 30, 2017
 
December 31, 2016
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
93.7

 
$
1,265.8

 
2
 
$
92.8

 
$
984.2

 
2
Total long-term debt, excluding leases and current maturities
$
422.8

 
$
456.7

 
2
 
$
422.5

 
$
454.2

 
2
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
4. Intangible Assets, Goodwill and Other (Tables)
 6 Months Ended
Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes to goodwill by segment Changes to goodwill by segment were as follows (in millions):
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1, 2017:
 
 
 
 
 
Goodwill
$
207.1

 
$
311.7

 
$
518.8

Accumulated impairment losses
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
179.9

 
297.2

 
477.1

 
 
 
 
 
 
Acquisitions
36.2

 
—

 
36.2

Currency fluctuations
0.4

 
16.6

 
17.0

 
 
 
 
 
 
Balances as of June 30, 2017:
 
 
 
 
 
Goodwill
243.7

 
328.3

 
572.0

Accumulated impairment losses
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
$
216.5

 
$
313.8

 
$
530.3



In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions), we recorded $36.2 million of goodwill and $35.0 million for licenses.
Schedule of identifiable purchased intangible assets with definite lives Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
June 30, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
90.0

 
$
(59.5
)
 
$
30.5

Know how
1-9
 
190.2

 
(149.2
)
 
41.0

Developed product technology
2-12
 
129.8

 
(63.3
)
 
66.5

Licenses
2-14
 
74.8

 
(33.9
)
 
40.9

Tradenames
4-7
 
3.6

 
(2.7
)
 
0.9

Covenants not to compete
2-9
 
7.9

 
(2.9
)
 
5.0

     Total definite-lived intangible assets
 
 
$
496.3

 
$
(311.5
)
 
$
184.8


 
December 31, 2016
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
84.4

 
$
(52.8
)
 
$
31.6

Know how
1-9
 
182.6

 
(136.9
)
 
45.7

Developed product technology
3-12
 
125.9

 
(56.3
)
 
69.6

Licenses
1-9
 
39.0

 
(30.6
)
 
8.4

Tradenames
4-8
 
3.5

 
(2.5
)
 
1.0

Covenants not to compete
2-9
 
7.8

 
(2.5
)
 
5.3

     Total definite-lived intangible assets
 
 
$
443.2

 
$
(281.6
)
 
$
161.6
Finite-lived Intangible Assets Amortization Expense [Table Text Block] Amortization expense related to purchased intangible assets is as follows (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
Amortization expense
$
8.7

 
$
9.6

 
$
15.6

 
$
19.0
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
5. Product Warranty Liability (Tables)
 6 Months Ended
Jun. 30, 2017
Product Warranties Disclosures [Abstract]  
Components of warranty accrual Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):

January 1, 2017
$
17.6

Provision for warranty
13.9

Actual warranty costs
(13.8
)
June 30, 2017
$
17.7
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
6. Long-Term Debt (Tables)
 6 Months Ended
Jun. 30, 2017
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments [Table Text Block] The principal components of long-term debt are as follows (in millions):

 
June 30,
2017
 
December 31, 2016
4.875% Senior Notes due 2020 principal amount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(2.2
)
 
(2.5
)
Long-term debt less unamortized discount and debt issuance costs
422.8

 
422.5

Capital leases and other debt
12.1

 
12.0

 
434.9

 
434.5

Less current maturities
(0.5
)
 
(0.3
)
Long-term debt
$
434.4

 
$
434.2
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables)
 6 Months Ended
Jun. 30, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2017:
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
60.5

(2.5
)
213.2

271.2

Amounts reclassified from Accumulated other comprehensive income
—

—

—

—

Income tax effects
—

0.5

(78.5
)
(78.0
)
Other comprehensive income (loss), net of income taxes
60.5

(2.0
)
134.7

193.2

Balances as of June 30, 2017:
$
61.8

$
(20.6
)
$
569.7

$
610.9


 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total accumulated other comprehensive income
Balances as of January 1, 2016:
$
33.7

$
(20.7
)
$
369.1

$
382.1

Other comprehensive income (loss), before reclassifications
19.5

(0.6
)
92.3

111.2

Amounts reclassified from Accumulated other comprehensive income
—

0.6

(0.5
)
0.1

Income tax effects
—

(0.1
)
(33.8
)
(33.9
)
Other comprehensive income (loss), net of income taxes
19.5

(0.1
)
58.0

77.4

Balances as of June 30, 2016:
$
53.2

$
(20.8
)
$
427.1

$
459.5
Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block] The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:

 
Income before taxes impact (in millions):
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
 
June 30,
 
June 30,
 
 
Components of Comprehensive income
 
2017
 
2016
 
2017
 
2016
 
Location
Amortization of foreign other post-employment benefit items
 
$
0.2

 
$
(0.3
)
 
$
—

 
$
(0.6
)
 
Selling, general and administrative expense
Net holding (losses) gains on available-for-sale investments
 
$
(0.2
)
 
$
0.5

 
$
—

 
$
0.5

 
Other (income) expense, net

Reclassification adjustments are calculated using the specific identification method.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
8. Earnings Per Share (Tables)
 6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Basic weighted average shares outstanding
29,613

 
29,398

 
29,597

 
29,381

Effect of potentially dilutive stock options and restricted stock awards
393

 
191

 
365

 
168

Diluted weighted average common shares
30,006

 
29,589

 
29,962

 
29,549

Anti-dilutive shares
—

 
75

 
15

 
74
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
9. Other Income and Expenses (Tables)
 6 Months Ended
Jun. 30, 2017
Other Income and Expenses [Abstract]  
Schedule of other income (expense), net Other (income) expense, net includes the following components (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Interest and investment income
$
(12.0
)
 
$
(10.6
)
 
$
(13.1
)
 
$
(11.9
)
Net realized loss (gain) on investments
0.2

 
(0.6
)
 
(0.1
)
 
(0.5
)
Other (income) expense, net
$
(11.8
)
 
$
(11.2
)
 
$
(13.2
)
 
$
(12.4
)
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
11. Segment Information (Tables)
 6 Months Ended
Jun. 30, 2017
Segment Reporting [Abstract]  
Information regarding industry segments Information regarding industry segments for the three months ended June 30, 2017 and 2016 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2017
$
179.4

 
$
322.1

 
$
3.2

 
2016
$
180.0

 
$
333.7

 
$
3.1

 
 
 
 
 
 
 
Segment net (loss) profit
2017
$
(23.0
)
 
$
17.9

 
$
0.2

 
2016
$
(5.1
)
 
$
23.9

 
$
(0.3
)


Information regarding industry segments for the six months ended June 30, 2017 and 2016 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2017
$
353.6

 
$
644.4

 
$
6.7

 
2016
$
345.8

 
$
635.4

 
$
6.8

 
 
 
 
 
 
 
Segment net (loss) profit
2017
$
(41.8
)
 
$
58.9

 
$
0.4

 
2016
$
(8.4
)
 
$
48.6

 
$
0.1
Reconciliation of segment profit to consolidated income before taxes The following reconciles total segment profit to consolidated income before taxes (in millions):

 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017
 
2016
 
2017
 
2016
Total segment (loss) profit
$
(4.9
)
 
$
18.5

 
$
17.5

 
$
40.3

Foreign currency exchange losses, net
(2.5
)
 
(1.2
)
 
(4.3
)
 
(2.4
)
Net corporate operating, interest and other expense not allocated to segments
(3.3
)
 
(1.6
)
 
(5.1
)
 
(3.2
)
Other income (expense), net
11.8

 
11.2

 
13.2

 
12.4

Consolidated income before income taxes
$
1.1

 
$
26.9

 
$
21.3

 
$
47.1
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
13. Restructuring Costs (Tables)
 6 Months Ended
Jun. 30, 2017
Restructuring Costs [Abstract]  
Restructuring and Related Costs [Table Text Block] The following table summarizes the activity of our restructuring reserves for severance (in millions):
 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance at December 31, 2016
 
$
3.2

 
$
5.8

 
$
9.0

Charged to expense
 
—

 
—

 
—

Adjustment to expense
 
—

 
—

 
—

Cash payments
 
(0.7
)
 
(1.2
)
 
(1.9
)
Foreign currency translation losses
 
0.3

 
0.4

 
0.7

Balance at June 30, 2017
 
$
2.8

 
$
5.0

 
$
7.8
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Jan. 01, 2017
Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Retained earnings $ 1,853,372   $ 1,836,180
Additional paid-in-capital $ 347,658   $ 332,911
Adjustments for New Accounting Pronouncement [Member]      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Retained earnings   $ (300)  
Additional paid-in-capital   400  
Deferred Tax Assets, Gross   $ 100  
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
2. Acquisitions (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Jun. 30, 2017
Feb. 15, 2017
Dec. 31, 2016
Jan. 06, 2016
Apr. 10, 2014
Business Acquisition [Line Items]              
Goodwill     $ 530,287   $ 477,115    
Goodwill, Acquired During Period     36,200        
RainDance Technologies, Inc. [Member]              
Business Acquisition [Line Items]              
Business Combination, Consideration Transferred $ 76,600            
Payments to Acquire Businesses, Net of Cash Acquired 72,800            
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed 10,000            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 35,000      
Goodwill, Acquired During Period 36,200            
Liabilities Assumed $ 12,900            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net       (3,800)      
Analytical Flow Cytometer Platform [Member]              
Business Acquisition [Line Items]              
Business Combination, Consideration Transferred   $ 32,800          
Payments to Acquire Businesses, Net of Cash Acquired   9,500          
Business Combination, Contingent Consideration, Liability     $ 26,700     $ 23,300  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles           $ 32,700  
Goodwill, Acquired During Period   $ 100          
GnuBIO [Member]              
Business Acquisition [Line Items]              
Business Combination, Contingent Consideration, Liability         $ 10,000   $ 10,700
Deferred Tax Asset [Domain] | RainDance Technologies, Inc. [Member]              
Business Acquisition [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net       $ 18,300      
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Fair Value Measurements Fair Value Level Table (Details) - USD ($)
$ in Millions
Jun. 30, 2017
Dec. 31, 2016
Jan. 06, 2016
Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Restricted Investments, at Fair Value $ 4.6 $ 4.6  
Available-for-sale Securities, Fair Value Disclosure [1] 1,332.4 1,115.6  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [2] 0.4 0.6  
Assets, Fair Value Disclosure 1,369.6 1,173.7  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [3] 1.0 1.3  
Business Combination, Contingent Consideration, Liability [4] 26.7 38.5  
Liabilities, Fair Value Disclosure 27.7 39.8  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Restricted Investments, at Fair Value 4.6 4.6  
Available-for-sale Securities, Fair Value Disclosure [1] 980.1 767.8  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [2] 0.0 0.0  
Assets, Fair Value Disclosure 1,001.7 790.1  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [3] 0.0 0.0  
Business Combination, Contingent Consideration, Liability [4] 0.0 0.0  
Liabilities, Fair Value Disclosure 0.0 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Restricted Investments, at Fair Value 0.0 0.0  
Available-for-sale Securities, Fair Value Disclosure [1] 352.3 347.8  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [2] 0.4 0.6  
Assets, Fair Value Disclosure 367.9 383.6  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [3] 1.0 1.3  
Business Combination, Contingent Consideration, Liability [4] 0.0 0.0  
Liabilities, Fair Value Disclosure 1.0 1.3  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Restricted Investments, at Fair Value 0.0 0.0  
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [2] 0.0 0.0  
Assets, Fair Value Disclosure 0.0 0.0  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [3] 0.0 0.0  
Business Combination, Contingent Consideration, Liability [4] 26.7 38.5  
Liabilities, Fair Value Disclosure 26.7 38.5  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5]   1.1  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5]   0.0  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5]   1.1  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5]   0.0  
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 15.2 14.1  
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0  
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 15.2 14.1  
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0  
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 12.4 11.8  
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 12.4 11.8  
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0  
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0  
Domestic time deposit [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5]   20.0  
Domestic time deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5]   0.0  
Domestic time deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5]   20.0  
Domestic time deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5]   0.0  
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 4.6 5.9  
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 4.6 5.9  
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0  
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0  
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 32.2 52.9  
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 17.0 17.7  
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 15.2 35.2  
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents, Fair Value Disclosure [5] 0.0 0.0  
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 3.6 3.6  
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 3.6 3.6  
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 980.1 767.8  
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 980.1 767.8  
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 13.8 15.4  
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 13.8 15.4  
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 3.0 4.4  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 3.0 4.4  
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 201.7 179.4  
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 201.7 179.4  
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 72.1 82.5  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 72.1 82.5  
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 58.1 62.5  
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 58.1 62.5  
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure [1] 0.0 0.0  
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration, Liability 3.2 14.5  
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration, Liability 23.5 24.0  
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure 391.3 383.2  
Short-term Investments [Member] | Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure 3.6 3.6  
Short-term Investments [Member] | Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure 39.2 35.7  
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure 13.8 15.4  
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure 3.0 4.4  
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure 201.7 179.4  
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure 72.1 82.5  
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure 57.9 62.2  
Other Investments [Member] | Fair Value, Measurements, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities, Fair Value Disclosure 941.1 $ 732.4  
Analytical Flow Cytometer Platform [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration, Liability 26.7   $ 23.3
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0.0    
[1] Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30,
2017
 
December 31, 2016
Short-term investments
$
391.3

 
$
383.2

Other investments
941.1

 
732.4

Total
$
1,332.4

 
$
1,115.6
[2] Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.
[3] Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.
[4] Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
June 30, 2017
 
December 31, 2016
Other current liabilities
$
3.2

 
$
14.5

Other long-term liabilities
23.5

 
24.0

   Total
$
26.7

 
$
38.5
[5] Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Fair Value Measurements 3. Contingent Consideration (Details) - USD ($)
$ in Millions
 6 Months Ended 48 Months Ended
Jun. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Jan. 06, 2016
Apr. 10, 2014
Sep. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value $ 26.7   $ 28.5      
CellSorter [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Contingent consideration milestone payments (3.1) $ (32.0)        
(Decrease) increase in fair value of contingent consideration included in SGA   $ (12.6)        
Business Combination, Contingent Consideration, Liability     3.1     $ 44.6
Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability 26.7     $ 23.3    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances $ 1.3          
GnuBIO [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability     10.0   $ 10.7  
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Contingent Consideration, Potential Percentage Payout 39.00%          
Market Price of Risk [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair Value Inputs, Entity Credit Risk 10.50%          
Projected Volatility of Growth Rate [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair Value Inputs, Entity Credit Risk 4.30%          
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Contingent Consideration, Potential Percentage Payout 20.00%          
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0.0          
Fair Value, Measurements, Recurring [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability [1] 26.7   38.5      
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability 23.5   24.0      
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability $ 3.2   $ 14.5      
[1] Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
June 30, 2017
 
December 31, 2016
Other current liabilities
$
3.2

 
$
14.5

Other long-term liabilities
23.5

 
24.0

   Total
$
26.7

 
$
38.5
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Foreign Exchange Forward Contracts (Details)
$ in Millions
 6 Months Ended
Jun. 30, 2017
USD ($)
Forward foreign exchange contract to sell foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Notional value $ 76.8
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments (0.2)
Forward foreign exchange contract to purchase foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Notional value 327.0
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments $ (0.4)
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Available-for-Sale Investments (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Millions
Jun. 30, 2017
Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 439.5 $ 435.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 894.0 681.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (1.1) (1.8)
Estimated Fair Value [1] 1,332.4 1,115.6
Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 201.7 179.4
Brokered certificates of deposit [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 3.6 3.6
Municipal obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 13.8 15.4
Asset-backed Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 58.1 62.5
Marketable Equity Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 980.1 767.8
US Government Sponsored Agencies [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 72.1 82.5
Foreign Government Obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 3.0 4.4
Other Long-term Investments [Member] | Asset-backed Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 0.2 0.3
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value 0.2 0.3
Other Long-term Investments [Member] | Marketable Equity Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 54.5 54.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 886.4 677.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value 940.9 732.1
Other Long-term Investments [Member] | Available-for-sale Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 54.7 54.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 886.4 677.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value 941.1 732.4
Short-term Investments [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value 391.3 383.2
Short-term Investments [Member] | Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 201.6 179.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.4 0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.3) (0.5)
Estimated Fair Value 201.7 179.4
Short-term Investments [Member] | Brokered certificates of deposit [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 3.6 3.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value 3.6 3.6
Short-term Investments [Member] | Municipal obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 13.8 15.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 (0.1)
Estimated Fair Value 13.8 15.4
Short-term Investments [Member] | Asset-backed Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 57.9 62.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.1 0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.1) (0.1)
Estimated Fair Value 57.9 62.2
Short-term Investments [Member] | Marketable Equity Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 32.5 32.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 7.0 3.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.3) (0.4)
Estimated Fair Value 39.2 35.7
Short-term Investments [Member] | Available-for-sale Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 384.8 380.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 7.6 4.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (1.1) (1.8)
Estimated Fair Value 391.3 383.2
Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 72.4 83.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.1 0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.4) (0.7)
Estimated Fair Value 72.1 82.5
Short-term Investments [Member] | Foreign Government Obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 3.0 4.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value $ 3.0 $ 4.4
[1] Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):
 
June 30,
2017
 
December 31, 2016
Short-term investments
$
391.3

 
$
383.2

Other investments
941.1

 
732.4

Total
$
1,332.4

 
$
1,115.6
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Amortized Cost and Fair Value of Debt Securities (Details)
$ in Millions
Jun. 30, 2017
USD ($)
Fair Value Disclosures [Abstract]  
Mature in less than one year $ 156.2
Mature in one to five years 144.9
Mature in more than five years 51.4
Total Amortized Cost 352.5
Mature in less than one year 156.2
Mature in one to five years 144.9
Mature in more than five years 51.2
Estimated Fair Value $ 352.3
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Price Change Debt Security 5.00%  
Tolerable variance Level 2 debt security pricing 1.00%  
Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more $ 8.1 $ 11.8
Cost Method Investment, Percentage Owned 35.00%  
Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months $ 164.8 160.5
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss 0.3 0.3
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $ 0.8 $ 1.5
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Fair Value Financial Instruments (Details) - USD ($)
$ in Millions
Jun. 30, 2017
Dec. 31, 2016
Carrying (Reported) Amount, Fair Value Disclosure [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Other Investments $ 93.7 $ 92.8
Total long-term debt, excluding capital leases and current maturities 422.8 422.5
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Other Investments 1,265.8 984.2
Total long-term debt, excluding capital leases and current maturities $ 456.7 $ 454.2
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1
4. Intangible Assets, Goodwill and Other (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Goodwill [Line Items]    
Goodwill $ 572,000 $ 518,800
Accumulated impairment loss (41,700) (41,700)
Goodwill, net 530,287 477,115
Goodwill, Acquired During Period 36,200  
Currency fluctuations 17,000  
Life Science [Member]    
Goodwill [Line Items]    
Goodwill 243,700 207,100
Accumulated impairment loss (27,200) (27,200)
Goodwill, net 216,500 179,900
Goodwill, Acquired During Period 36,200  
Currency fluctuations 400  
Clinical Diagnostics [Member]    
Goodwill [Line Items]    
Goodwill 328,300 311,700
Accumulated impairment loss (14,500) (14,500)
Goodwill, net 313,800 $ 297,200
Goodwill, Acquired During Period 0  
Currency fluctuations $ 16,600  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
4. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 496.3   $ 496.3   $ 443.2
Accumulated Amortization (311.5)   (311.5)   (281.6)
Net Carrying Amount 184.8   184.8   161.6
Amortization [Abstract]          
Amortization expense 8.7 $ 9.6 15.6 $ 19.0  
Customer Relationships [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 90.0   90.0   84.4
Accumulated Amortization (59.5)   (59.5)   (52.8)
Net Carrying Amount 30.5   30.5   31.6
Know how [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 190.2   190.2   182.6
Accumulated Amortization (149.2)   (149.2)   (136.9)
Net Carrying Amount 41.0   41.0   45.7
Developed Technology Rights [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 129.8   129.8   125.9
Accumulated Amortization (63.3)   (63.3)   (56.3)
Net Carrying Amount 66.5   66.5   69.6
Licensing Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 74.8   74.8   39.0
Accumulated Amortization (33.9)   (33.9)   (30.6)
Net Carrying Amount 40.9   40.9   8.4
Trade Names [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 3.6   3.6   3.5
Accumulated Amortization (2.7)   (2.7)   (2.5)
Net Carrying Amount 0.9   0.9   1.0
Noncompete Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price 7.9   7.9   7.8
Accumulated Amortization (2.9)   (2.9)   (2.5)
Net Carrying Amount $ 5.0   $ 5.0   $ 5.3
Minimum [Member] | Customer Relationships [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     1 year   1 year
Minimum [Member] | Know how [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     1 year   1 year
Minimum [Member] | Developed Technology Rights [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     2 years   3 years
Minimum [Member] | Licensing Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     2 years   1 year
Minimum [Member] | Trade Names [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     4 years   4 years
Minimum [Member] | Noncompete Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     2 years   2 years
Minimum [Member] | Other Intangible Assets [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     0 years   0 years
Maximum [Member] | Customer Relationships [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     8 years   8 years
Maximum [Member] | Know how [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     9 years   9 years
Maximum [Member] | Developed Technology Rights [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     12 years   12 years
Maximum [Member] | Licensing Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     14 years   9 years
Maximum [Member] | Trade Names [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     7 years   8 years
Maximum [Member] | Noncompete Agreements [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     9 years   9 years
Maximum [Member] | Other Intangible Assets [Member]          
Finite-Lived Intangible Assets, Net [Abstract]          
Average Remaining Life (years)     0 years   0 years
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.7.0.1
5. Product Warranty Liability (Details)
$ in Millions
 6 Months Ended
Jun. 30, 2017
USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]  
Accrual at beginning of period $ 17.6
Provision for warranty 13.9
Actual warranty costs (13.8)
Accrual at end of period $ 17.7
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.7.0.1
6. Long-Term Debt (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Dec. 31, 2010
Debt Instrument [Line Items]      
Debt and Capital Lease Obligations $ 434,900 $ 434,500  
Less Current Maturities (500) (300)  
Long-term debt, net of current maturities 434,386 434,186  
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]      
Debt Instrument [Line Items]      
Unsecured Debt 425,000 425,000  
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $ 2,200 2,500  
Debt Instrument, Interest Rate, Stated Percentage     4.875%
Debt Instrument, Redemption Price, Percentage 100.00%    
Long-term debt $ 422,800 422,500 $ 422,600
Debt Instrument, Interest Rate, Effective Percentage     4.946%
Face amount of debt sold     $ 425,000
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]      
Debt Instrument [Line Items]      
Long-term Debt and Capital Lease Obligations, Including Current Maturities 12,100 $ 12,000  
Line of Credit [Member]      
Debt Instrument [Line Items]      
Line of credit maximum borrowing capacity 200,000    
Outstanding borrowings $ 0    
Line of Credit Facility, Interest Rate at Period End 2.55%    
Standby Letters of Credit [Member]      
Debt Instrument [Line Items]      
Line of credit maximum borrowing capacity $ 500    
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.7.0.1
7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Selling, general and administrative expense $ (213,027) $ (205,536) $ (407,967) $ (395,252)    
Other (income) expense, net (11,757) (11,208) (13,175) (12,385)    
Accumulated other comprehensive income 610,948   610,948   $ 417,766  
Total other comprehensive income (loss) net of tax 94,305 44,220 193,182 77,422    
Accumulated Translation Adjustment [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Accumulated other comprehensive income 61,800 53,200 61,800 53,200 1,300 $ 33,700
Other Comprehensive Income (Loss), before Reclassifications, before Tax     60,500 19,500    
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     0 0    
Other Comprehensive Income (Loss), Tax     0 0    
Total other comprehensive income (loss) net of tax     60,500 19,500    
Accumulated Defined Benefit Plans Adjustment [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Accumulated other comprehensive income (20,600) (20,800) (20,600) (20,800) (18,600) (20,700)
Other Comprehensive Income (Loss), before Reclassifications, before Tax     (2,500) (600)    
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     0 600    
Other Comprehensive Income (Loss), Tax     500 (100)    
Total other comprehensive income (loss) net of tax     (2,000) (100)    
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Selling, general and administrative expense 200 (300) 0 (600)    
Accumulated Net Unrealized Investment Gain (Loss) [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Accumulated other comprehensive income 569,700 427,100 569,700 427,100 435,000 369,100
Other Comprehensive Income (Loss), before Reclassifications, before Tax     213,200 92,300    
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     0 (500)    
Other Comprehensive Income (Loss), Tax     (78,500) (33,800)    
Total other comprehensive income (loss) net of tax     134,700 58,000    
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Other (income) expense, net 200 (500) 0 (500)    
Parent [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Accumulated other comprehensive income $ 610,900 $ 459,500 610,900 459,500 $ 417,700 $ 382,100
Other Comprehensive Income (Loss), before Reclassifications, before Tax     271,200 111,200    
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     0 100    
Other Comprehensive Income (Loss), Tax     (78,000) (33,900)    
Total other comprehensive income (loss) net of tax     $ 193,200 $ 77,400    
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.7.0.1
8. Earnings Per Share (Details) - shares
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Basic weighted average shares outstanding 29,613 29,398 29,597 29,381
Effect of potentially dilutive stock options and restricted stock awards 393 191 365 168
Diluted weighted average common shares 30,006 29,589 29,962 29,549
Anti-dilutive shares 0 75 15 74
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.7.0.1
9. Other Income and Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Interest and investment income $ (12,000) $ (10,600) $ (13,100) $ (11,900)
Net realized loss (gain) on investments 200 (600) (100) (500)
Other (income) expense, net $ (11,757) $ (11,208) $ (13,175) $ (12,385)
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1
10. Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Effective tax rate (350.00%) 33.00% 18.00% 36.00%
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit $ 3.5   $ 3.5  
U.S. Federal [Member]        
Statutory Rates 35.00% 35.00% 35.00% 35.00%
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.7.0.1
11. Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Segment Reporting Information [Line Items]        
Net sales $ 504,666 $ 516,777 $ 1,004,717 $ 987,974
Income before income taxes 1,120 26,864 21,267 47,059
Life Science [Member]        
Segment Reporting Information [Line Items]        
Net sales 179,400 180,000 353,600 345,800
Income before income taxes (23,000) (5,100) (41,800) (8,400)
Clinical Diagnostics [Member]        
Segment Reporting Information [Line Items]        
Net sales 322,100 333,700 644,400 635,400
Income before income taxes 17,900 23,900 58,900 48,600
All Other Segments [Member]        
Segment Reporting Information [Line Items]        
Net sales 3,200 3,100 6,700 6,800
Income before income taxes $ 200 $ (300) $ 400 $ 100
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.7.0.1
11. Segment Profit Reconciliation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and Development Asset Acquired Other than Through Business Combination, Written-off $ 7,500      
Income before income taxes 1,120 $ 26,864 $ 21,267 $ 47,059
Operating Segments [Member]        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes (4,900) 18,500 17,500 40,300
Corporate, Non-Segment [Member]        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes (3,300) (1,600) (5,100) (3,200)
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes (2,500) (1,200) (4,300) (2,400)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes $ 11,800 $ 11,200 $ 13,200 $ 12,400
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.7.0.1
12. Legal Proceedings 12. Contingent Liability (Details)
 6 Months Ended
Jun. 30, 2017
USD ($)
12. Legal Proceedings [Abstract]  
Loss Contingency, Damages Awarded, Value $ 10,920,000
Litigation Settlement Interest $ 141,608
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.7.0.1
13. Restructuring Costs (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2017
Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve $ 7.8 $ 7.8 $ 9.0
Restructuring Reserve, Current 5.2 5.2  
Restructuring Reserve, Noncurrent 2.6 2.6  
Restructuring Reserve, Accrual Adjustment   0.1  
Payments for Restructuring   (1.9)  
Restructuring Reserve, Foreign Currency Translation Gain (Loss)   0.7  
Cost of Goods, Total [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve, Accrual Adjustment 0.1 (0.2)  
Selling, General and Administrative Expenses [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve, Accrual Adjustment 0.1 0.2  
Employee Severance [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges   0.0  
Restructuring Reserve, Accrual Adjustment   0.0  
Life Science [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve 2.8 2.8 3.2
Restructuring Charges   0.0  
Restructuring Reserve, Accrual Adjustment   0.0  
Payments for Restructuring   (0.7)  
Restructuring Reserve, Foreign Currency Translation Gain (Loss)   0.3  
Clinical Diagnostics [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve $ 5.0 5.0 $ 5.8
Restructuring Charges   0.0  
Restructuring Reserve, Accrual Adjustment   0.0  
Payments for Restructuring   (1.2)  
Restructuring Reserve, Foreign Currency Translation Gain (Loss)   $ 0.4  
EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

  •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

    &PO=V]R:W-H965T&UL4$L! A0#% @ M7L' M2VWH( X8!@ G2< !D ( !>'D 'AL+W=OP=+A?@"\/(! *!0 &0 M @ ''?P >&PO=V]R:W-H965T&UL4$L! A0#% @ M7L'2\I-N,CL! ,!L M !D ( !5X4 'AL+W=OP=+.8P&PO=V]R:W-H965T&UL4$L! A0#% @ M7L'2[)5%<$P @ Y@8 !D M ( !F(\ 'AL+W=OP=+_*&L("T# E#0 &0 @ '_D0 >&PO=V]R:W-H965T M&UL4$L! A0# M% @ M7L'2Y]2%4O3 0 000 !D ( !?)@ 'AL+W=O MP=+_;.437@# !5 M$ &0 @ &&F@ >&PO=V]R:W-H965T M !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0 ( +5[!TM(XNU\2 ( M %D+ - " :P3 0!X;"]S='EL97,N>&UL4$L! A0#% M @ M7L'2UBP,(PI! %"$ \ ( !'Q8! 'AL+W=O : M " 74: 0!X;"]? 3 " 8<< 0!;0V]N=&5N=%]4 ?>7!E&UL4$L%!@ [ #L #Q '\> 0 $! end XML 64 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 300 233 1 true 74 0 false 4 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.bio-rad.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets Parenthetical Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets Parenthetical Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - 1. Organization, Consolidation and Presentation of Financial Statements Sheet http://www.bio-rad.com/role/A1OrganizationConsolidationAndPresentationOfFinancialStatements 1. Organization, Consolidation and Presentation of Financial Statements Notes 7 false false R8.htm 2102100 - Disclosure - 2. Acquisitions Sheet http://www.bio-rad.com/role/A2Acquisitions 2. Acquisitions Notes 8 false false R9.htm 2103100 - Disclosure - 3. Fair Value Measurements Sheet http://www.bio-rad.com/role/A3FairValueMeasurements 3. Fair Value Measurements Notes 9 false false R10.htm 2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther 4. Intangible Assets, Goodwill and Other Notes 10 false false R11.htm 2106100 - Disclosure - 5. Product Warranty Liability Sheet http://www.bio-rad.com/role/A5ProductWarrantyLiability 5. Product Warranty Liability Notes 11 false false R12.htm 2107100 - Disclosure - 6. Long-Term Debt Sheet http://www.bio-rad.com/role/A6LongTermDebt 6. Long-Term Debt Notes 12 false false R13.htm 2109100 - Disclosure - 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes) Notes http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeNotes 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes) Notes 13 false false R14.htm 2110100 - Disclosure - 8. Earnings Per Share Sheet http://www.bio-rad.com/role/A8EarningsPerShare 8. Earnings Per Share Notes 14 false false R15.htm 2112100 - Disclosure - 9. Other Income and Expenses Sheet http://www.bio-rad.com/role/A9OtherIncomeAndExpenses 9. Other Income and Expenses Notes 15 false false R16.htm 2113100 - Disclosure - 10. Income Taxes Sheet http://www.bio-rad.com/role/A10IncomeTaxes 10. Income Taxes Notes 16 false false R17.htm 2114100 - Disclosure - 11. Segment Information Sheet http://www.bio-rad.com/role/A11SegmentInformation 11. Segment Information Notes 17 false false R18.htm 2115100 - Disclosure - 12. Legal Proceedings Sheet http://www.bio-rad.com/role/A12LegalProceedings 12. Legal Proceedings Notes 18 false false R19.htm 2117100 - Disclosure - 13. Restructuring Costs (Notes) Notes http://www.bio-rad.com/role/A13RestructuringCostsNotes 13. Restructuring Costs (Notes) Notes 19 false false R20.htm 2201201 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies) Sheet http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsPolicies 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies) Policies 20 false false R21.htm 2303301 - Disclosure - 3. Fair Value Measurements (Tables) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsTables 3. Fair Value Measurements (Tables) Tables http://www.bio-rad.com/role/A3FairValueMeasurements 21 false false R22.htm 2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables) Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables 4. Intangible Assets, Goodwill and Other (Tables) Tables http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther 22 false false R23.htm 2306301 - Disclosure - 5. Product Warranty Liability (Tables) Sheet http://www.bio-rad.com/role/A5ProductWarrantyLiabilityTables 5. Product Warranty Liability (Tables) Tables http://www.bio-rad.com/role/A5ProductWarrantyLiability 23 false false R24.htm 2307301 - Disclosure - 6. Long-Term Debt (Tables) Sheet http://www.bio-rad.com/role/A6LongTermDebtTables 6. Long-Term Debt (Tables) Tables http://www.bio-rad.com/role/A6LongTermDebt 24 false false R25.htm 2309301 - Disclosure - 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables) Tables http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeNotes 25 false false R26.htm 2310301 - Disclosure - 8. Earnings Per Share (Tables) Sheet http://www.bio-rad.com/role/A8EarningsPerShareTables 8. Earnings Per Share (Tables) Tables http://www.bio-rad.com/role/A8EarningsPerShare 26 false false R27.htm 2312301 - Disclosure - 9. Other Income and Expenses (Tables) Sheet http://www.bio-rad.com/role/A9OtherIncomeAndExpensesTables 9. Other Income and Expenses (Tables) Tables http://www.bio-rad.com/role/A9OtherIncomeAndExpenses 27 false false R28.htm 2314301 - Disclosure - 11. Segment Information (Tables) Sheet http://www.bio-rad.com/role/A11SegmentInformationTables 11. Segment Information (Tables) Tables http://www.bio-rad.com/role/A11SegmentInformation 28 false false R29.htm 2317301 - Disclosure - 13. Restructuring Costs (Tables) Sheet http://www.bio-rad.com/role/A13RestructuringCostsTables 13. Restructuring Costs (Tables) Tables http://www.bio-rad.com/role/A13RestructuringCostsNotes 29 false false R30.htm 2401402 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Sheet http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Details http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsPolicies 30 false false R31.htm 2402401 - Disclosure - 2. Acquisitions (Details) Sheet http://www.bio-rad.com/role/A2AcquisitionsDetails 2. Acquisitions (Details) Details http://www.bio-rad.com/role/A2Acquisitions 31 false false R32.htm 2403402 - Disclosure - 3. Fair Value Measurements Fair Value Level Table (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails 3. Fair Value Measurements Fair Value Level Table (Details) Details 32 false false R33.htm 2403403 - Disclosure - 3. Fair Value Measurements 3. Contingent Consideration (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails 3. Fair Value Measurements 3. Contingent Consideration (Details) Details 33 false false R34.htm 2403404 - Disclosure - 3. Foreign Exchange Forward Contracts (Details) Sheet http://www.bio-rad.com/role/A3ForeignExchangeForwardContractsDetails 3. Foreign Exchange Forward Contracts (Details) Details 34 false false R35.htm 2403405 - Disclosure - 3. Available-for-Sale Investments (Details) Sheet http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails 3. Available-for-Sale Investments (Details) Details 35 false false R36.htm 2403406 - Disclosure - 3. Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails 3. Amortized Cost and Fair Value of Debt Securities (Details) Details 36 false false R37.htm 2403407 - Disclosure - 3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Sheet http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails 3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Details 37 false false R38.htm 2403408 - Disclosure - 3. Fair Value Financial Instruments (Details) Sheet http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails 3. Fair Value Financial Instruments (Details) Details 38 false false R39.htm 2404402 - Disclosure - 4. Intangible Assets, Goodwill and Other (Details) Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails 4. Intangible Assets, Goodwill and Other (Details) Details http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables 39 false false R40.htm 2404403 - Disclosure - 4. Intangible Assets, Goodwill and Other Intangible Assets (Details) Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails 4. Intangible Assets, Goodwill and Other Intangible Assets (Details) Details 40 false false R41.htm 2406402 - Disclosure - 5. Product Warranty Liability (Details) Sheet http://www.bio-rad.com/role/A5ProductWarrantyLiabilityDetails 5. Product Warranty Liability (Details) Details http://www.bio-rad.com/role/A5ProductWarrantyLiabilityTables 41 false false R42.htm 2407402 - Disclosure - 6. Long-Term Debt (Details) Sheet http://www.bio-rad.com/role/A6LongTermDebtDetails 6. Long-Term Debt (Details) Details http://www.bio-rad.com/role/A6LongTermDebtTables 42 false false R43.htm 2409402 - Disclosure - 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables 43 false false R44.htm 2410402 - Disclosure - 8. Earnings Per Share (Details) Sheet http://www.bio-rad.com/role/A8EarningsPerShareDetails 8. Earnings Per Share (Details) Details http://www.bio-rad.com/role/A8EarningsPerShareTables 44 false false R45.htm 2412402 - Disclosure - 9. Other Income and Expenses (Details) Sheet http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails 9. Other Income and Expenses (Details) Details http://www.bio-rad.com/role/A9OtherIncomeAndExpensesTables 45 false false R46.htm 2413401 - Disclosure - 10. Income Taxes (Details) Sheet http://www.bio-rad.com/role/A10IncomeTaxesDetails 10. Income Taxes (Details) Details http://www.bio-rad.com/role/A10IncomeTaxes 46 false false R47.htm 2414402 - Disclosure - 11. Segment Information (Details) Sheet http://www.bio-rad.com/role/A11SegmentInformationDetails 11. Segment Information (Details) Details http://www.bio-rad.com/role/A11SegmentInformationTables 47 false false R48.htm 2414403 - Disclosure - 11. Segment Profit Reconciliation (Details) Sheet http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails 11. Segment Profit Reconciliation (Details) Details 48 false false R49.htm 2415401 - Disclosure - 12. Legal Proceedings 12. Contingent Liability (Details) Sheet http://www.bio-rad.com/role/A12LegalProceedings12ContingentLiabilityDetails 12. Legal Proceedings 12. Contingent Liability (Details) Details 49 false false R50.htm 2417402 - Disclosure - 13. Restructuring Costs (Details) Sheet http://www.bio-rad.com/role/A13RestructuringCostsDetails 13. Restructuring Costs (Details) Details http://www.bio-rad.com/role/A13RestructuringCostsTables 50 false false All Reports Book All Reports a10q63017.htm bio-20170630.xsd bio-20170630_cal.xml bio-20170630_def.xml bio-20170630_lab.xml bio-20170630_pre.xml ex1017272017.htm ex31163017.htm ex31263017.htm ex32163017.htm ex32263017.htm true true JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a10q63017.htm": { "axisCustom": 1, "axisStandard": 21, "contextCount": 300, "dts": { "calculationLink": { "local": [ "bio-20170630_cal.xml" ] }, "definitionLink": { "local": [ "bio-20170630_def.xml" ] }, "inline": { "local": [ "a10q63017.htm" ] }, "labelLink": { "local": [ "bio-20170630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-doc-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml" ] }, "presentationLink": { "local": [ "bio-20170630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-ref-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml" ] }, "schema": { "local": [ "bio-20170630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-parts-codification-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd", "http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd", "http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd", "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd", "http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" ] } }, "elementCount": 430, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2016-01-31": 41, "http://www.bio-rad.com/20170630": 3, "http://xbrl.sec.gov/dei/2014-01-31": 10, "total": 54 }, "keyCustom": 7, "keyStandard": 226, "memberCustom": 19, "memberStandard": 54, "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20170630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.bio-rad.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther", "shortName": "4. Intangible Assets, Goodwill and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - 5. Product Warranty Liability", "role": "http://www.bio-rad.com/role/A5ProductWarrantyLiability", "shortName": "5. Product Warranty Liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - 6. Long-Term Debt", "role": "http://www.bio-rad.com/role/A6LongTermDebt", "shortName": "6. Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)", "role": "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeNotes", "shortName": "7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - 8. Earnings Per Share", "role": "http://www.bio-rad.com/role/A8EarningsPerShare", "shortName": "8. Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - 9. Other Income and Expenses", "role": "http://www.bio-rad.com/role/A9OtherIncomeAndExpenses", "shortName": "9. Other Income and Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - 10. Income Taxes", "role": "http://www.bio-rad.com/role/A10IncomeTaxes", "shortName": "10. Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - 11. Segment Information", "role": "http://www.bio-rad.com/role/A11SegmentInformation", "shortName": "11. Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - 12. Legal Proceedings", "role": "http://www.bio-rad.com/role/A12LegalProceedings", "shortName": "12. Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - 13. Restructuring Costs (Notes)", "role": "http://www.bio-rad.com/role/A13RestructuringCostsNotes", "shortName": "13. Restructuring Costs (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies)", "role": "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsPolicies", "shortName": "1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - 3. Fair Value Measurements (Tables)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsTables", "shortName": "3. Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables)", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables", "shortName": "4. Intangible Assets, Goodwill and Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - 5. Product Warranty Liability (Tables)", "role": "http://www.bio-rad.com/role/A5ProductWarrantyLiabilityTables", "shortName": "5. Product Warranty Liability (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - 6. Long-Term Debt (Tables)", "role": "http://www.bio-rad.com/role/A6LongTermDebtTables", "shortName": "6. Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables", "shortName": "7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - 8. Earnings Per Share (Tables)", "role": "http://www.bio-rad.com/role/A8EarningsPerShareTables", "shortName": "8. Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - 9. Other Income and Expenses (Tables)", "role": "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesTables", "shortName": "9. Other Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - 11. Segment Information (Tables)", "role": "http://www.bio-rad.com/role/A11SegmentInformationTables", "shortName": "11. Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - 13. Restructuring Costs (Tables)", "role": "http://www.bio-rad.com/role/A13RestructuringCostsTables", "shortName": "13. Restructuring Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets Parenthetical", "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets Parenthetical", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "role": "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "shortName": "1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "I2017Q1SD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember", "decimals": "-5", "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - 2. Acquisitions (Details)", "role": "http://www.bio-rad.com/role/A2AcquisitionsDetails", "shortName": "2. Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q1QTD_us-gaap_BusinessAcquisitionAxis_bio_RainDanceTechnologiesInc.Member", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - 3. Fair Value Measurements Fair Value Level Table (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails", "shortName": "3. Fair Value Measurements Fair Value Level Table (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - 3. Fair Value Measurements 3. Contingent Consideration (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "shortName": "3. Fair Value Measurements 3. Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttosellforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - 3. Foreign Exchange Forward Contracts (Details)", "role": "http://www.bio-rad.com/role/A3ForeignExchangeForwardContractsDetails", "shortName": "3. Foreign Exchange Forward Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttosellforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - 3. Available-for-Sale Investments (Details)", "role": "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "shortName": "3. Available-for-Sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - 3. Amortized Cost and Fair Value of Debt Securities (Details)", "role": "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails", "shortName": "3. Amortized Cost and Fair Value of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403407 - Disclosure - 3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "role": "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "shortName": "3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403408 - Disclosure - 3. Fair Value Financial Instruments (Details)", "role": "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails", "shortName": "3. Fair Value Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - 4. Intangible Assets, Goodwill and Other (Details)", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails", "shortName": "4. Intangible Assets, Goodwill and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - 4. Intangible Assets, Goodwill and Other Intangible Assets (Details)", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "shortName": "4. Intangible Assets, Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - 5. Product Warranty Liability (Details)", "role": "http://www.bio-rad.com/role/A5ProductWarrantyLiabilityDetails", "shortName": "5. Product Warranty Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - 6. Long-Term Debt (Details)", "role": "http://www.bio-rad.com/role/A6LongTermDebtDetails", "shortName": "6. Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - 7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails", "shortName": "7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - 8. Earnings Per Share (Details)", "role": "http://www.bio-rad.com/role/A8EarningsPerShareDetails", "shortName": "8. Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - 9. Other Income and Expenses (Details)", "role": "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails", "shortName": "9. Other Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413401 - Disclosure - 10. Income Taxes (Details)", "role": "http://www.bio-rad.com/role/A10IncomeTaxesDetails", "shortName": "10. Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - 11. Segment Information (Details)", "role": "http://www.bio-rad.com/role/A11SegmentInformationDetails", "shortName": "11. Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2QTD_us-gaap_StatementBusinessSegmentsAxis_bio_LifeScienceMember", "decimals": "-5", "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - 11. Segment Profit Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails", "shortName": "11. Segment Profit Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415401 - Disclosure - 12. Legal Proceedings 12. Contingent Liability (Details)", "role": "http://www.bio-rad.com/role/A12LegalProceedings12ContingentLiabilityDetails", "shortName": "12. Legal Proceedings 12. Contingent Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - 13. Restructuring Costs (Details)", "role": "http://www.bio-rad.com/role/A13RestructuringCostsDetails", "shortName": "13. Restructuring Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - 1. Organization, Consolidation and Presentation of Financial Statements", "role": "http://www.bio-rad.com/role/A1OrganizationConsolidationAndPresentationOfFinancialStatements", "shortName": "1. Organization, Consolidation and Presentation of Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - 2. Acquisitions", "role": "http://www.bio-rad.com/role/A2Acquisitions", "shortName": "2. Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - 3. Fair Value Measurements", "role": "http://www.bio-rad.com/role/A3FairValueMeasurements", "shortName": "3. Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 74, "tag": { "bio_A12.LegalProceedingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "12. Legal Proceedings [Abstract]", "label": "12. Legal Proceedings [Abstract]" } } }, "localname": "A12.LegalProceedingsAbstract", "nsuri": "http://www.bio-rad.com/20170630", "xbrltype": "stringItemType" }, "bio_AnalyticalFlowCytometerPlatformMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Analytical Flow Cytometer Platform", "label": "Analytical Flow Cytometer Platform [Member]", "terseLabel": "Analytical Flow Cytometer Platform [Member]" } } }, "localname": "AnalyticalFlowCytometerPlatformMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_BusinessAcquisitionContingentConsiderationPotentialPercentagePayout": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "business acquisition contingent consideration percentage payout", "label": "Business Acquisition, Contingent Consideration, Potential Percentage Payout", "terseLabel": "Business Acquisition, Contingent Consideration, Potential Percentage Payout" } } }, "localname": "BusinessAcquisitionContingentConsiderationPotentialPercentagePayout", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bio_CapitalLeasesandOtherDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capital Leases and Other Debt [Member]", "label": "Capital Leases and Other Debt [Member]", "terseLabel": "Capital Leases and Other Debt [Member]" } } }, "localname": "CapitalLeasesandOtherDebtMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_CellsorterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CellSorter [Member] [Member]", "label": "CellSorter [Member]", "terseLabel": "CellSorter [Member]" } } }, "localname": "CellsorterMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_ClinicalDiagnosticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Clinical Diagnostics [Member]", "label": "Clinical Diagnostics [Member]", "terseLabel": "Clinical Diagnostics [Member]" } } }, "localname": "ClinicalDiagnosticsMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationDetails", "http://www.bio-rad.com/role/A13RestructuringCostsDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_CostMethodInvestmentPercentageOwned": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cost Method Investments, Percentage Owned", "label": "Cost Method Investment, Percentage Owned", "terseLabel": "Cost Method Investment, Percentage Owned" } } }, "localname": "CostMethodInvestmentPercentageOwned", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_DocumentAndEntityInformationParentheticalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information (Parenthetical) [Abstract]", "label": "Document and Entity Information (Parenthetical) [Abstract]" } } }, "localname": "DocumentAndEntityInformationParentheticalAbstract", "nsuri": "http://www.bio-rad.com/20170630", "xbrltype": "stringItemType" }, "bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to purchase foreign currency [Member]", "label": "Forward foreign exchange contract to purchase foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to purchase foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3ForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttosellforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to sell foreign currency [Member]", "label": "Forward foreign exchange contract to sell foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to sell foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttosellforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3ForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_GnuBIOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "GnuBIO [Member]", "label": "GnuBIO [Member]", "terseLabel": "GnuBIO [Member]" } } }, "localname": "GnuBIOMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_KnowHowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Know how [Member]", "label": "Know How [Member]", "terseLabel": "Know how [Member]" } } }, "localname": "KnowHowMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_LifeScienceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Life Sciences [Member]", "label": "Life Science [Member]", "terseLabel": "Life Science [Member]" } } }, "localname": "LifeScienceMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationDetails", "http://www.bio-rad.com/role/A13RestructuringCostsDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_MarketPriceOfRiskMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Market Price of Risk [Member]", "label": "Market Price of Risk [Member]", "terseLabel": "Market Price of Risk [Member]" } } }, "localname": "MarketPriceOfRiskMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_Paymentsforproceedsfromderivativeinstrumentsoperatingactivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments for (proceeds from) derivative instruments, operating activities", "label": "Payments for (proceeds from) derivative instruments, operating activities", "negatedTerseLabel": "(Payments for) proceeds from forward foreign exchange contracts, net" } } }, "localname": "Paymentsforproceedsfromderivativeinstrumentsoperatingactivities", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bio_Paymentsofcontingentconsideration": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments of contingent consideration", "label": "Payments of contingent consideration", "negatedTerseLabel": "Payments of contingent consideration" } } }, "localname": "Paymentsofcontingentconsideration", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bio_PriceChangeDebtSecurity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price Change Debt Security", "label": "Price Change Debt Security", "terseLabel": "Price Change Debt Security" } } }, "localname": "PriceChangeDebtSecurity", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_ProjectedVolatilityOfSalesMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Projected Volatility of Sales [Member]", "label": "Projected Volatility of Sales [Member] [Member]", "terseLabel": "Projected Volatility of Growth Rate [Member]" } } }, "localname": "ProjectedVolatilityOfSalesMemberMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_RainDanceTechnologiesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RainDance Technologies, Inc. [Member]", "label": "RainDance Technologies, Inc. [Member]", "terseLabel": "RainDance Technologies, Inc. [Member]" } } }, "localname": "RainDanceTechnologiesInc.Member", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestoneminimumamountMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone minimum amount [Member]", "label": "Sales milestone minimum amount [Member]", "terseLabel": "Sales milestone minimum amount [Member]" } } }, "localname": "SalesmilestoneminimumamountMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices [Member]", "label": "Sales milestone percentage of annual invoices [Member]", "terseLabel": "Sales milestone percentage of annual invoices [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoicesMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoiceslowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices low [Member]", "label": "Sales milestone percentage of annual invoices low [Member]", "terseLabel": "Sales milestone percentage of annual invoices low [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoiceslowMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SeniorNotes4.875due2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 4.875% [Member]", "label": "Senior Notes 4.875% due 2020 [Member]", "terseLabel": "Senior Notes 4.875% due 2020 [Member]" } } }, "localname": "SeniorNotes4.875due2020Member", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_StatutoryRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statutory Rate [Axis]", "label": "Statutory Rate [Axis]", "terseLabel": "Statutory Rate [Axis]" } } }, "localname": "StatutoryRateAxis", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A10IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_StatutoryRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statutory Rate [Domain]", "label": "Statutory Rate [Domain]", "terseLabel": "Statutory Rate [Domain]" } } }, "localname": "StatutoryRateDomain", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A10IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_StatutoryRates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statutory Rates", "label": "Statutory Rates", "terseLabel": "Statutory Rates" } } }, "localname": "StatutoryRates", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A10IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "bio_TolerablevarianceLevel2debtsecuritypricing": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tolerable variance Level 2 debt security pricing", "label": "Tolerable variance Level 2 debt security pricing", "terseLabel": "Tolerable variance Level 2 debt security pricing" } } }, "localname": "TolerablevarianceLevel2debtsecuritypricing", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_TreasuryClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class A [Member]", "label": "Treasury Class-A [Member]", "terseLabel": "Treasury Class A [Member]" } } }, "localname": "TreasuryClassAMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "domainItemType" }, "bio_TreasuryClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class B [Member]", "label": "Treasury Class B [Member]", "terseLabel": "Treasury Class B [Member]" } } }, "localname": "TreasuryClassBMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "domainItemType" }, "bio_USFederalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "U.S. Federal [Member]", "label": "U.S. Federal [Member]", "terseLabel": "U.S. Federal [Member]" } } }, "localname": "USFederalMember", "nsuri": "http://www.bio-rad.com/20170630", "presentation": [ "http://www.bio-rad.com/role/A10IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r432" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityFilerCategory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r432" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Notional value" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bio-rad.com/role/A3ForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable, accrued payroll and employee benefits" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r51", "r57" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r8", "r36", "r38", "r66" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r83", "r88", "r270", "r326" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Defined Benefit Plans Adjustment [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r61", "r226" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r82", "r88", "r326" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from the appreciation (depreciation) in value of securities attributable to the parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Accumulated Net Unrealized Investment Gain (Loss) [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r85", "r87", "r88" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r84", "r88", "r326" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r80", "r88", "r326" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Translation Adjustment [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentForAmortizationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Amortization [Abstract]" } } }, "localname": "AdjustmentForAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments, Noncash Items, to Reconcile Net Income to Cash Used in Operating Activities [Abstract]" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities [Abstract]" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r147", "r148", "r149", "r150", "r151", "r152" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "All Other Segments [Member]" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r118", "r211", "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r1", "r6", "r10", "r140" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r118", "r223" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset Impairment Charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r383", "r413" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r32", "r34", "r78" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r65", "r181" ], "calculation": { "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Debt Securities, Amortized Cost Basis", "totalLabel": "Total Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [ "r174", "r177", "r190" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Available-for-sale Securities, Fair Value Disclosure", "verboseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r182" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r183" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "verboseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r193", "r195" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r193", "r195" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [ "r192", "r195" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value", "terseLabel": "Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": { "auth_ref": [ "r192", "r195" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value", "terseLabel": "Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r65", "r188" ], "calculation": { "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after adjustments of available-for-sale debt securities at cost, maturing in the sixth fiscal year through the tenth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Amortized Cost Basis", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r184", "r188", "r403" ], "calculation": { "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the sixth fiscal year through the tenth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r65", "r187" ], "calculation": { "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r184", "r187", "r402" ], "calculation": { "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r65", "r186" ], "calculation": { "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r184", "r186", "r401" ], "calculation": { "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r174", "r177", "r181", "r399" ], "calculation": { "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of debt securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities, Debt Securities", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [ "r185", "r189", "r194", "r195", "r198", "r400", "r404" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of available-for-sale investments" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r174", "r175", "r176", "r179", "r180" ], "lang": { "en-US": { "role": { "documentation": "Investments in available-for-sale securities.", "label": "Available-for-sale Securities [Member]", "terseLabel": "Available-for-sale Securities [Member]" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r334", "r337" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Foreign Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r289", "r290" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r308", "r309", "r311" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business Combination, Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r306", "r308", "r309" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Liabilities Assumed" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r317" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "verboseLabel": "Changes in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r307", "r310", "r312" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r287", "r289", "r290", "r291", "r292", "r293", "r296", "r297", "r298", "r299", "r300", "r314", "r315", "r316", "r318" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r294", "r295" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r294", "r295" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "terseLabel": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r363", "r364" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying (Reported) Amount, Fair Value Disclosure [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r4", "r29", "r58", "r120" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [ "r3", "r4" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [ "r111", "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "terseLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r4", "r39" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r405" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Domestic time deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r50" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r50", "r252" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r320", "r328" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]", "verboseLabel": "Contingent Consideration by Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsSold": { "auth_ref": [ "r96" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs related to goods produced and sold during the reporting period.", "label": "Cost of Goods Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated cost of goods (such as cost of goods sold, or purchases) for the period after providing for returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Cost of Goods, Total [Member]", "terseLabel": "Cost of Goods, Total [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r391", "r419" ], "calculation": { "http://www.bio-rad.com/role/A6LongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.", "label": "Debt and Capital Lease Obligations", "totalLabel": "Debt and Capital Lease Obligations" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r44", "r46", "r47", "r384", "r385", "r408" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r377", "r379" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt sold" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r68", "r377" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r68" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r69" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r406" ], "lang": { "en-US": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Debt Instrument, Redemption Price, Percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r69", "r126", "r253", "r256", "r257", "r258", "r376", "r377", "r379", "r407" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r378" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r37", "r264", "r265", "r266", "r267", "r268", "r269" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]", "terseLabel": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r9", "r280" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred Tax Assets, Gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r273", "r274", "r275" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r118", "r224" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3ForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r335", "r336", "r340", "r342" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3ForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r130", "r329", "r330", "r331", "r332", "r333", "r338", "r340", "r343", "r344", "r345" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3ForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3ForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r93", "r136", "r141", "r142", "r395", "r421" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income per share basic attributable to Bio-Rad" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r93", "r136", "r395", "r421" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income per share diluted attributable to Bio-Rad" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r97", "r136", "r138", "r139", "r142" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of foreign exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r128", "r276", "r277" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r66" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r40", "r45", "r172", "r390", "r409", "r430" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Marketable Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r348", "r361" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value, Fair Value Disclosure [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities": { "auth_ref": [ "r271" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities", "terseLabel": "Excess tax benefits from share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": { "auth_ref": [ "r271" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities", "negatedTerseLabel": "Excess tax benefits from share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r347", "r348", "r349", "r350", "r356", "r357" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r348", "r360", "r361", "r363", "r364", "r368" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r348", "r360", "r361", "r363", "r364", "r368" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Estimated fair value of financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Information by level within the fair value hierarchy.", "label": "Fair Value, Hierarchy [Axis]", "terseLabel": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r348", "r358" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Fair Value by Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r348", "r360", "r361", "r363", "r364", "r368" ], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r355", "r362", "r365", "r366", "r367", "r369" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsDiscountRate": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.", "label": "Fair Value Inputs, Discount Rate", "terseLabel": "Fair Value Inputs, Entity Credit Risk" } } }, "localname": "FairValueInputsDiscountRate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r17", "r349" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r18", "r20", "r346", "r349" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r19", "r349" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.", "label": "Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]", "terseLabel": "Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]" } } }, "localname": "FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r352", "r357" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r347", "r355" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "(Decrease) increase in fair value of contingent consideration included in SGA" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r354" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Contingent consideration milestone payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r352" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r347", "r355" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r218" ], "calculation": { "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r212", "r217" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Acquired Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r218" ], "calculation": { "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Purchase Price" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r212", "r217" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r218" ], "calculation": { "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Average Remaining Life (years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign Currency Gain (Loss) [Member]" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r370", "r371", "r372" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign exchange losses, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by a national, local, or municipal government not within the country of domicile of the reporting entity.", "label": "Foreign Government Debt Securities [Member]", "terseLabel": "Foreign Government Obligations [Member]" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r335", "r339" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "negatedLabel": "Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3ForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfSecuritiesNet": { "auth_ref": [ "r396", "r423" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) realized from the sale, exchange, redemption, or retirement of securities, not separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.", "label": "Gain (Loss) on Sale of Securities, Net", "negatedLabel": "Losses (gains) on dispositions of securities" } } }, "localname": "GainLossOnSaleOfSecuritiesNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r202", "r203", "r204" ], "calculation": { "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill, net", "totalLabel": "Goodwill, net", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r206" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r208", "r209", "r215", "r221", "r222" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets Disclosure" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency fluctuations" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r205" ], "calculation": { "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails": { "order": 1.0, "parentTag": "us-gaap_Goodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r205" ], "calculation": { "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails": { "order": 2.0, "parentTag": "us-gaap_Goodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedTerseLabel": "Accumulated impairment loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r95" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r127" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationDetails", "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r129", "r279", "r282", "r283", "r285" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r13", "r129", "r284" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r122" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Income tax payments, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "Decrease in accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r117" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "(Increase) decrease in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r117" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "(Decrease) increase in income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r117" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedTerseLabel": "(Decrease) increase in Deferred Income Taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r117" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Increase in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedTerseLabel": "Increase in other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r117" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Net decrease/increase in other long-term assets/liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r137", "r141" ], "calculation": { "http://www.bio-rad.com/role/A8EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of potentially dilutive stock options and restricted stock awards" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r213", "r220" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r210", "r216" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Purchased intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestBearingDepositsMember": { "auth_ref": [ "r381", "r386" ], "lang": { "en-US": { "role": { "documentation": "Cash on deposit with financial institutions that earns interest, either at a fixed or market rate.", "label": "Interest-bearing Deposits [Member]", "terseLabel": "Brokered certificates of deposit [Member]" } } }, "localname": "InterestBearingDepositsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r375", "r378", "r397" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r122" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.", "label": "Interest Paid, Net", "negatedTerseLabel": "Interest paid, net" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r73" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r30", "r76", "r200" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r75" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r74" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r100" ], "calculation": { "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "negatedTerseLabel": "Interest and investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of amortized cost and estimated fair value of debt securities by contractual maturity date" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Proceedings." } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12LegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r64" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r56", "r387", "r416" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r67" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r47", "r385", "r408" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding borrowings" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r62" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.", "label": "Litigation Settlement Interest", "terseLabel": "Litigation Settlement Interest" } } }, "localname": "LitigationSettlementInterest", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12LegalProceedings12ContingentLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r47", "r385", "r414" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r47" ], "calculation": { "http://www.bio-rad.com/role/A6LongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations", "terseLabel": "Long-term debt, net of current maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligations including current maturities.", "label": "Long-term Debt and Capital Lease Obligations, Including Current Maturities", "terseLabel": "Long-term Debt and Capital Lease Obligations, Including Current Maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A6LongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.", "label": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year", "negatedTerseLabel": "Less Current Maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Total long-term debt, excluding capital leases and current maturities" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r59" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Other investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r69" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r69", "r250" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r239", "r240", "r241" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss Contingency, Damages Awarded, Value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12LegalProceedings12ContingentLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Loss Contingency, Information about Litigation Matters [Abstract]" } } }, "localname": "LossContingencyInformationAboutLitigationMattersAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by major type of debt and equity security.", "label": "Major Types of Debt and Equity Securities [Axis]", "terseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]" } } }, "localname": "MajorTypesOfDebtAndEquitySecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain": { "auth_ref": [ "r171", "r172", "r173", "r400" ], "lang": { "en-US": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions. Equity securities are ownership interests or the right to acquire or dispose of ownership interests in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock.", "label": "Major Types of Debt and Equity Securities [Domain]", "terseLabel": "Major Types of Debt and Equity Securities [Domain]" } } }, "localname": "MajorTypesOfDebtAndEquitySecuritiesDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r159", "r160" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items [Member]" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r427" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5ProductWarrantyLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Obligations (Member)", "verboseLabel": "Municipal obligations [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r111", "r116" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r111", "r116" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r111", "r115", "r119" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r21", "r22", "r92", "r119", "r141", "r394", "r420" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to Bio-Rad" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [ "r0", "r5", "r11", "r14" ], "lang": { "en-US": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Adjustments for New Accounting Pronouncement [Member]" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r5", "r11", "r14", "r24", "r131", "r132", "r133" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Notes and Loans Payable, Current", "terseLabel": "Current maturities of long-term debt and notes payable" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Segment profit (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r27", "r28", "r123", "r143", "r322" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1OrganizationConsolidationAndPresentationOfFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r43", "r382", "r412" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r77" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r320", "r321", "r325" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of (increase) decrease in accumulated other comprehensive (income) loss related to pension and other postretirement defined benefit plans, attributable to parent entity.", "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent", "negatedTerseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r88" ], "calculation": { "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r79", "r374" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r89", "r90", "r91", "r252" ], "calculation": { "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss) net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r86", "r286" ], "calculation": { "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r81", "r85" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Net unrealized holding gains (losses) on available-for-sale investments net of tax expense" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income and Other Expense Disclosure" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9OtherIncomeAndExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r59", "r418" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other Investments", "terseLabel": "Other Investments" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other Investments [Member]" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r35", "r36", "r66" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r70" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestmentsMember": { "auth_ref": [ "r410", "r426" ], "lang": { "en-US": { "role": { "documentation": "Long-term investments classified as other.", "label": "Other Long-term Investments [Member]", "terseLabel": "Other Long-term Investments [Member]" } } }, "localname": "OtherLongTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements3ContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r101" ], "calculation": { "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r12", "r109" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "terseLabel": "Payments for purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r115", "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments for Restructuring" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAssetsInvestingActivities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.", "label": "Payments to Acquire Assets, Investing Activities", "negatedTerseLabel": "Payments for acquisitions and long-term investments" } } }, "localname": "PaymentsToAcquireAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r16", "r105" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r16", "r106" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payments for purchases of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r16", "r107" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Payments for purchases of marketable securities and investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r16", "r106" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedTerseLabel": "Payments for purchases of intangible assets" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r16", "r106" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "negatedTerseLabel": "Cash paid to suppliers and employees" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r359", "r360" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r7", "r31", "r33", "r201" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r112" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Proceeds from Customers", "terseLabel": "Cash received from customers" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r12", "r108" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock for shared-based compensation" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r16", "r103", "r178" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.", "label": "Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities", "terseLabel": "Proceeds from maturities of marketable securities and investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherOperatingActivities": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from operating activities classified as other.", "label": "Proceeds from Other Operating Activities", "terseLabel": "Investment proceeds and miscellaneous receipts, net" } } }, "localname": "ProceedsFromOtherOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r121" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net payments on line-of-credit arrangements and notes payable" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": { "auth_ref": [ "r16", "r103", "r178" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.", "label": "Proceeds from Sale of Available-for-sale Securities", "terseLabel": "Proceeds from sales of marketable securities and investments" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r16", "r104" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from dispositions of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantiesDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product Warranties Disclosures [Abstract]" } } }, "localname": "ProductWarrantiesDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r245", "r246", "r392" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "periodEndLabel": "Accrual at end of period", "periodStartLabel": "Accrual at beginning of period" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5ProductWarrantyLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r243" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Actual warranty costs" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5ProductWarrantyLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r244" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Provision for warranty" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5ProductWarrantyLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Product Warranty Disclosure [Text Block]", "verboseLabel": "Product Warranty Liability" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5ProductWarrantyLiability" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r320", "r323", "r324", "r327", "r328" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net income including noncontrolling interests", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r60", "r225" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r41", "r42", "r227", "r417" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r422", "r424" ], "calculation": { "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Net realized loss (gain) on investments" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r88" ], "calculation": { "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification Out Of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r158", "r160" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r158", "r160" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of segment profit to consolidated income before taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r12", "r110" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term borrowings" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r214" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Research and Development Asset Acquired Other than Through Business Combination, Written-off" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r272", "r431" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted Cash and Cash Equivalents, Current" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r428", "r429" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Restricted Investments, at Fair Value" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsCurrent": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.", "label": "Restricted Investments, Current", "terseLabel": "Restricted investments" } } }, "localname": "RestrictedInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r230", "r232", "r238" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r118", "r228", "r232", "r237" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring Costs [Abstract]" } } }, "localname": "RestructuringCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r229", "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r228", "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Restructuring Reserve, Accrual Adjustment" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r228", "r236" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring Reserve, Current" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveNoncurrent": { "auth_ref": [ "r228" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Noncurrent", "terseLabel": "Restructuring Reserve, Noncurrent" } } }, "localname": "RestructuringReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r229", "r236" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r53", "r259", "r415" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNet": { "auth_ref": [ "r94" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.", "label": "Revenue, Net", "terseLabel": "Net sales" } } }, "localname": "SalesRevenueNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A8EarningsPerShareDetails", "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "verboseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of identifiable purchased intangible assets with definite lives" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Available-for-sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r2", "r185", "r189", "r194", "r195", "r196", "r197", "r400", "r404" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r289", "r290" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r69", "r126", "r253", "r256", "r257", "r258", "r376", "r377", "r379", "r407" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r130", "r329", "r330", "r331", "r332", "r333", "r338", "r340", "r343", "r344" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Discussion of current derivative risk management" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities carried at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r208", "r209" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r208", "r209" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Changes to goodwill by segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Components of warranty accrual" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5ProductWarrantyLiabilityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r230", "r231", "r235" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r230", "r231", "r235" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs [Table Text Block]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r153", "r154", "r155", "r159", "r208" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r153", "r154", "r155", "r159", "r208" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Information regarding industry segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "terseLabel": "Summary of fair value of gross unrealized losses for investments with unrealized losses" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]", "verboseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationDetails", "http://www.bio-rad.com/role/A13RestructuringCostsDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r144", "r145", "r146", "r156", "r157", "r159", "r160", "r161", "r162", "r163", "r164", "r166", "r167", "r168" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r99", "r199" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "negatedTerseLabel": "Selling, general and administrative expense", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r117" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r45", "r388", "r389", "r390", "r411" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r388", "r389", "r411", "r425" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]", "terseLabel": "Short-term Investments [Member]" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r25", "r242", "r248", "r319" ], "lang": { "en-US": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit [Member]" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Statement, Business Segments [Axis]", "verboseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SegmentInformationDetails", "http://www.bio-rad.com/role/A13RestructuringCostsDetails", "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r48", "r49", "r50", "r252" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r72", "r252" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10IncomeTaxesDetails", "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A8EarningsPerShareDetails", "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Statement, Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A8EarningsPerShareDetails", "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10IncomeTaxesDetails", "http://www.bio-rad.com/role/A3FairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A8EarningsPerShareDetails", "http://www.bio-rad.com/role/A9OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r50", "r54", "r55", "r169" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "terseLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r23", "r50", "r54", "r55", "r124", "r125", "r170", "r251", "r252", "r253", "r254", "r255", "r256", "r259", "r260", "r262" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7AccumulatedOtherComprehensiveIncome7AccumulatedOtherComprehensiveIncomeNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income and other taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r71", "r261" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r71", "r261", "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury Stock, Value" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1BasisOfPresentationAndUseOfEstimatesOrganizationConsolidationAndPresentationOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "US Government Sponsored Agencies [Member]" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3AvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueLevelTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r47", "r385", "r414" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured Debt", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r135", "r139" ], "calculation": { "http://www.bio-rad.com/role/A8EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares - diluted", "totalLabel": "Diluted weighted average common shares" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8EarningsPerShareDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r26", "r134", "r139" ], "calculation": { "http://www.bio-rad.com/role/A8EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares - basic", "verboseLabel": "Basic weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8EarningsPerShareDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Glossary": "Accounting Change", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6503790" }, "r1": { "Glossary": "Antidilution", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6505113" }, "r10": { "Glossary": "Diluted Earnings Per Share", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510752" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585" }, "r11": { "Glossary": "Direct Effects of a Change in Accounting Principle", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=66092750" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r12": { "Glossary": "Financing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6513228" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "c", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3098-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r13": { "Glossary": "Income Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515339" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1500-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r14": { "Glossary": "Indirect Effects of a Change in Accounting Principle", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515603" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8615-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8654-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8657-108599" }, "r15": { "Glossary": "Intangible Assets", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515781" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8660-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8663-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8672-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r16": { "Glossary": "Investing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6516133" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "35", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8475-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r17": { "Glossary": "Level 1 Inputs", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51652821" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707" }, "r171": { "Glossary": "Debt Security", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=6509901" }, "r172": { "Glossary": "Equity Security", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=6511694" }, "r173": { "Glossary": "Security", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=6524771" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Subparagraph": "(a)-(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=27723805&loc=d3e24584-111560" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=27723805&loc=d3e25065-111560" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26853-111562" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26817-111562" }, "r18": { "Glossary": "Level 2 Inputs", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51652837" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26828-111562" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r19": { "Glossary": "Level 3 Inputs", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51652851" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27340-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r2": { "Glossary": "Available-for-Sale Securities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6505594" }, "r20": { "Glossary": "Market-Corroborated Inputs", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6517519" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a,h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267" }, "r21": { "Glossary": "Net Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831255" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r22": { "Glossary": "Other Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831270" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=68055307&loc=d3e2420-110228" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r23": { "Glossary": "Preferred Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521494" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349" }, "r24": { "Glossary": "Retrospective Application", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6523989" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68077669&loc=d3e10037-110241" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=73718786&loc=d3e12803-110250" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=28361426&loc=SL5988623-112600" }, "r25": { "Glossary": "Standby Letter of Credit", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6525665" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r26": { "Glossary": "Weighted-Average Number of Common Shares Outstanding", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528421" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q1(c))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q2)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(c).Q3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65897934&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65896087&loc=d3e11374-113907" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65896914&loc=d3e39076-109324" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73531372&loc=d3e2207-128464" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472" }, "r3": { "Glossary": "Cash", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506951" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5263-128473" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5263-128473" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5333-128473" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5419-128473" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5504-128473" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=66022390&loc=d3e923-111674" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569643-111683" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2),(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=d3e41678-113959" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=65894324&loc=d3e18349-110257" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL7498348-110258" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19279-110258" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6447952&loc=d3e13217-108610" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13467-108611" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13476-108611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13504-108611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=73530178&loc=d3e59706-112781" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.6(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)-(g)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803" }, "r4": { "Glossary": "Cash Equivalents", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6507016" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=50488274&loc=d3e64164-112818" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f,g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "325", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6485959&loc=d3e22529-158502" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S35", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488548&loc=SL6090579-123006" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C.9(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r432": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12b", "Subsection": "1" }, "r433": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Glossary": "Change in Accounting Principle", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6507316" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Glossary": "Contingent Stock Agreement", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508534" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r7": { "Glossary": "Current Assets", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509628" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r8": { "Glossary": "Current Liabilities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509677" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e),(f),(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580" }, "r9": { "Glossary": "Deferred Tax Asset", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510090" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669625-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004921&loc=d3e1436-108581" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.21)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3,6,7,9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" } }, "version": "2.0" } ZIP 70 0000012208-17-000041-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-17-000041-xbrl.zip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ᤦYF![BB M2CF "GK=W39Y^O?I:Q"J%G$]_P>1%1PWID M/9#9:Z6@AW#KAM!]6LR3UPFMEV.[E,[X2SJ8O$@6O,SA8IUPB1& ]2))229" M\0LQ#%8 X"'C0G&[X7M6FLN'(9MS&M%U020'TP=L5,UAE[Q(W-*!<+9!Q$0& MA1P0M?(K:5\!W-H_LJ^-O63%4J1NM*[@LTC0)%[7?Q+KT5VF_!H7P#CXG)QM M&PR_5=!8Y[WO#$5^PV6Z:3C3A!BVD#4W9"]5E)4F"\69S,@ M]3_I:Z3/(DY*I%64<\Z ]CF?SI$I$O3]6L@UY.:?9DP%"!G+.E6X=6/_<#;U M19K,E0T( '-@L1FHO@TL+4&8N!20=LD]P >[9@ M.Y8J8=E%WS$"X81$.Y#T4,JX:80KG'\*J,!'@N)[D7&K5=$*UA= 7,M$V'M% M'5_=9Z/0\7GXKU DALTVL4DS%_62;GB5N-U+E2#!1(8*^$!^Y< [6=9 M0LRAL3YW=&@.U??:GH6LB20K\K-P-?DL6G3]KQID&%UH-F33%T>&CW9;E6X6 M^R_EMM&56\Q!I8$'MB+NKKE:,$1!49U#!=H/\:P=BL7'[Z4 $ 15_=QJ*%T^ MNW'_=)T)[>,??%;Z!HJ^%ZP/'XW1'-% +!VQ-J$J2LZZ*[G?=8"EZ07DB.Y< MNBR7?9NS387@!,4&HA MF$Z() .D-^=JA_0N"L^ (^00*5WE'1,NMPTY?61"M80D&[A8]D_+?:Y9=&MI+A5@=L MA]KLAGKW;IC:Q%;OK>QSR#X 3SC;V00N5;9'9I]%EKC)A'R: Z &X!!)7&0 MB> @<9ES_\TMVD/92JL7-ZT,RW6%%;KW&F\?\DB\0(YTJV!Z.]*_[(Y1\BN0 MIP0<=-D5J!U2Z]ILF%3'2-B#38-+*$NY;-4%GRXKFR%]@I&LE" IYB"$#2-G M#QL!]91RMC3* 'JSA*L=&#G!%Y585(=A+8M\S5UD()K[0!^*GQ3*?]/-<+XW?@!"OVYD?Z(-/),E M[79>5SV7*BC%"=J74$(B0@85>O$G8QOY#?).MB"K5H'<+T$B3]&"6')1";_# M&8.RS?VMH ;*:O_<1H#:,%G4FO3VEO#:::$D6'2]P-)[2Q-N'O8IY^"1=IRI M<(!*'@.1H$A(JR%.F7S^^6MS&MJCT[#G]3O*:6@>'HLVY.KL([HGC4L=8.5A MZ<3Y)247S944KG 5%TD.<@W7^[@X/.E%:$B;6>NI*+A"+0P, #3W1W1A ,Q MVO'J5 RH?05W29#%"QD"7L4'5$K+H'@=# 84&!($8OR.*HLH\>**X=*PY1+' M*$)P^$,)?EN5H+2:1.,2:MG0R& M6\'G=1H7"IDL%Q.0'*4?143'$=/!@8CJ%E(HX3><[PLF?Q4QX,.^L8D!]QU- M]6S?,'QM:KEJZ#IV,'7=*+)FAF_,9L\< SY$Q/=G./)%/:](TO"SQ6=NE$/G MP%6"1B'@]O.4 .#. '#?5Z-@&IB1;DZM4+4].PQ= M:?!S$&F6:<^FAA>XD:/KGNI:871WC/2][]D- #=N#0#_''WY^OGOP=>_?_[X MZ624:JA<]3Q"5;]F0A6AZ%>RN<$SGLI6XGB&[3'#:0U8 M0:#Z^M2(K&@:6FZ@32/= ZK6+7WF35U[)X.MATSP :-I_?F\ 'W/7V!\ ^IZ MVE,F]JI[K*0':6< M(NR?;8P[R9O"=Y7>D/V#APKG"GH%XC4>;.%@FJ,0"L(%R$AY(9P1:RR"A4HN M*S#Z 5[$<925HH*GIVP+D# \\:;R$6:. =!E7X+N,V@) MC^?%7S##H$[9;\M;N#(ZE>_.PS*"F36-(ET-'=>R=&OJ .)3,^U3=,THJ## MAFUSIOF:YP2&;5J>Y7FV8=IP#F=^Y$TC,[B33]W[GATVC :799ZF^34)Q&38 M*^OU&NCV7XP[ &(N=-Q([V;_7!0< KB 6P)!<2'[>U!]Q)DL?_A1N9M_/V[; M[^?V#UB&WDM[&=WJ5I=(_-P=548VF5XRLZ;RC':^?'.6IN)7L@#C9YCM7'[> M0[%?0;TJE4_L6OF'G1]F_Z[3]I=_SD'';;83_9S_FRA\WL_DJ- M;Z;:5W+% L)8C]D9R_"(+P\%^2)5.^8.CL MG(W;_^ZV/X#_4MQZF,27&4@^R?R0PJLC&;QN,OB:5W%Z4$'BV^L+6TM.MQVN7!VY=K-.LF'3?UIYPI7MN M,#*]ME2G/;4UVPKMF159E@T*JFFZ:N!I@6N$H1I.'V(PVC(/?:3:1&93)+XI M(3\57C+1 Y!7I;](\O]%(43(((/5C'_R?H"/)-$3J/@V(M"(0*>!0);6%EW3 MM9D1N&X0>K.I%?J /='4=V:^;UE!Z,]VZK _"0)).;@C!@^&1-:P[?Y&)!J1 M:$2BP9#(:)%(U6U+5TU5=RS5FD7&- I-+0HU33.T('#]PY%H !3QSM4WC2(O M:E%]"HTR6,7%)??]B9I2[]RPT$CPF72J?[$B7\3E"G?8U37]IP$AZ&3EE?', MO8HSY[3]S0,G\ W?<:>V%EFN!KJ#J0>&X82V R?0N3OJ9< S-Z@6,9Z]\>R= MZMGSVJ[?9F1'L^G,4CW7LGS=\<*IJWF8/#DU9IYSM_K^X+/7ORNGNNDR7*W; MD%+64_HB0U?&\_=.'3IM^.)Q$OA;MEX\&*H&7833P#!;;Z/T3$^?J8ZF.E%@ M6F%H^@$H_Z%GZR[V,=,>Y 1Y1-3L$TGQ]DL@V>D9$L8#_4X/M-&&P;MZZ#D@ M@82V[ENA8WIPO!VL(N"[YFRJ[Y0,>+X#?8B*,![L\6"_YX-MM4V;0\>>:IYK MSQSL:Z+[ONN:@>OYMCWU0MNRG^I@OS']X_0.]]LS_\/6R8J-[SVD\C5;0KZ_ M!YSE0=M3VJNF^[T]G4M@+/MD">F$:.94>SF:-% M;C";[<@13WE4GS+V2!LT"G(\LN.1?=XCJ[='5@5>ZJB>9\QFEA5&@3?SK:EA MA@Y\Q-H-1Q_908Z;]RZ/V_MQ*\@N>KP>]/P&>^%EI2AHG.9ER0X1]D?3Q4[? MX-T&P&_0M.%86EM[=CI5PTC3?-/6+=,TIK-@"G 7 -ZY?N ^* [Z:TN,K7GC M1=6)$M84OKM'KS">K/WT(\AH-&R.Z'!:Z."T+DK#T:S05@//\GTK#!W/-\/0 M5:>^ZFNA,;V[Y-A3H\/1&LS#4,(<46)$B7?G_G Z]>D=)S)UW7*FGN=;GA;X M@1I9NNE-/3W0[.F.A?%X%!CV! ]I/SR]$_KF?!B=I'@JS;Y=(.]]&5P>P4\, MX">+O,;Z49*A')0,QA]*1:EV.-1I)H0]=!D&G_6S8K+;"1[3-,^(W,!RHT"U MPJDU]1P;8-K' J-:8&D'9HT!_+ZPNT '@GZ<3T2C$/.Z$=J^$SVJL4ZZK)(YMH*A[N,,C5&\ M\L(%PWXOHI*Z2 (K95L763 =*Z]?%GE9PHB*2WC\ILBQ]1S]T/2DJ7E1[&0M MVN&U36'@#SK*F6S&V1:$G_!78W==K-D^+QC?+^I0=B4;SXA2W'EQ&6?)O_@5 M;;5WWHV(=QVJY).PE#<,A7B7J6?PV"DQ_YMFV]C#W4D"!4=L.I>%HP]H3T3H<;6 S3R7-4=%YYGWPU+;C M<:0&H3[555.;S2P-ZYKXKJUJL#.!IJFA_I!]^)1S?OZ$6Z&?VT_8?1KW(L&V M.*#0))NX%50V<;(CI""2QFL0(:NR%5"N&77%6:9;XH44A>X4(QZX?_>$(WN:UJD9$'JV M8>F!Y]IN .CH !/U/5.;ZAK@9O!4F8A/OX$/<^7OHO / Y_]3 %U%'3ARXEL MJ<7Q>;%.,NR.#/.^8E*I>]9SK+6EIRS',6;ZS/3<,+ B/7(UTW!M37>LJ0I0 M/6BF^6//L5B^G_GB^=G"[RU=)-3A]W.\[]G6CE,WM S=M53#F7K3J>5JD>^Y M>+J=66CYH&F^Y.E^_FU]0HE+]%0.WV]O M%ZUA/CRYP5K?CO"B?U>%?,@FOF1G%P6+_SR+ES"D'^/T.KXIX55_715B-B]@ M4[]O*9^OCV_3S-H+ EO59QIFF%JA!F)^H#HSX""&$1B>9N*2/:B9]9:_S=YR M1.+GP5V)]+'?__HCP+&BGRN_-J9[*D[A_%0JV,.Z+DMIW?:S.+TI$P+N6=/A M'7$^:2S@G]N&\+\U#>%?VC7SQ*?_ZPK69-&N5;F27>?A/)'4"]#TCSKC$DIK MZ\\XA^9]ZC-TB'"5%@AB17;_'N-L5[S#0B7CO&%Q<1RS$0&WPD&XW5D*! 5L M*B7[* F>M-5,Z3!>C,-?-G,K=^@RY1R'+_! M8RY$A!::Y(2?DO 'Y++J&KMK;_)"]!L6,5P3I=M;DMZVK]O@I,6X=<(A$9Z) M/E:<$ VZ@EEQX4Y!V1%./KV\RO.T5#+&\(#@^;](@-POZ07W3E+.[4V3ZX>_ M_8'[D::\L3B91MP)0$&SQ;0^J*TF<^X7CV&1@'Y+AJN&GOF+&/_.UR".HWH& M5"7V9$D>=[[,$V7%XK1:S8%>)PJ#1[=N[DL,]\K(RP\\#X07>'I+LH 8,,9% MKF1Y16PQS>%]_ZS1[%MQ"T^7]<47>5T172^2Y9*A>?N6N<0E1A$ M:+#'K56 M) "8(+RJS&E6BXZ*D7,U-,.&UM3A??_Z8&S"M5A2R8Z$OQT>]">KNM<45^QY M>["_"'EUT(@O5KW9X()BU_IVN_'LQDH19Y=DJ0-1YY)C1+S9Q,".:K[2[)]U MLI$U>TM&/W'J2]DW9;YB:]I&O+1SV($V8'AQRI\!=R8+(M ;-"2"%/HO$@0*(OF#WLS* M2D1*P,S6-PA[.*H44BB*CD M!YUQ=Q**TD6>=D&JS+ELN6'GD417RO+ M K^0%_( *-@,N"//)L)Y.5_1(1-VM;^??SD'.@6*(RB]P,B/%?> R=G@8#> M=]\2/$=P=)]2UC2\?S\JV@4/$ZHOH/2>H:;SI(,]SKD_[^IC&0/"BE.! NX M!4/(Y'XJ8L])5^-8$C_;EMC:$5NR,YL$352-J)H*^[64\D3,W@4CZQWL94KQ M2=76;3R03\+C5U)_N[^W*TGWHXF0X0'>(_628DCQJ%G/8Z<0D(^2R[A"^R MAH?]L>]1G>LH=$^^EW8JS:\9#IM[Q/EHZ0>I-?37O.7SN'=E4G$9ZYI$(1## M\^R,7DW\/P$&R@&I\ZK^\]KP21F6R45!V/L:QHY[RHTD?'4)U42$6QNU*9U_ M0&7L,B\2?@6&;I!1B5@(W8KO68K2/>R;P,BB.6W=F^*VMD_&Z@K=CB M)C"? M9(E2*BHY$]%3((T%SG+FUMZYPBBC3/!^$@C>NBCX,5-F[**HX^*&; A$14Y?,_2Y^.(F>CG[M$S@?'!9J)QN2*Y O9Q%9-HT1GU40%1WVGJN7K\BA,- MP#%C9Q5(X0T8P+*C"-<+E29"%('<7$.+.X%">R.#I'.JQ+>9WX3'NV?D M$+:/QB9>M ;NO#%PMVR_^VR29LB: R^)YW-TB0F[!G[1&F! ?[D0QB 88G,D M_H(": V:BL!71-L477,U?-@@VRU ]D1Y=0EL*N<:$==R%<2#LHU&A+>1-:E1 MUWJ&E4X8_@(>F[)*A0H:\@#!^HD?WV^ DM\V$?27C OSW,PC#4*P MG$5\5L)&)R31+EC%W8^T><#?0-%7KD"I;U\^Q^4INLQ*D)0 HB1;TB-JLLNS MN$3 81G@/)[(9K1XH&'VK2R!+"_)KH W7&$8+VPE::6;\H9SL@L&?/"*<7KK M[I-8MC-NA"A%%D#)4QY 2&.$C@6M]8K;V#*4W7@4#,\. .4411L88&^M26AH MN#X]I4E@$*P*)X&+%?)1*&%RB;9,H%G3U7]2?@\^@T"#8@=!65^%;\?*SUZ? M3+)ZGC)8_G@.*]%N3'> L#)?&%,^ :4H.M>.4+^7SO^>$+7/SO_6N2@B#@B, MJ%]FR$F!;PH1&A<8%ZOA&D>RBN$@&$>U#<*3(T9F6$.,#(W(-9S;F,O>%0J! M%RCC(HTE)4_<:>U_*/>1,J%@J"EE)"W@4,^)HS2H.>&:/SSQSRR_5E;P?P(Q M<4IXG@72^2K9E$>MP0!\G,RY^T60R7'A5-\9]KD^R/B0W2+L2=E?,.08X ,0 MB+*1XF\#A6%_I^GGWO&C[N32T'G<2V3<%M.;!(;Y'RLVN>?&X!-H9'2DD58K MX[5,A1 D)XDG!GTY+2HE91^ORD9P1',[(D+2F%*%Q0V-N16C=U_%:=U#M\X: MGN^Z$D\J1L9]=S$RKX>-@O[R7W$F=5%[2Q=55O"R;M8F=Q-P%Q$6)E#F-XCG MF#DJ4R:YT/X[RM&I\DM\42K?\P\_"'V"9+>,/*#QXBJF7%9$@2Q'WY%2ERA$ M(5/BKR6;PIRN(._N&?HZ^"O%RV'L^X2L'7&/O"+H]A6G%7,F"&JV-9<'*A4R M\>(ABLY?'JWB"$!9QDE!IY^5\N@C_-# RW:KNHL>-U?NJ$TD"J' 6:R3)O'W M&/:FGSO'XRR,%AA @J;=LY0LI"VZ-3,]B@VKY]H@PVRY\#L0KUO2D_1$$N%" MJE9WT1G\=A15'2_4 92M$M(*Q>D\?#S>N<5MQT>3$&5DD:9=KM":18LJ+%J- M7>/P@>K&$&(/CZQ#V89"$7I[WE@N0!4 !8M0'$"$(T\O2AEIX];'('UT8(CK M]TA2:+ZX$#*LB!8B.*!X=C)CHJ:_(YBMT'X@K6W<0@^39*!L9"C#%]*PC2AY M\,([:@ M;U4K^!/F(>IBS=&=OBG9C_*/G5R+#TWAYZ94N:9_N+TN-'^'I?W[3_*B[=^\ MVW^ZXZZ[?CKPMA-\XHL6VGZITO?6<[;Y$F:T06"Q8$SY-:=DA@B3&?;/<]S' MT]['+\FW^W9Q/)8'-!HYT>WN"7[CB7VK6ZSLW]U3Z60Q5$G<9^E ]<1K,=S& MO]\6'N]RK^UQKT]@KP\KL?Q&#OTC)C]2R0M3R3ZX>&ORP"=I17NF$_'"I?$U M53U7CYCJHQI0OVSS@W]_G\SN^2P*KY,H1[H;Z6ZDNY'N1KI[0KI[L)2XIW7K M?+F"/!V"--\(0;XU\^//G1# -Z/?6";6B7_T9$X6Y=XZF(U4-%+1 M&Z8B;:2BD8J.I"+K=5'1N[&_/:(OU#N0\O6#..;I2?DG1;6GA(ZOC" -;S3, MC01Y0@1IJN>'Q$".!#D2Y),1Y"&>X-,CR+=FF/O<+4VY8%'UATD3YV^V/3:#76? MFEHFCY6<7IE$K[T1@?ZD"/*4@.^5T:-Q;HWT.-+CR="C=GY(\NE(CR,]/A4^ M'N+9/3UZ)$GRKU0)K?E^<=+UX(9]X]_^3ZPDB__\4#J!XYK1+-#]P+8\7?4B MRW5UVS:-0 >2MN !?XT?.=3#B(M_Q,OOZ!$=P(U4;MSG1;GA "B_YW!Q(IH' M1**>9'G0(K^>JHD^]0^XPNX[HN4;-@!NBH[[68;]BSXSWBHT4V98.UU3S_[O M*^]F+]IJ87MCWJPVP5JB+3'@[$05R"K^AM5^>[T29,5NWJ8D1WRE"N.\K/C6 MQ4EV!:^@]GCPVK@H8FQ#BHV-BJN=)^/%924Z>&.CAVNJD(_C6>3U1;6L4SG. M4C1)J9)+43H;:Z)2']Y25#!NYK/I$K^$?S A@?/IVZ(K:]N-N=Q599 M.?9#N!%UB(G8+QC+L!?"8J(@@2^[C1U[CV]&U'E.FOR)C?Y@:OE\3BTW\;FR M^S/\(KHPXH/V-H\2O3)_C;/XDM?5%CVZQ K C07K##3+E1*X.+8ZC[$(L!CK M@O? Q-?<>OZ[^UMA"<0C2OC>53R]>V69?#O\+>N<:OL]/9 .6%)8H@8OGBL[ MK[=,)!;-0^71N1^/@ Q;ZOA+J82\!ZELB^%CGY R(7":-106Y!EO>4/7?&X; M8OS6HME=_(RO1H^I+>&]<-WKY&WRG,VH?0DPC%3VW^+ UJ;=SI1?HF"7OYU4HZ/M'*+%V.AH&-'AL16< M^N2Z3^WH*AG;Y Q:*W6O1IJ^O2CO(HH@]#SVCOU"T=F9\@6KL$U Z"HN$]'0+!+]X-_TJG5JT"G? MTW]^:$2;?31YYV&_17(I&7;6/5Q2^6<=%]B0[O &(@\2L(Y3 8YI@_N@X7UG MJ>80G5CF+4]XXO%J]A#=8X5&_OZ(\1BC'O9\G1>DOSSU0,^-P]MG20TM^H9= MY*0Q0YA/8." 1 !VF3*OBX)E\YO]K8Q?D@Q.%Y XIDLR6"@7-[S#VS?2;].; M)QVZ=FX?T52M"U$5=11;-XHVP,')GCM)SH$@5R5C=85Y@=M[T3;\ANE$-;;W M4TCFP-G^_?S+N:)\1"M.ERMVEZMD@)#Q#=I?B,[]*&AXC+- M+_#%<$>*[8S+BLSGT>??E?*FK-@:W_P'@[^*9@3< !3LCQQ!X@/PTU) M:9F([1"S07&D:X7DAZH+D?PF5F[87)A&,R6 V\@,%B;Q99:7,$GR!Y3BX,-+ M%S59CF4_ M)5?Y#1NXSK=9"_;O!OCD9)UDDL.\GCF?VA$\;0&#-P3=+U_(W2=>VA,QD%F% MP$Q2T/7#Y!+M(__Q;Z[IZC\IOP>?)6]3B)]+,>0S,+60=Z5O^T]/%-@[T<0U M7RZQO3O*E8TP .^"A\VIE?NJR$'2S"^+>+.Z4=; Z#&RHL_96\:^(1%; MQ"G#Y3?H&]S>3;7TM\@'X$3]TGO(V\]37P5D/7S[57 MQ5N-<^L0/L/)^_!>PT,SY5;M>UH[C#,RY5/6^K>X,K"[(KFH>?-@6/6%Y$HP MU21;,E U\[I$E95N)GZS7M=9OF+(5=/\\J;'MX'<+G+@A*1GKN-_ BOXZQ> M@F+(M<&6R>&SB(VC<0'#YX2)E9-QM<7K@&,2D5\RSLJ3N7*5L.O);5*(A'^Y M=81LB_PZVQH!7B,89[E?K+@L\FN8##+8#DM_+5SVT#<&>4:]:DCZX$VZU\(K M]>1, JL>'H$B(^<_+ 7=G4)TN:SN6;&;7XQ)O$Q0W6$ZQRWVN=LXA7?::V[ MC]:\8&55U!+/YR!\H[:TU\K5QXWWNV%'2.2MV+8$19;'^H$,6/!@2"$//K-3 MQ5,7998*"3KP&=3WY5WR'+2&KDHM\<<.E ME"*O& P$"(9R$^;<%\*'V!H$T&9PEUXZGH:C3T-K67PTR7]-UB 6?F+7RN<< M1-('A%'Q*)XL+]9QVHOB$5_=:I=TASP?S;&_10$D4UQCIPZCJ2\VWI M/8LBN6(94A&'FRXB\+P?"18\"FL97\&*(';TU9DK>!Q:)TOEBA5E7>X'Z/.W M[N=Z1 G:4OG^R\__$:\W/_D_=,[SX;+FA[]]IVO&NA-BP^.U+;B^M:PF$$5">AK^<8$[H8=D#A M,BP Z)()SI-C&IY2L?4&!E?<4+0'\*I)YPD=)Q&ZV/!#N6T_D[XB(2?(#:67 MRT2DQM<&4G8\3S"5%0UZL%68)(8B+/Q9)@L184)/+/-E=0UG"@21:(TO8^Q, MCD# <7A//'A%\!-E@F_I;Q35\58$C\M\V[0 MB30DBBO19]"+>LG_5#9IC-F\*&*E^;PQ'A+'IX0V)M>[$R5#QD,DAA5A">8- M)R@!\#2%"2K(=5H)8Z=01-CVVO I=4;;#@VF\IE1E(](E5NQ>$&I>CPWC*\J MI8/BW_-*9L5R;:03D+6[1A_OTO,*9] P5(TXX)%J MK[%9 &<'-]_M"A]QU.^P,N]8:N%1(!/D6:/;X]2^,T%LV.&IIY3";6P7IQQ3 MN&\C!RG^W2EZ[Y4"?TH[MI M3J=[7QS@?1;W$1*>#Q(:@VJ<\;I+RJ8&05><6Y+]8XCD/0D$7&'!M(.$TAS(Q\/2% BJYJD9,,P**^7,N<:T1:=Q0R"2 M#&D0>AO\_;:C/#I>CL?F*O_'O[FZIOT$BEMV)E).LLLWO5@?_O81^1-:,"2W MN\LJMG/WRT/%<,ZWH\RGUA B_C"67.O<'LAK\!I)X0AGVBU.^WF\(2#I^='Z M9T;4PCL@87"3QM42"Q_=F1O8AO>A1; 4#()?2V\NV!I$"8KU7_$P_F436B]? M07R%V];:.=&;Q&QX/3D^:9X/";==Q\5"SD\:.X4D4LKY=6:,]KLLOR923EG% MWKSM:[:51HU)$51#3KF,9;6+-"]Q3\C.#,O7TMF>-&QN,HW)3KK["![QP0I" MB@S#0RN2)9.KN/'J;N*;]@.9C/EX@(:6(%-0*4@FMT[NL!Q&,WJTCQ;(NI]@]86M'TS0^:,46E_#,-W^N?B,/T?>\ M/NH/$FG[)/.:^-++BRB:=NX.)!B(JK7#R"O8'VC8<;U&^C@Z<;&7H2@P2&#' M%QAA7B24\G"%M8@79*@ER4*N55XLDDRZ*#=4F)'\@.@.;!A]6S@8[V\?Z_^\ M/^"0RQ*]NW"#WK8""M@%2\66E&=RQ3HEGI4"R][B_AR\V=\;EOK#$8;Z.PO- MWG>W<4QN\J,.Y9'E=(5QS\SB6?BU8Q9\FXAO*;@0'PND1*;8M.[3P&H M*_B#>/EZ'KX$L 8"3M7V(, ;T_B:ZV0%NZQ3_AM7P@#X8G%F)KU:\8!ZFQJ) M=1V#V 3'H:T=M3L:E(+R](I&4)9U:Z(1.B*]:4WQ4 BH;:@4_9!B(%' /@F >HM3U"H70AA:MST3%#B!4;Q2YZ/&TH%\X')HT:](+-4DQ2[ MKZ<"]@@!.JXO5^0&$X\#*LK36II$T5^.:=$(ZLV!O&V8V',BNY&6$SP]VV-N MJVYQZV;CK>E4 N,""[ )D8[PSHFRKW0TK!!7]X*UY=^$KWA9 U"SB<(2LK/( M3) ;A8BX^3AI4!:S0_*B;+DZ_%171*LI(!@G[,Y)C;1,UV;"B/[HH<_;%+CD"IH1V&P%%]D0@#'NBY M592<-:!V-6G[WU"#&1D_G-<5,4H8I@2BC@!! MF]MA[I(AP^U)T?AZ.*70,XC..^ CG]DC8O*R2/3F)8^ J@7=9W#L%4V7^FE2 M88N=3O<;@,B28(K;%V0/JJ WZWV5&.>V&&L9VZ\$Q&FMX'>9!'12V?J6/#RWJ M_P6XUVOIF/"HE[SEEAGCAC^J*<8IGO&CW\@_'A0#-O:K>'"_BIW;>8GH59R" MGK8\W%;^0F[68RI H1OS7%4N3B,"S'/=P3+'[X@M/L7]/ZJQ0UOVY"C-1CNF M7.#CVS:\INTYNN?"$;52;A_7D]69/KRTXM/63>RF*G1*&=]7W9<8(\?)QIX$ MVT"VXSV5]T78X]V-$;9Z(*!+D& $RPL?$PEF(=4>CHQJGZ6RO3OH33]XZ=8L&7*I%?C3N:U?P+= MNL!CM?G'59L_L5/XPKS%-LUS\W1XBR[TD(-J2YQ:C?+)+Y@E4A3^6<=I]C\B[).\K1???W0*NF]+1!1 MC'C,Z\TNOR!G;HH@B]Q*5%3?[7\BDK!>"7LX](U/5":=BF-KSQ5"? ('\*6+ M^EG6NUKN8_!NNW;X#G8\9]WP4US<= !;TJ<@# 5;)FG6S@ MW]6J08IZB_L[I<5EF>_);A7Q_46_19QK5YTK\ILXK6YZ50'BMN;$9<%X M\C&%-9*5&A9FO4G;0N*PY5A=$8_#4!7$W]BY> I;MGJNGW:=[J?:PP:BG[ < M]INW-;]PQ6M3'7BYO ]_,]5ABN&](RP;QG%M>-:Y\>)%J(D U/=( ,]8 M%WJG=O!==95W9+"'UU-GBL=#R\Q5:_NYE*BTKO&Y$V\_V-GW.>4!- M#^[IS@ZO82[//U_/NVJ7MUAQ?_'R[1+E7RG9IN'+-.K]_AIY-"AZ/=]? !T> M.$5:R 0)TE(W11%%/MP#]F)"@?6"$*GX3 YB*=(9NF-039DCJ= IH]KXLDE@6)VQ%EE.KAOT8Z>?EZV$.!"^#UKD>RUS? MREM/F5.-I57'TJK/08 GY0T ]>96=9,$*$[5;YS$J0#.9OOES=-,G//L<+ MR8HY;J UND8CW@56$L*2%-RFC(C;B@+5JJ""YF5]4<("HHK'C4@87PEZ&2!T M4JY:4(?;_F157P( *6W!I.7OYSQ?\+X';?((OSU6RC66O,WJ]047Z9IB_B+Q M"AN3K%A&EJT-%Q%Y$.0"TRXPG9K2#3L!H#!X(2I>YT6Z:++IJ6(P-Y,A?TA( MMV5%":(%6_"WR:K%XKJ2(WDE3-W(IIK?D.F!2()%QF#2*>,AK^T==&4R;]>@ ME\F%TQ)Y).A%K_%9"5GOP-$KC'>7QG#1._L1ES0O>BU3+_3&. ML*(862TG-$';_36#%8?_PD)5F-(&_UD"TR.=77@"N,$,#@\V1)BT/@'!:S#= MAP\"(\/AH8L%!=# C6ESZGCYY@525'P5)REE#UTELZVHG5/EREJ[.2S8GJ M V+3BB_3! 4#Q\ I4&-*:N11<I_B9ETS;E7A;!XCD?.BR*])ON$-0'!= M00T!M*PHF6VY000E._C K$-I:"_^?E-<&8A;*69U *2 )I#HX M7W\290JB$6U+1/2WS).")<4H<#@3FQK^*F4/DU6,1([4ARXZ(N6+?5/:G.,'.J U0:YTVJJH0[^7"7FA-%RX^V-X;UACI$QE4P MBB"GBO%%NT&2G!!U;[HE,79V:QT3B'2CX3V1+I$CT?"-;@;3^"UNH_S)'>/% MFR_K&)36BF$:1X&2M1"3KSG%#57]75>=(6(1VE.)6])97IA)7:*#[2AJ'YB4 M!7N/RX8H!JRG;PYARV\\^SU2/X1B>"NBIHCC19S]R74XD;6$7^8@"5W*6HMH M%(GYS;+)@3!B5"L$V,Z! 84NOV2$DJ1\SN-RI2 /%CD:3:#4A&=V "B#./5/ MZE6$P,Q8U4ODR"_^P15PGBK3O?\VR6#2HK9@WOS>?GHOW=01M":4="*RI8 = MB$8K7L=&%+84W#SKI?%3TI/H[< HN _SCWF%3-Z-"=[*<^=I MC,TQ$:,^\6YB [S1KUX/BQ/8^I3C_<[1]'-O"&5I$ %7+%W(2H?2^-NH=$TGN5X[%KQT!=HS26"D#3QR MI78L;7>\G]MV>ZH/ =M%+J*C)+KQ@)?LDK\M ^6HW J)ZI:\)9]%VRT.M:1V M+6AL&9D-OU2D%J/,NTPQ]Q+!=6]P!474;*HFG*8WT\8+.H?QO(G M?M;5V=KD!1[>A7Y2.6%8!@K%:M4L#,\NRU;(X79##,Y> MYS!3X:D1%M&>F-6$[4CN4RK?T^(#G-,GRN04RN$/E#N[B8$5-,%J.74[@VGP M1296)1P+J-NW2F&WQR&GGDJX!Z2?LPU,0\EQ;OH-._=,GKC3.=D*T;):ZUETBCL\S& MII9*(G:+NMHMBABY_YRL&60Y)R,*;\]$<4QEVX9*D#<(0<*"@4)*LK[ X[.6 M*;=5$2<-U B)B])5A;G]$FDOX])'G7$[#D_W6>4E20CBN!: 6D1JBQH>>M-- M!^JD+8!L@?";D"]>RF+N[13AE;P28+ZY%M^(03_N76('%QG=&(1PJ"Y;&-[QV M+ _ Q+%??*E?!ZXMJ6:?-793\_643 MXYY_!"(&>OT9%&D!>[_#*:@OD=\=L0/?&=ZY-U PUU$[\)VAGSM#U87=ZN/] M!YED,?HZ7\/Q%NK>4&;\?(4$J]]2OE[=MJ>/W/T_)VLI'&/KW&F!X8:V5'DJ(ZESD+?L4)5 MB]R9%D2&9[LGYFL,\%3,2&@F\:1-=3N!17W*-V)7+(($@M6%D++;1+\C0AW=&2>[S>#7WWC*V%P^D?&[;U3$BS--WM]B6:UK% MI- MH7]-UB!N?&+7RN<<5,>?E%T65P$OK1;RYNMD4:U^--W--_SMK]4"?Q1__)4N M[5T.@@CIE4)VJ/+-P^4&7$,QG3,,=_M1-_E;'[T/F*ZLVS]M,6H^]MM'^@@1 MYU#X)>V;XV^<+*1[(DW0R8':9TI"(HB?;?X^M1>1Z@GCT9@R_K;)%4-;7)(E M:WC55@FUK;I=NUF*G8Y6]Z=93AK?P !%!B;*G@TBFOHKT?=(YJ^5S+F5A.B\ MH5N2LV33G#8[96^BW&Z>;==[ME-[KD/NB*H8YD %VB8R"+W@.1E- G-W7'P@ MMO2=HS54CI:L,XWE.*7V/HUU%VZR]B8ZBR3B_DF3V;S\I$U&PG^;A"\H;(^A MO"'XKMC*RR.5_+]-.=&"M-DA1+A_?2$ M;/;^O/#S^VCEC:F^!YD%/I)O"GF*W_CXWHN!H!;UTI)F#5H_YW$9CM]IIM.V M'GGYNC#JN?&TA6%&S?[-:?;]A&RLZ"!QF52A3NCM5CA$-_ABJ\4#EW^W5$1) M5UO!6&T]Q*\R?HN\J1^S^3DE K*+HL8P!^(137+4UE-B$HDQ9ICBP7CJ8)S> M$(?C 6[S&Q382?"5U7@(&D6!1XP2C3/Y)KLMNM.+2.=UG 47>W,G9=AC\*"6 M@Q/9+[2IF4[:_68EJ+&O;K2*O:SKLZ/6=^(_&B*4^08)!04FG:Y2^[(.E#0I MR67%@&R #GYO#!C]O-]]_;K;;D1&&S/6\XG+<$1:F#9B$<_6GUE^?;8"4J5< MC T/@FES1_+EDF%L9-D94]./$2^F@&?.UF"HW'='N)3R6[]411-/BRYCRH1 BH-U;<.N9+0:]HJ:)QM2V1N_AXARXD%?;?Y# MP8CB&GF;>UPE\2<(W@Q#-(15KE.\161DM;(3C@5(%.LK33CHRC:1'2KCL<7Y M&EY8UF($0!?HHA;%IW"R3;8\/@SFE3*>],VKP[_QC?^#B6+__!!AR!*F2^5E MR5N,=1EOBP<4)8=+UJL436F&=]0/%A&7 @8Q0 \)J+'SP(G.D))2"L^Y*/(_ M1:@ZH79-)-DFXDEGP!^\786P9?'>UEADH::>#*(I 48(DL0-JOYML^MF[XFR M<%TC6<$P!@N3FU&4X-E"6V&AO&!<)Z*3 ^T-O[+72$$>A48>*=G^8<&2_7\\ M?T8& V+JMXS&DK'UU&*.UPO(;L22E:RS#C@]F>^$L;L%]D_ Q("VM$!_-2B6 M,5Y>8NB\)]8]O_.MH;(M'MJL?\[RQXB#OW-2:VC?G>_ MYW;OV0)D1;8O2G@7UL@2: M(/ENDM BKF(26.I,MLJL-Y>82LY_9]D*7RN8JMX]BV:S!,#Z*APF6ZA )T%US7[8O./-) MIV /N'[O[>WU!<2]N%%!A3LFT36\G+'E WV%N;KQ<],);FFZ^ M<>[SAZB!V2V$\X5E6 $>^X7RN!U3[X0YBE1TZJU0T=[6L'3H>M'5[:SN5C<@ M3@"';$_*]:G7FGK1"I?/3Q&HT4USC+>!50J3@O$:F"M,*:NK55XD_V(+H59N M.FZQ>H,[^IWF]KL+[S^HG:(&W^EMQ *]Y8;)]A_M"Q:OJ^[2 SJ..:1PK^.% M")'FKCJE!W+F!(:[5=,\2..R5/S>:O)C1\\2UNSF*1BA7U QJUS)+[C=FD+Y M%MT.P#*EL)N%CCGNW(>W%18JO4#4-SHA?9R#;YTEE:R!L*<2TPTOFDHOD;F- MY/7HF3?DA#YFHA&%,*_0!',HE+X_: M*:[#,6Z3\Z #.7O9.+N[ @KPCD@7B7[@S<9CDG9\!G4R,"3D4(%.I_'VSP (:KWR1NK\"O?\:WPAD0$(3JC"PJ+TKP"'Z M>XKR5'^:^5^F]*?VTP^R=M0="P>\_;RYU__R]^96?/V9ZDV4#U_F $M(D[_F M"W)2$5:TSSS_H"API[Q#F:<@["U)527S95MWF"(Z6+$FSR(BH3#[4LA.MW*Q M#)&(*=IS79<5U9[BKQ3>.F #Z\Z J$A)9Q3<I\J#E7IWWSN)"S+<@2!% M?65;;:4=M7@&KVN!2X,&+F'&SS>T7;C7G#GP9!;Z 4FC\[9[.X9)Z$+>C)-J M\KG)0PLW8',;*N]:YFFRX ;@AGBIV JWF;^UTXIB:.>\PA%LCEZSOO#CAX]- MVC]O)DS^EB89!.T_OQ./2^;P!SE!E" 7,FC_5_BV8)6(XE"FO 8X7=P_C@ZG M(4%^&$XD&%$ALO/+#>Y60=5",E*5^*,VXOWPZK\VM30W_=B2N<:!L1D#8IJU93G:<@'R/CO5*RQM[;M MM&C"W<&(@.KOA8/HVD4Q&837@F$*E.M,R%D M]V31IK9U&[?#L!%?4XR'HXT=M'ZBE-"-:#:!.]LCD6S?Q2L8VB2XJ[E#:Q[?W*@15%&%9*"Y! 9_[U.[&"-*UEW<2/.."+G">:%: M1RV3G9^P8EU1T&QYYT9>+AS43/1'-PT=)R0GM-7$>3DT<6-;'4\.ZKR_+CUH MZ,L^/*:+ZESM.__WP8:W]28!D_),49PPLKIX?9826R37:0SK@7-ICXAP;^]; M5 +O;7$K;XF*EWIR>!GLSN1D(6S,*MD@"S?*F5-:R-[4\ MD^+9W4)9TQXIWCL=*?/E<\**A5C8K=F<@F1W4EYINS^\=^"5'AA;@; ^!*11 M-M :\CJ+3;+'5%:DZ\&JUFIW5*BB?T\3]X-*5$D-&CQ]';+Y'U<4B''"F.TJ6@6AM0+D._TON4&(21-7B>2 M]Z7@D3"\+@%B'M;LJCPL7$A!C%I$V&H_2%KHE2WQT*AJN*W-:OXC33Y M&QYP)*;.%7@2%[G05Y&5OA06WR:&7$2\MDLJ9,6)0E]3 8=ZC7(:_+*I.3+& M[9)P;.=-%JA,M:Q)W6^X16%06/^Y2:?OF [1FU2161]>T.J7]*]RNZVX2Y,A MXS*3V'$: =]T*@0),@ZU+^E,$_8+(]R1YTKLW*/?=^[@Z15<* .%?8FB:'^2 M0@*/FSI]M.^=D."[=7CMX0SFKTDE4#"=01$'-QFL;53?V$1MO97Z5XTC4.-T'KV]]UX]>EVMFH#N+93;D[ MOR2I#$LZ3+JHA0ULLU6R0\56B>7[:\ M,^@0HT"^4K"+&\%/TY1*Y=(O>#4:%?"1HCJ6[#1Z4=]@[8VR&8ZLXR(&]2^> M4K.0G8^I21^7%_C9Y*R&*<_"ZN>0C)A#\",^61Y<.OW6Z% M_)"AJK=["G84/.K3(=)V!%S<;R(6&]*E#JHZNA3EG4&AY 8IWC$4#5GDI^BM M_YZ=[NW!UK;N["?A%87.4@ WEP2Y>4<^&",9\E2DM5*R*K:3[D8+<"'D03)( M=[9/CX/=!Y[W#R(P.RR^W(%JDB(:/T,/N 7=R.Q 4%OK-?6,O&)GDI87_ZA% M4N." @E2X?%%-PP\KVF1&3?TU\Y0?"&2A5$P$EX-CN%WVJ_$^[MSHTWEH2X/ M5(W?&*S[]25ZU#BJ[T=TBVM=9=DZ_&#= ^$VHUC=S]UV!/3-[[)X?@_5+:IW MC)7R%]QTR7OVR*YWU0V/ 1-E]>%OE+.D@XZ.;2P:I-)&BT&U4/(0R<-ZYM,T M$3ID*Z93KK3L878(W5KWT&W'D--?A[=%N[)WUYWRB '4^RN+R[IH"$-$H?R2 MEQ11DW6!;HT#7!!6O(:+:S_(M^I8]G7%'_F*&DU'0+I 7"HNER&3N&XX<:B]W]0Z("?,E!3,AXATSHOC=V'>EW MG6Z*2>&.=(%W<#(BZ7?]0E$D4XHB$?QH?ZB*W<17R),F"EU(P9YO&@].X5$6 M,A212]TM!]KQ]35BHKB1.L$@W15,],Q>\/"0&-,6.Y$J"!W"2;D5$$<>"6X3 MDMZ[QA,C8MJX;E-1*Z$J7\3<28)3H6 YWD^I:7[9!+. 9G]Y2:5$E#21)K6. M#4NT!:6XF5C9 (W.@<"I2 LOJB*NE07:EDQF6](1N>$> W%*^A8KVH.^7^=> MMP?:6G9L7!-1\61QY! [EI56SL04I,YXN82Z,P".FE+N;2L<=TQ&./#/.Q*O M#(6GK)CO.D6[).K(G_VVD1&64#KK9+GBA>&._E>*)S;I/'0=?*&UK^BF/S01 M%T$3RA-T46D:I^1>_K)BK#H%.#HI3X\S>GKN"8^Z$]6=?3[TMMRS,/E' -4 M3[\RP"Y2!5MLGWP0'FN&P<49^2]V/!7YKLFQB0)A_-EK_NQNYZA&""%'D*P= M2/)<(EPZ/**Z9\ZG_F5D2* Z2NV-C#4A3%+.DA$HD][CR1'0AA"V9[&]JG$U MMT-I6O^0Q"FENEA.K&,(VS/KLA=E\JC%ZH1HMU55&Z]?7N/*XZ'-=?J,Y7<^ZZ MPM0$50HTW1"Q4:6U"78;*WON,:'2D#0%$DY9\4MX\$/K6I5B2<(U-S(."594 M$BM2E/^FJE.<]<8\"%'"0100H K8=$XH]:D3"#.1 M#1BI$W(F[!(\%*K3YJ 7V\@YP^VU)K^>WR()JK0.H+50BV%&/#'E6&IZ^ MLWQY1I$TPC/?IAL*P[K,HNE0]JM!$OW1\1UW HE&[MC6#(]KOV6[Z>0_M*#0 M?OE+9Q%1OX/;%GQOZVZ8,'_7'EB2^A\/8T!; >=M6Y5BX/!WN4%C4/B^QU#S M%N&$]:$N&S- CV>B?M% X0_\>(F&HT#,<-"Z!J).F(@TLTL%HHT"ZSN +TA* MV&,[\T(\95W_31M!7+ 51HE?2168/TM,<[L ((B^"\H! M%G$6O-M\\YHMA\D>TN*$]S!'RJP=1Z\RK=!Y[QN+4.>0([6"$2GKC7"YZ):$ MZSOA<>7Q@0BG"'X=T]T18T(RX!'TU,VO-<)QKK!):TJK@3OKLB-7=5POHBO[ M!89OBW[G%,7-=QUKW/8C&[KNP)+M'SN?;I<\FAI +7UV3N 0?/ W];_W]ZW M-K>-9%E^WOT5#.]VC!T!J?2TK*KIBJ HJ=K=+MLMN=K[%222$LH@P $(RZQ? MOWE?F3YYQQWKDOBCW65+J5.&-B,RC"PI[V7 M]&00NVJ:8[MT;UO.B&MYD[T^H?2125!5NA /;OUA]%4K, L:FU5QDT+7SJ,7 MA#XX[O-X)JT*[0\;[,V$K.1#B.YOM6J0X4FTN_ DVEW;M&^:^^":<6CC//+P M!>Z66QK-,;(NB'38M%>JCAS3BR<^ J0AH)PA=0.S+\6MP=*K0X5U1\U&U@%0 M!-:60#<(K$>RX2_?G_SG%:KZVG^0 8FEW=Z&2="]8*]]AMGLOAMS#;ZX8MX, M[N397*A!Q.,-AS; 4Q38&-1 K* MU@$ORE?>RL";#', 8+O! 418M2^MA/ N?B44AOC7(B/K>CO8E77R'[\*/C=1 MZHUH%8=V!6!W9X:3CN@D37"2%V"3?#'A.R+8!Y56>[-*JST4*\I=R3L+C>@. M%F=XRYR ?GC-W5^#@O59F )16 XCV3O-F-#9H"!'H!I4L.N>[F _XI)-5'F5 M6@U>(_/TO@X&Q#26$VP_)&%RH.&5ICQ43."]57L1,!X2KJL+I6W>N6NO-:Z]/K2,JR']10V0DZAAM$8-1#WZU7DVD1O_"@V[#P7!_W"A4>S,,5A M)]U][Y)0=6O#AJHH2X&0[T%1ED:0*?8D:)8D/Q73=-1[O6$O>:6M(&DTUKK. MX[*$BF UE2IDT*G(@PMG#1^'=^E2@ 1D[][C#=:HNS\8/&J\$R#'/N>1W5%) MBE!F-T0(L>ESOMG?D6'SB,.A!5VD]E3*,"LTA&)CU.JW]"(&'%L#_8Y\R30U M]Z#'+&]S>T>>.#5HL??J]/'%[55;^;R4 8?A+[\WL5=?S M3YM71WK;1=.RCNPRE>.S@#0%6?UEZ'(R27B[FIA63.I:7,(D)C16MPJZ2H&4 M,@/KX/6A;9'^CRM\J0=]/MCB"U8(GJKREL\9&[=7>9WA _#+:+N(;W DZ!?Z MU=UU)BD%4^OQ?C5S.W.LM?$ MX%%0,S,T]-MU6\Y)_Z%$YY-IG=VF$/!?M2Y)W53ZL*DM" )A)QX K&XV[JCQ MVK)W@>B85_NBI>[13?8],=,)P">0'\S153H9A,2&$-!//113)'WR1&X4IN]< MJ1 ( M0, 1/]')Z6!D>@OR2]NWL)J^?RC_UJ4^)19ZSV-RY4!+/&[O*.BOEM1J-YPT!$!30P':'Q^[>WIN] MK>W!T?;VF]V--X?[]N>-H[V]S=W-H]<'1T(7-W81_\OT4I[[*=B2:U7W"!V_N;^]@ M#(*1L/%,COJ#0LL8,4JAA %8'*$7$%A/2,Y%HQ^0GDS"HSYF:G$66.,1VDU M*85"W33#R+>JAY-4=X0$PTXK+FB;))(H#?Y9U1-@^O[+)(ZJF^K"+G/(I4W) MX7%+)TWF:2A,Z>XXL*%C2CIR92WA&#PD44/3V/$-Z6>'U.&(8W&32-:')7UH M2N $M'%B?&:HCNXSGT@.>YZ:L1V%'14ZKW8JL.(_2DD=SD;&<9E0,IG?G%^G1!E&KUV M3:K1!*/URQ>U>F#=RD!0TRM\G9P/R+="GQ[R:B-K22IRD43T!BL &A&$4PFI MZP#(7B"P(>)*H8UB:Y@6K&F3R!V'P%[\TB4_+Q\>;HP)(@(57)Z1[7[FKO*< MX=KHY0;6.+'87\0A2I90L9 4^+-.2,8IS9L]0% Q7!.F.(S,X8V?ITCEXC0' M+Q\9LRK3PU!'R/Q*,X,*69*> Z1>3I><% M09:8\ K22C.W_0Q*.^=@8O*B^2YQ?#1:S&/8C8I48%C[M-L'Z3"Q?WN&^_*L M .E)!BT#]J\ >5#87'QOS\CZN!C9?]@('E3]=O]YU&_OX.6>LM8JXXB0,IU3 MF=9X@K4%H$734D5*R168"!##RG45/-6./M#)=?PA0OB[L#TE82TQY\3KS!L; M;]W5]:YB>MR%N(5_!/T0Y(4@.N/?1#-LC6@[$/VW-7@'DE)&@R*&%4H\V*WD MGTC2WR($")^/^/[H("1X"%]QW*CN[LN4HE(1'$X*/8F=9/@=YYJI\U /OX, M5(;RNAK'3]"872G0&7B^[K=@P'*LP^+;ZWV 'AOOB;D:U#,/?3@%!TM>V+PQ MS* \"[;32XH*R^197.>C<^Z$(4:3Q$##J:#?,)SI?^SA"8($SM!$:#\]0I84 MJLB3FJ9U@X]./EI7V9[UGZ'QJ(K\*N1QT4"A=P6\-CD&*+E3:54GN&9JL\$*=""J?CIU@Q@[QQL9N?V?PYGA_X_APX_A@X_5&?W=P M_..2ZAV.RL?^R:?>V[>8;-S<_*7WX=,_CDYZ;]\??SCYO?_I[8?W#^!=^ID< M'&]O]8]>V_\-=H_?O-G?VMW;/-A]O;=QN'6XVQ_\=08:B0! !!GA%MS(!EJMLRDTV=-S0("!^\=GP9L41^MK24K M^3;JT823_W1I;/;$7\(E&V=S>^_U[L[18.]@L+>[N[G]YFA[9S!X<[2_]WIG M?_MPXP%LG/XZX@QZQS&*]SV V7M@(>4'$+! 3AZ60IB=]\[@",XIXCCS#J0] MH'/FE"'YN[00&!O54SCF0*#7,4MZ $RXMI[41P&Y80%EA$UGS2:.. '@HR>/ M(9]5?/*( QE2KPN=;>\NN.SH[7BPCS?P[5<:E>=*7^BK8NR*'BVJT>9%O@:- M.UCI ;2MTRI\^?YC_Y7/J.&;/00@X$S"X7_6%1(7OCS\\,]7CK/U"J6LEZ=' M@U=R _7CM-:F7T<$E<6Y@_:EE?O4%_O)X8&?.\9Q@X8^4W^@2=EZ# MF^,#D>H-3#YIW,364U9+VT;B<<;89E>SF!#7"=1WTNJL*%6FP$NX>@%8Z.P M=&Q*_7EAL#DJ5'I3(4>I>LJX4NDFN2A<=^D'197\)E)(:IEBFE[^-NN@NDK7 MW#5U$4LFR:70OV2FL,&!VENPZN39SNEVSSU<_B)O=I%6)I(NV"%*64D"OK$WAG,GV>3/"FPA&M7+X9CBZ6@38.%AD&K! 4PM:G&-/$1;" *2L?,GPJ-?Y1[J=O>MZ MG+W>[Y#PX>J#:P*1!$]('=0]61BB=YWQ@'N $:X5%Y"]=S]R9)XAI)MI:W&V MSHL*"=B8IR8> JBM*%-?IKWB$A1_P#XE/ 40_W'.4,Z>RNB.%^9KP&_IO (Y M$"[#:U'N\S6.=1=B*:+((@H3-)E!( M 1L8^\\% _\QWO MY;?OFM*8&S 0H'=8D KXQQN.LVH/>V;&S^\ M0PPILOBBTIN6G&],JA/Q8*$SYFV[(%RI%3=)51BA)4%EBPYFN\7SVAZE4,; MYBY[K@(:#YO;QEE*S6V=X_'J5IY*RBY$Z^H XV#Z-1XYI4[R=%YZ6"$3(6&+ MH?+V8O245-429F.-*J5V_NV2!W'Z> P;J!P6+AQTGQC8YPVBT300;]F-5-#C MH]FC/]9PVC_RJ$_/4Z")$=**]DU<[)IZ2I77#@06/C7JTG;>M/<;L5SU#F'* MK%LYXZ3*B9ME,=)0[Y,>>6IL9B8\&_JBM^61=/BR(B2_I7]!5] :RO#.4O&" MY25&4)T$UQ*'7@)OL&@<" MLC>*;7!9G?LY+A VBEQGO">0Z4RP#1'W4K;N_<>_>@=0F[.'&P3==F8V7#2C MOT.S*?HQ]KU0R,XRZWB,>G\8U:R@= I^+;Q%#K7=IW':)W7N]EU(E_"L%ZC")A$E4!LRA'L-82=UHL %V1&/$'@ M/MH7!]:)D+05+4_B6?L6PQTBQP@W+N,ZJ3-,3($%/K//:5"FVYZ[P,Z*^ /7 M/>M4@*D..8[3K*8>:ASZG(TUO_TQL?&$@(9P?^@X&K(B$(X!V+.J&$9!FMX0 M:T;B6BD-/\6X2+.%_AHS>P,$1,*@9@M^7-,X6ZG"5O@1 6I2WRB3Q#P M@B;$"*&M$[1WP'8$=.^@VY2.@(N<> 2;2/_VM4%3"BOH_DS4[U*!-63&FNCB MQY0TOH7-^Y]F;I,W:>H Q2ESF3[ MVL_*6+HHY'2@R7 R79B@XH6L?*APXCJG#!'GS7EKWJ5A XHQDO/4H%]8P*TI M(LBQ)P4WA8\**&/;R( D\00L19A$H1Y4NDK/,5*I/:I->S_I! 0( MVK5<^:7#;;&5.7,4K\QC;3QFMZ13'>5GV9/\:MP9 CVW8%,_(5C=!BL5HN\,\P2E1)ODV42;=9M6R#YZASF$(K"+4*BNG7" 7-I[BI2%F0O#E2FM.$O>)&$"?]I3F M?,-$N,/!D$^G5+9BN]V; 554D15GJ7)&VDP]W+FMBP0%JK^,:Y)>-4C/@XD. M\"V+*<'\K8=1@YF@Y(=?T? 3VS%(EEN;6:"WHR:UF1CS'37.=9%7T[4K)%1J M6LEQG6&3UXANZ)RSDB)2CLTC?,NFY&P=\JAP+Q41L1'9"C.QD2EU%1-0 X@= M3S3%.4F)*7E'R^CN)+6":6W#K5$/%>AD.1#_FAPI?F82XI/351WP->V-/@F:MBV%^E9?,> />#<0.9HW"Q,\.=4]_*:ZS@P27X6WJRL7G.-7 8ID&S MUJ37.U!BTT3OZ7P7N>D:=NV[ZX)&)4Y[U+TYD%8 YR(^LQNE0DYG"=GAZ>PK M! 0B.?6-2*%A[N#-_%2X[R"Y5\6(YN!=ZMB6Z= =F)$0)Z)\YE>VX''NX)ZDV$:;2[AL-=UV;9 M=G0A'DV9O%*0\LKM)4>8%%&]X9=3!#]#'0'R>7@N^BQ"!RJ?.O78?7\@C:C4 M@1J"U%9,IL8>"&6TP+/Y8LRT5T\Y*Q RA7>>[NQOS:,@934K">( RFC6Y-CC M$&X:?!&,1V&'#3(*(Z1ULP<.CG/,9W"OSF58ESV>Q[&TIY;.66K7B&22]=Z)K M@F2I&\(79Z&]E*\0BZ2V)2=3KV)PL_ MG[I^<%U_V+B4B6M_"32Z<1$,.%/E\!K ,&^D##2C!C+VX>QC^F8^_> M? _4P/1X)ZD!$DGB"'7="2HYSB I*O6:ZQ?MGRY8]G; L4RWP$WD<5#%1U"D M[_%NS!_3\P*FB0OS4K;4M7FP.D!V?4%I;=>WJ:_AY$((?C4+E.FPDI8464;A M$RT=@GY@G*T72(\J%'HII:Z'DGH8&Y;^-5_"S9NYT1STM> ML'@,C)?Y4=UH0_U1 I!6X"ZYZ%/#;_DI+A]DKD:H' M[J_G%ZOT.<]#Y 5L]:TN#'1?["NFCS.N MCK&DD)N*T&4\O4CM@70,K?)1[Z",_THA@=T[,0SQ.:EMP J_J)%9!GW7YK0T MU_&RE00GP"#DWR9EQ*7YGM/127'K:HJTJ\*?@J7UJ[0&/_T7Q14I70&CF"J+( M6A7PB2%B),X=<*=%A>)2)RUJ,1N;QA,U.MS=.@4@&G0AE,[)I=H;G->3.&_L M:)?!)@L;+$HF/W#1O%K)^B842D0]+S/M092<7E7K'M6!YN$%T@JP)(Q4=SWW MD_E3-Q=. F88S MBSV,$'Y#I:[:]%*O0-4+/[XF K$>2G MQS+QI3 &J#8/C5]PR>Y&W?-8 R\NPBB-EV+C,9%(W^'3!Y(I.50)#ZY!Z?YW MPB@JY@W*Y>!99N0Y7=\*A#O -N-/+:\LA%1])D7%-UHGB),WQ@>9 M[4H#)%EPZ*[+R+TZ-T2\"R, /U_&*](F"$F5_,(>7:(=%R^?<1R)[ 66<06R MM=AQF7RU:P9EG-6J\5EJY(R327 Q,HG T:)$3]:N0E%O^\QUW-9 23B*KP%5 M^SD!A1KZHTC4CYH'Q5J&&@1^C[2FZ"ISK[&Q_,J%6<%>FJ<6K%+KC0#)G:N. M %H3_7(*J5/3@"#J_?S56?;[C9J=P6< MW= NY^"X>E6('6!F%_;W&.>GP M>.H6%;NU7",069&$\ 18&:6+23$_7@(#"*\,8 DBU!T1Z^D%FN\ALA4O00MJ MZ^7LU7MK&\]!3;F$:7(?!OAHI1J$&]U,$[0I1'@M&#VGG3HO+"W>)FJ>49< MH)005*+XBFY7MZ\#3_<.0"^G"O2RS-FK_!)U]XB93_@#/;V=2^835D^(X M: M^TG[KN)).A$>OTSY(2&_X-)LNISEWZQ;\J]Q#H;65G4$%Z4)U@U[*GYC\J2X M]@']:%UB;?GT5JM; DEA&7#,=]%9!1>@0 MAOZ=EQ'C):^]DD#MFDGAYZI!8\IE;QO7IXA162#T_MD3*8:B<9!O,R@8Y]8F M5%YR"D$[^!2Q!N-$3%DY9SMJ_6H+EV+SMQN1\V%H;0$G-.(!P3%+0+4@65K2 M4#'Y@@%?C_7353Z& :=DB&AXYFOW%$Z\KMFF:E$+5L)B'X(64:T3G&GU?Z<) MUDV=/K%0E\S@G8[TR>H)N;D+BD2EXCH!B"F/(BN-R&-LKKWWXEIFYR*YL;6QL<3I;VW(Y6\#=Q\,&4F!V MHXX@)VS-*#P1G2.*,]PA($'4<>3@R5YNA#T*/_CPM%'RFYP5=&+)RM%M'EW+ M-U[T78><.K7(K,$<77[824>;/I=J?]PQ2-J?>I%:B3<\Q2@E+[PVW:PW7!'O M%OH QIN B6;G+KD/'ZO-N9+;=H#MJD9M8?\VA#A:07BNR+JALO*-_.:C.@9N MI;.&.BI\>A^#F@%)ZQK'HL&)'^PUH233C#+YM.]F#:^2SG%/I235SUD1D!S MGLC/H,=6,; [8)YT;%AW(@>N)*Z93 HV4=)L*+TG:85%"'K5G\T0,2,JS\%- M(;KE3@^9]&DP%Y0:[KYUX9><93GU+-LE5Q*0717RPHQ1&%B07I.]:3EOSQ.8 M-P@2(:_#R4F?AI=05*,JJ0+J&IE5BE QV%N_#*BD7 '(\Z]738BXPSG/95.% M]UU:+F]4(.24=_6/(.'"&;=@"OS-P[9H7'&PM56A.025(4-&1<2(TMK.[" U MZDG%HR_P*K%F8WV&R11+[5/K%AP6;/=*S I!&=#"J%B_VOF % IC(.SDT\^HA1%=\ M0I0:TG!L-R$@X9#;(<,DHHE+3G$/X=1MPLG<"\*CV.%F%:D8L_-PN7\N20[X M%+A#ZI/# (C'9'+4U.,_I"-8>Z]9S5!.J;^.H / 1A/%*!64I]_!'G\ C?GX M1QR>ZEKS+==(^P_PZP5)4T"BTV@0HU,%*%/ C876JH1 MR>)1@S*.3(XMG8UB*&"C!MA=4FZ.UI+^%*U M!(?YC.N<)4P%+% NS"E>AND<)RYB0B)[4EJ_!TS#3 $A$@.%04^X@+B--3 ? MT+"5*[Y)1V(L::F90*J6OC4.CZB1KT=-E)HQ94D;R=+KZK2.8W!!*\WT5Z@8 MF9:C>O*5R) QMPX-K$B[:7+,PY-XI'2=3$P,7@TTBDP]CQ02H5J#3+W*D,0R MOG>%\3O4/%:[1SQ&&% U(UK@.H_KV7F!2J:-WFRR;^2>\/%GW]SBYR=)([2 M^9E=4\PW2TP?0$ :JY3S-G7@1 MU(*7-@C1)(22F5W/;9U5S$[3HHS\JE4']M)E # G/4@GF>+AE0^[<+>]*MQ= MT=KA_KJL,:VKI5,(% (\9DQ$4KS-8>?Y@[RNO**]V"[<*2E>'7T]\B%P#;*V M:#[W7K#GVG%N\M XLAHHQX!SNXQR 4, ;SA[QTCK %K'L.3M?PE/ .[,Q/K( M/;9G-&;<31Z NGP+$1 *XX3L88QFBT:)M\G=LM/'N6=4TY M@;EIQ5Q@=B>F'J)PS=V R>#, MG47*A3T-VWM(I(STAUT,U8 _/C7.XP>6X_N-,?EVSHH))7.%.X3SN K5T8GH MOE'^[L=/[RW<\6TNZ1SA #&*;P-T!A-6$@$&1_&*$$.U<);!M'"R&ZH-@,5U M.!C8)LUOFOQK6A;$' 5FV%<%$B.0?W JN[@IP9!U1#R)*[-\7;@_A M"\.,?=6Z$(.[[/:6O.5H/B)D>)_;RAB;/8%22-?:PJ00Y@6[EI3+ X:-HOY9 M=@,LP8V@32#G7<[I@FG@+Z'I/@6]?-X]2==?0D1 M]BA"YB6SH3B2T\$:2HIZ. /G7KZ"_)&G4SO)4*N)P4O]S48Y#+?[:!W(^@SI M2V_^Q/]W>W]]GQYY J*D17[C2S7QA'&OLD_'*YV90G@!#L[AN#*\;1U[A %Z M*SKRD(XIZB%W,%'=V0 %_)HT6Z-]QO 67B5>K1"-C:L$,^,LE\_0:THSWKA1 MZTB]!@]/42YHC749_3*HH"H4*UB,C*=&=6/^R_Z<%)/_@E:N$4(3T3LT\% ! M,S$1)&-1$$1F\+G&3+/JXCX@@G)2\N(JY#?-1SR7DMZ)2>J1LYJ*A1#8R<0+ MQ@I"C$H8O0I"3BYN4,&G)=5QF]3[BU;=,\LL?:A#+12D*&^(E722]&C-DJA+ M%*4I=F@OQ:IRLC(SCE*(U+D=8^.*1T;$U%0NT_AKK2.=L<]3R!.R-B MN'DIR"517P%>7Y@.J-4]Z!B#R_+.P9#2#@3LG[7*#2&ASE>!"&L_<=;W(_Y7 M>%SI6YK-IU2!1TY"WT0%[IF0_OK\N;P.K(W8S8-$;=PT)@1.Z.\!WI!]#PC$ M(4MD_T)P(#>]-IKO,!%<)?7K$T6="<.![J7$ZLL_13<'#V'$'-$IV(?DC'D* M8^98^DL/;EEU[[ M;K/2_G\B7[:GR.S\YYTWTV_PMY]F"?R1__$3?C3X.)#]PVG)4S KIE=/8L.+ MY\=9@[G[>6N'[GH#@_)F:^MUPZ+PV!>/]!KY]N\A$]:4@14#3P$O"##567%& MRG^81U'+MS104I'DH8VK4TRR2,=XOH#V1?4$\Q52'[L#-)IL$.6;?7I$)T+4 M(!A)509X!B%U90CFHFWG=YHTUE&0)F>ME]C#@C?BM#IOW1SUV%Q +8^0K="7 M#A$V-8=!^H2 FNC!X$VQ<_V,@$B 0D&.73 I-@K'8UY8DIT3$+))SM@N,:H\ M5EV!7/H<9D6!Q^1N>#A %:7&6X%*UU?+[(Y0\RO#>QM@$\>G.;/@W>. M.:6VTR[)@/6.W8H&YBP;3];I(4+0JLBE22=#J%,I62C.DT[P8EF8)A81*5UN3+VAC)=)WLD;>!>/PHW==]T\O)-X?=X[-M#W:^]2V\=Z.7AW M?/H*GM7,"X/JBZ_\SSJ\H$A$O-W M[?T.2[=[7Y\*\?[+P>^GKT1]840@1!3AQKU!$KIUFOB=!PL0<]:RY#A?TK0! M1' 'P%]#'/!8_3!-4W0B W@,?O >@6.T82:HOD]_ -]0/H( M?.W(#HI^_S9^ P )EPU6:HOX!6DX8A>]:X7?=_YAY8PM M-<=WXXS=36*GA]L4]QF6TACC;D_[K?7MOP%W*$"D0/N2'0=&EX];OE9B:..E MGM\U\J(C%#B'.!W@J6(E5;!RH2_4X9\YTC>'&L6=K:E@^JX' Q-X:,B ;L2: MHWJXWGNWWMOO +&(YK8=Y\$S$A#Z>= +LTNR@0;H%L M"U#8J"]\5 MFCV)@M0GLK2HCL#DA8L2'94Q7T3)NT3;#B&]$7!MSI@*.' A=S-QM1-.T$Q, M3/HR_@QE;@7XIF\=ISTD)]V5CQ0J3N1"W9OI4]L>N5DZ21TGCD]$-$*,H<%< MBBEAQ(1MQM+0!.KUEX4K^%QXG:L5,Q;)#KAJ1I?N@"O@S!KYW.9[4\I0W2DT M)G"4K',(J?1@07M!EOK#EJR8:"TXUQ5Y9&6DE,(=K1:S4&(RXI7^NEX3_,ZSDKX$69"!/"-CSK5OH?TTN_!;NJQ?!< MP/'2GJ5VOZ39?!''K/OLJ\AQ#Q5Y@]I24 NP'=@D?=ESPIG0*ADCJFJ$,@*N498.\$VD?V&E"*$4<98UMS,4M5"$ MG6M% )8YKV< PD#Z8K=](YRPI(PO"//HUR=&LF[IQIF-VI,Y84U$+-,W$EO# MB[2&U]2P>2I%HRXF0-PZ+)*;R.NY. M/PP]/>>_7 LF<@=/V\JKP*,C"3%)3X )=NN&SGU>4DIA/4Z*:<#ZI.T*3M#7 M5#>8JS]3XQXD9[B!6O89!: PDBGV9,_FN;I>/ M*3FZCBN=9O(-?>SJ,[NWZ-^I#]CC%#!P^5EF]!6(A QJT()LCV?J[P[=2^Y7 MH);K05?G14^TLP)F40#EE;5/ZRT>N:^;D#+93)T?(PC-$*H+Z5CI@6J;?'<. MP9?@HS3-0"/N@B$@C<2D0[I#^,IX.,F#OT:6&GU&^OR*<(#T]2YTQ%$NDU M[Y^VW6%!KU9V3\U%K3.3"Y,L(C&I40L"(^:NZ:JQ]SO/@ M=(,6U=@PF3_JA #G0]/ (.\RGNB):6P9G-&Z:H6C#[R1=?=Y%,P>9>,8RE9+ M,*2!P;A;I%FHK(4"2EO-D%J/VZKIR"?:I9)_LA;<4*X%,K:N%[VQ\J$$B)$& M@Y!])Q9[WT -$X0V3E@M]*7D) 9+L.8(H/P&8R=54K4<7ND6X 4GO _$W,7P M\*,D(/?#-*5; GF1L)OD8UQF:8Q6YFO!/?[6V[=W'J=-?X<5=@EN3U9,U9I2 M8CKL>#7V]E_365EH'T'<2 S%FV&K/W1(>]U/G7N/C9.'5-&X-C S>%%AHUM/J0EC3?\ M]-O]3MR M1*U4['GM*0GQU#^#R]?/F,T>*O*QR\&SNT37PIJLZ_Z D0/M&PT^[,8?Q5-Z M5GJ:4 %F&5%WN>,JA T M<>2#N[H4%:WX<24Q+RDWZ\GTG+X9)82Y^P:>!&8+-XJ>0B'^];I%65K-EM4; M*9AI+"":G6!Z<[H1V9'$!6!X!.E=_QV-BH^Q7^ 6[LBY?[00*O/9F?07V'3- M+(T'I4XX(@FY)FSS MBSURFXG2,WGS4+!',49_NA:WIZB##\ PH0VC6@WX]9N%; M-=MVE><6T&M=J$9F/HR!TN ,>3&9*E7U249!9JS!"B7M>/CAN>+'S(A>JOOL MA\X[^S14ML[%BB>,8O4H6AX.Z^T\:*-Z!QG6?H5GG-N(W"G@\BAHS,P923.A MD0GG"PTL]OZ+]B=S3CAZ0VR::[]FA#6H]\Q*CXBB)$90_YX5O01)D*1,? 3$ M1%V4OS^O@&5/ >4/GAQD#JAYMND2$<]J3NCYMDGI>IX TK1:%8]S53"YMGOC MSE:Y#.?JU3_15P]^]P0.=9^%4'+.HKR8$^N:K(O5:GBBJT$)F:$G@?$[D]8[ M(44Y)%:KX(FN@F5AA0\>V(]-1XUL"N@,K"S$4UT;\+):(D]TB>C,%U4&.R%\J_?_1-\_L(,5.?B4D+U,@+$CXNH7HK[/)U67G8\E(#Q,2C\N%HE3W.5 MD#,!O,*CVA'6.?E1TIHQ5 P=,:VN$KI8H.S'>=0KBDA^5\=>NRD?4\LI:B_\ MO(8O[%'6#*%HYQ+\F)J>ZW0U(W9!:H=RS!GYA "F5B4"40" BD)1S[#FX0#4 M5<])'B_1H_2D1Y (YT8P3>C*I;4@EZYU)0,A,F+%[%()=[!>!^)P;(^J1>[" M!47RRO@ M21?]05%B:.D?,.H2%%=&7C-9M)RH/YE$3Y;H>P9$=NI26KT+3I$B5\V!;4T; M%A=4K1CPW@&9.W,(''N>D"!!C*X1')??R-:RF/K<\1@7Q:SG 'KAO'00S9,1 M)DPGW[(H%SQ!!'163DF2SIT)]CR@C(Q&CZ +@&A)Q(\$N!<\A+'=N#)Q.3KW M+9'D&CK='1JTO<^_P[>KE!*IZ0)F,XOKG*Y%!%[JA=EY@ -=S7?0,M6N0+A%]MXH$\K!4PC:1Y*0!@9TE<'P1+B6Y9S M0)]P8"#XN)FK($8?/84XTP+?(_I;,NHIZ!I^R8N+S"1G%.?0_16' M:]@IRK)"]/QR2Z_BJEIG&TW>53$]!R,Q6\ BZ^LR2A?5='22B(;#]OWW19WX8:R^,Q-W998 _N*$89;Z\-"]JB M1C9X?<$VJKWT(/)#@:=+:]LE_Z2/DS=FU?;%J"\83 I( M/4>-JG2:VX^A,U&UU=E+ZN(BG6NOY=B6D8XD93.L2^L\X]OB1E $R;#$=&9B M:A(3M7AH%+47J,:Q9V^$S>,S; M#ZL3@DC.*AUD-MZ?>W<2*:K[-]HZ[7%C2I"Y"5^E_9_4L/ CHCCDL@14AMHQCM4:X;NZY8 M XB7\K">*7;:LSI&AA9)MXH6 65X,>,7 KF]%B0>M)DAYGCS!=U(RG(S^85( M%K4WCWO\2/?TB19VI9/=RR?.N@5%9MP$- UVXOHO-2A RU/":2%,E+0WCX%@.YK1%VAGE58AW7Z)27.D:\&+RH,CD1YS&T4GZ<[,D3U5V.QU$X'CB8Z'91NZUY\29P_"0%'8YKI"P MEV<)I"54?X[N<[&95,-H!1Z/2UKM?LXR7DB!JKO72",)$G+BV9. M^+DJL7Q M#BHQSC&)N%KERIL$UEMROY#KB^]^2TR2D.FY;U:C^UX2E#A8,/DOWWYZ%;SQ M.)>WE@6M0OY5H+<(')=XZ"A -G_R[2=WP=M44ER<1_L,^CF8G.5+J1%0 (>] MV]AL5+GU"2U,N>.(8]7<+O%7R3E\"*^,.86'7;7;>_95NQLC/D#NE3M*C7B* MULR)=*(_[EQZQCM6F*Z"'+1FW \Y>5HD7I&C5&J>F,TV*.K%=]<2^G=9I9]; MVLU+=RA[/>!)Y, ]Y4H3SF',S0P]2;@/=>XO+M*3]\I8 7LMA%N+?^AGE)TG MZ>IEXC.OC2(S/IH_-_K4#Z%WXT[5,)T)TTI^5AE/TP0\3>$+X:2="W_\.H(O MY6$[.D,JQ<1<* $&0Y-?BW"?'2H";=!,L_A >/S[51>USWM* M64Z%#4S!I(";%3(U,EY#>A',9N5SCKA@2RP+2EL\*#=Y# M!84:[>**F&=A11]45<^J+NXLE'#D^LY"?Q!!8HL8ZJ M3KZ:%Z'>TI%*FT2! ^N6LEL"[C=V#$E1-M"Y89Y?U?=_-%KE":XJ1+,P[YO' M383I+TY*>\*3\,4*B(7SJ!<&%E[>%&\[1IK)J'=J+?U?IK3'F8U*?S,E)L3@ M#J?V&K$U;4N4'KNO31QAJNRG.62,O<+Y_]3Q%T1)IEDR3M$RCD'*L0*:NCRI MLC0QNNR6-W<1P43 ]4?Q#TT[ U6$$?E (X=U4/L$"@$%9@_=)N=6S@@U=8Y(CGES"Q$GX8/P7CG [G]CW(__T%9"L#7*PCF>,/3XL* M8V:XIZ_@6$\ C,A?-H8IZI L]0)L71>$B4IQK:?%IQ,YD19QVD4W7]Y59PWP M"S.CL)GH,&.E<*G"F_ M8O+,1++-RUXB+N+;8F" JQ@#@& M(UASP=FN=$5'S!Z%)B_D>K,*MU0N"B,Q''DI4BH+GHPE933$.]PM-MB><3X; ML%;>5(RYKHNKUN\'=QG:!]]M'V8<21#24 ";O,FI(ADC=G -/J=((<,O(&-D MYVW'E(; O:JFL)7Y%5ER1Y4X>K-LR]'F5&.BV8HC[_I/M/GYCBW51#3 MG+IP8#>I;Y&5U8!\O@J MY_=GG9P14,KA[]"U$'TUR>DC[.T"BIA+QD E#"*"A'( $8N" BD8.&_U/"4Y M/CXL'=]; %I..1\'R!=M_:\)*:8[KG [6$>ASUB\^@T# AK.(3P!*#)\^55FV2EKAV8!8#OEK>B'2ZER%-599^ M,5EZ;@-425T5]0PW1"-P$(_0K4CNRF$10^(XQIZ^0"=HP4:#W%4&$/@SW-D@ MBV&^&C=+IJ(=4['V=EP5"!^DF2?!$;FUIV;'%P)3Y)KH98YA"9%_Y$%: @P" MB&X*55288Q.?;/4X"3C]@_$MQB-RMK+02I7"%)_,)0>>K"-FS>122$B M::0UP;M8']R&)$EN:'G$?Y%G2=82'<9PAE+8!8D)==ND_&E?>@6F493/J(+F M\ZI:^!B.2? 8(I^#]I]]<8P]I42[-:"J. M/=Y80D_1=DH?U8%^/RX2),_ "DF%AU1(<*(YT'BPBB(A>^D^%<-(*Q>0)GVQ$Q2%F9>CK\?E$]+\[*4.:(]-B0^2"OK!-AM$C* M<5&ZS@N/#?KYOI.#*UZUQ\FKAG$ R)P&/C_KQ&(B$;L4YPT'0^78-'J$:$"( M! )^9'IP9;I@J:^H')_H8@IE@!*LN /&U4$'^-TPR7 MU]CEQCVHMRY!0'#%-?I4%VC0,_ZUSH"=PSNIS-;AFV-TZD7(&GP"?[5,GNHR MR=))RI%>9KY)!1X8EAC #\8CHLHR%\5G11#YMU!_E K )<3YL68F=[6:GNAJ MPD9C1%<#+XIF6(&T:/+5GHN ,T6:F%)2I-B'[!)0CG6&0C<,$Y!(%=VI%>_Q MTUT\WA2I@ZH8DAZ33Z>P9^[5E#&5#BX/IZ[1K)%K#^DGQW_'\TQQOT!5:,/I;!>0BENYC

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

    ,\R@ %_/^'V,]1!@;+.5;Z*F7# MWH0K:\N79\J4U;>BV8GR3\7%,BM2R^%Y:I75$/S&O1@7YJR$=B,LM:G\/'AI M-2+I8WUTU5+_2O'TB+,/U?MC_WY&X(QE.8L)]"$%:81@FOB#)UF>(;UO$?;L MN^;B_OY^N7UL/SB[:,PKWQS,*Q?84WI-Y[SZEI?='N?OZ\M=TOSA8 M;#?5[PJ7:3+]KP?/CH\4"RTG+E^[4E.=V*S8 MEM\.V7*SV^X['P;S(?49"S)&&?/:V9?.[=[^LEG>%\%P7NJ;2JY)V0M7U\7ITTCOQS-X_\[PS1<@)WX7IK_G?5(.RV4>7 /)OV5(/U:;)[]%NTS8GG M7N^Z)WR_.+U-I!XA^B0M. _*3Q-J?8$>HOG9CSR2)>\7J^+SUZ+8_;RM]P]E M=7J5''E,_.QVW-3W7&NBM^ MDYM2ZZ?7.WIQ],H**?-)S59;S .I]L,Z]Y',KFX&^[J:X017 MG,59&J44YC'PDXP$27#89QNE)/-#_4TX\C:FW4G37.R4XS&1U/:OJ&L[CZYF M)Y2W=Y+HZJ.^;-<;;_>G-&5KG#R>_%MW9"D(6(Y3 A#.(D CR&WGO1LI2K#> M\ITEXQ-^>AXZY*G+[;!Y\@/3 X]MM8GJNMX%FD-_?<].2SA>XY-35&JMSW+C MS(.G[L([N_;G1$?I5.8D?;H6VG-[^'O9+/PPBU-$K]UGBGF&;H*RF43$XBGEC/HZ.:$.:\K,T(<0RGGP1O3(&JKKY<<:V[*>O&) M/Y8)L'TI5E^K>E/?E47SOEK]]9?B_J;8+N(X3K,P0@3[F*$LC,4A-@>+68:E MRLYLV'%,G<$][]2_*T]XZ/W6^2C)'RNJCD-H:D'52#0W+=?UJEU!;X?LV6CZ MQ*N)M'W&>QZR@#CR8^BW")?0X!6.VU3NLC"W&DEM_[V2Q_K/U9Z\_W!X/(E" MR&)(\CQ)@@R1!(%ACI?!0.I85^6'.@9VYXL&3M24>9O#SD11@^Y$>LBSU)DN M>N"4U4<&D:>AG>&A5O27AY^>V[5AJ^M])CM9RKH>K@[*40I@CD+*W12-QY MS*3MA'+FVZ,%?0P^Y].Z:DHN7[?#5AP8V\WRP0)'@ &$:9J0'(8PQ=#O7< ^ M1*GAV:OZAJ?BV),C-)^XZYWX:WP@JD$+J%%NH^U3U%V3'2;FAOUVO8TD^6H1^7C]V>A?IPKFCO4]'\6NP^W-)E\[4_<7018Y;B( 8T M#YE/LC@)@GX[ P:*>P>L&G;,T-Y7;U?WIPM[1W>O/.ZP*"00+@^G#ZN!U&XS MR('T8BV@!E*KXCNAJ8J0(S1UTA[SH*F;T.H)WF?CC/1S\;#D-"\VC\=#G5NN M+U==?=YZW2;+RXW8Y+FIQB=A7CV9OHI(O3Y4XYQYVG=$.\V> M[>MA(S.?]LV8*JNWV61J$X&+O"SS&.UFH\;;TXT+MI+9*L^NK.[X8/]DNM2? MN?:X(,R/$CY5RD("HLQ/2!+2WI/ 1TK7++JP?ZDUGX/73Y?M12BU5&133>6KJY.8XCC">0Q1 M!" "(63#@A3T\VSQK=C>U*HW0[[Y6)5N>NJ!_(?LV5_8+"O1/+J)NMOG+FQ6 MB]O!9Z234UW?5^TQ3#SK@6D.,(1AFH( IW'HDVQ8EXU\K0_BCEQQG':\: ML\])6BUA_0.3ZT9P^LGIZ34-O?]S2#EDM;;S:=!V*F"U?]\9:[Q)>YN M_;78+<0F/1QE$&0X2?, Q3[M-Q]A"C.E4U.F]NTBTTSCVSEY9)>[EE6JR;7' MD=FTMHV!Q6E#S_[&5>Z\VO S2=O/=CR:)GJ'-ZNJMX+,+H*/VW)5T*^\LQ6L MN-D=#DCG4_ M!-%6K-2JE6H\X>B'#%8FJXKN++),,B75_/H%>,NL2S)Q):FQVVY+ZA+/=SX MWP$.@(,YB!.[G2! (,M%A3,.G[FS($O/\M<7I#THU746=I6](=Y55.>_I55. M;XE]S+YE>YL6<^UKN3X_$3!Y<;]!GH4=2%K9I.^1V@F,$!Z,X\A+6(57H4G- M6CPB-0:H1HO5L%]4NWTV>KSL@J.2]LNBO1#C?#K^:-.+47,<.WGYL;Q[\0!. M^S#1;^TK1J^>RLEJ(R_:AXJ,I]Y'P[*-Q]9#,A+(KRK..NZ+]0"VI-3/T/A\ M(77RN;GAE 5UZ\T[28-G5T;GF_%I;/?.O2OCV*G6\DJ=5#--9*R6[ACKR%PM MS@+S"WISM@K+&HN>!/R4-0_E[BB]UQD9LF26=I]]_EYDNXWO![$#,'2"!'@ M8B](XL$J="'3TTVJ;&F.1NTQX [C22RZ,HXPC18G^P1?"<&7EU%S<\LG]BNE ME7W!-#>]8BNE]VFN.7AF62(Q<'%F;:22Q>4714J]*?7TM;F601^SNKYY2%^$ MKV/8H@\!N,CS?*B-*]0G=,G+-#S!\5Y?K"RN+BA:;2$AE5=8^?/38JXT%9=%3; M,O.M#P?K4NO:[MIIXOUK'XJ?R6T03ZA^)KDQ:[M-J] M!/-,)*$ZI/LOY7Y/Y.4[^8&-A5PW]@/?![X;^;X=QFA$@A+,=(I8IWW-\\L! M,MU5&$ ;KP8R?5VSQ6W\09$;/73.LNI:&H=--Y=N%SX9U=(D6I15@-<)H=79 M2NO07:T>EO/U>9D9TF!W@T++$;R:TSL:[=^N*:-<9O=YT61%_=TU[?[(&<%8D%"12:96ECDT\-1 ^GM MY.1'DQ6[[+P@+CFW',ABGDURL[L.'9-U8G+&*,B)G!H=9ZL?ZOJ0[38P=!*0 MA F9CEJ1'R < F\IN=)[LK*^-Z#5:%,_.3**)56 M7G4J5_MP896E==:VP,DJNG-D#1 M _T$$@-6 !W']9$?XL%HX)CFILCN::[M1E88F2TR#=RP&[AOP'',W!HZ<1L$ MT=B6=<.Y6R++K(P0J MU H=Y 1!$@=! ),XB;$3#,:$:+=Z9\^1\9$Z(H:9668=(ZG+N3(EJ+1RRBNIXJKTO9_>BC-TG M,ODE&':?:0F\0U7EQ3WY@=_+HAI^&Z5U7M_04Q(;,PCBP*8E,@((/#L6YX3EC M&[-I^CJ;ET_N3^[,]8C[ZZX3;7BI];1HOC*R)\+!_ VZCDBQ@-_ETD.)+[Z< M>7 D>KXAGX$_\GKC>@&*;"NF)?S\, XM%!SM!J'%$S?DK6F.!^?>[S%NGPV* MT?B#HN34=P4_L@EPO6IE$_&'3=F$F6(IRD7O.M2/.?E74Q;98U[DCX?']+$\ M%,VG[/$VJS:.'UC "8((8"<$B1OC!(UJFH0N:TDN>4N:%:T%:(P(C1ZBT6$T M_NA0,DJ:(FZGY6Q^6CEW8%?(*'LAKGF9%2O#),TDX5_*\)N892[ -824 M$L@1]O5R)Q+LEU>>]XFY%-?%F5R'XL@Z\5X,E^6$N=C'HS!E V"D*N:AX@!S2HS8C(^W^[S^S9'61N_=.#^,G/U MAW?XF1@P4G2N8[C(N?"Z0(,\'\P[YFG] (L=_7_)?Q_R;^F>CLYVBQXDH>.; MR$.!$\<6(O^X\6#0LS'?,2!Q,[KWR FD]EQ@^XL3<&('?R3H9-P6GX=)SOUP M41+U[(2?I6AJ"UR>UW4HD0I'7F]ZJ^*&596^D&E"E6^;;/>^Z??_M!?*$#I^ M[(? VZ8A%X4!&C8CXE=[#&]NCX+D.643>CDC]Y&85._U;2',GU=QM5R@]_.>N'Q\S*IM3B]I/V75L"7N$E,N=-_IBAK'W3;! SZ,<6]!WR7=>RPMCWHS 9C'E6R)7, M$32A66%P667Y?6%09,8 35!F1$EDTYD9^.,3&@J(ESM9<3(: M\WS$M7\N:$+WSA9%972PC!:7H!R),LBF1#.0QR="(KQI*@;_'C-3&X)R5*Y# M=62=>%.U70$G/-N";U-(,/0MU_)-;(

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end